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But of opium he said, ‘It frequently produces so material an improvement in chronic 
phthisis, that the patients fancy themselves cured, or almost cured, after taking a few 
doses.’ 
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Keywords: Gene expression, efflux pumps; ion channel blockers; proton motive force; 
intracellular activity. 
 
Mycobacterium tuberculosis strains with multi- or extensive drug resistance are a major 
threat for human health. The main objective of this thesis was to understand the basis of 
the development of resistance in M. tuberculosis, in order to design strategies to 
circumvent its development. 
First we started with the description of the molecular basis of drug resistance in M. 
tuberculosis clinical strains circulating in Lisbon through the determination of their 
resistance patterns and its correlation with mutations associated with resistance. The 
results showed a clear correlation between the presence of conserved mutation and the 
resistance phenotype. The description of the resistance profiles of drug resistant strains 
adds new knowledge for the design of more effective tools for the diagnosis, treatment 
and management of tuberculosis. 
Next, was investigated the contribution of efflux to the emergence of drug resistance in 
M. tuberculosis. The study was based on the in vitro induction of an isoniazid resistant 
phenotype by prolonged serial exposure of M. tuberculosis strains to the critical 
concentration of isoniazid. The results showed that the increased activity of efflux 
pumps allows a sustainable resistant population to be maintained in the patient under 
therapy, from which genetically resistant mutants will emerge. The addition of an efflux 
inhibitor is able to reduce this level of resistance. 
Finally, the mechanism of action of the ion channel blockers and inhibitors, verapamil, 
thioridazine, chlorpromazine, flupenthixol and haloperidol, was evaluated both in vitro 
and ex vivo. All compounds exhibit synergistic inhibitory activities when combined 
with the main first line antituberculosis drugs, demonstrating their role as efflux 
inhibitors and displaying rapid and high killing activity that could be correlated with a 
decrease in intracellular ATP levels. Overexpression of efflux genes was detected in 
response to antibiotics in vitro and ex vivo, indicating that drug resistance within 




The compounds lead to a decrease in the intracellular mycobacterial load as a result of 
their ability to induce phagosome acidification with consequent expression of lysosomal 
hydrolases. We hypothesized that these compounds inhibit the mycobacterial 
respiratory chain which leads to the dissipation of membrane potential, depletion of 
ATP, reactive oxygen species generation and cell death. Disruption of the proton motive 
force (PMF), results in the inhibition of PMF-dependent efflux systems, therefore 
promoting the retention of antibiotics subject to active efflux. Concerning the host cell, 
the phagosomal acidification stimulated by these compounds synergize with several 
components of the host immune response, restricting M. tuberculosis intracellular 
growth. Altogether, we demonstrate that the compounds display a dual inhibitory effect 
as they target both the bacteria and the host cell. 
This thesis aims to contribute to the knowledge on M. tuberculosis drug resistance 
mechanisms. The understanding of the activity of the studied compounds will contribute 
for the design of new drugs and can provide the basis for the development of new 








Palavras-chave: expressão génica; bombas de efluxo; inibidores de canais iónicos; 
força motriz protónica; actividade intracelular. 
 
Estirpes de Mycobacterium tuberculosis multi- e extensivamente resistentes, constituem 
uma ameaça para a saúde humana. O principal objectivo desta Tese foi estudar os 
fenómenos subjacentes ao desenvolvimento da resistência em M. tuberculosis, de modo 
a ser possível desenvolver estratégias para reduzir o seu desenvolvimento. 
Iniciamos o estudo com a descrição da base molecular da resistência aos antibacilares 
em estirpes clinicas de M. tuberculosis circulantes em Lisboa, através da determinação 
dos seus padrões de resistência e sua correlação com as mutações associadas à 
resistência. Os resultados mostraram uma clara correlação entre a presença de uma 
mutação e o fenótipo de resistência. A descrição dos perfis de resistência de estirpes 
resistentes aos antibacilares adiciona nova informação para o desenvolvimento de 
metodologias mais eficazes para o diagnóstico e tratamento da tuberculose. 
De seguida, avaliamos a contribuição dos sistemas de efluxo para o desenvolvimento da 
resistência aos antibacilares em M. tuberculosis. O estudo baseou-se na indução in vitro 
de um fenótipo de resistência à isoniazida por exposição prolongada de estirpes de M. 
tuberculosis à concentração crítica de isoniazida. Os resultados mostraram que o 
aumento da actividade de bombas de efluxo permite a manutenção de uma população 
resistente num doente em tratamento, da qual irão emergir mutantes geneticamente 
resistentes. A utilização de compostos inibidores de efluxo demonstrou ser capaz de 
reduzir este nível de resistência. 
Por último estudamos o mecanismo de acção dos compostos inibidores do efluxo, que 
partilham a característica comum de serem inibidores de canais iónicos, verapamil, 
tioridazina, clorpromazina, flupentixol e haloperidol, quer in vitro quer ex vivo. Todos 
os compostos apresentaram actividade sinérgica inibitória em combinação com os 
principais antibacilares de primeira linha e foram capazes de inibir o efluxo activo 
demonstrando o seu papel como inibidores de efluxo. Igualmente demostraram potente 




intracelulares. Foi também detectada sobrexpressão de genes de efluxo em resposta à 
exposição aos antibióticos in vitro e ex vivo, indicando que a resistência aos antibióticos 
em macrófagos é também mediada pela sobrexpressão de bombas de efluxo, a qual pode 
ser inibida por inibidores de efluxo. Os compostos estudados potenciaram a actividade 
antimicrobiana de macrófagos infectados e induziram a acidificação do fagolisosoma, 
com consequente expressão de hidrolases lisossomais. Com estes resultados, foi 
possível propor, como mecanismo de acção para estes compostos, a inibição da cadeia 
respiratória micobacteriana. Esta inibição leva à dissipação do potencial de membrana, 
depleção de ATP, a produção de radicais de oxigénio e morte celular. Por outro lado, e 
em simultâneo, a disrupção da força motriz protónica (PMF) resulta na inibição dos 
sistemas de efluxo que dela dependem, promovendo assim a retenção dos antibióticos 
sujeitos a efluxo activo. No que se refere a célula hospedeira, a acidificação phagosomal 
estimulada por estes compostos actua em sinergismo com vários componentes da 
resposta imunitária do hospedeiro, restringindo assim o crescimento intracelular de M. 
tuberculosis. No contexto geral, demonstramos que estes compostos possuem dupla 
acção, uma vez que actuam quer na bactéria quer na célula hospedeira.  
Este trabalho contribuiu para o aumento do conhecimento sobre a resistência aos 
antibióticos em M. tuberculosis. O estudo do mecanismo de acção destes compostos 
poderá contribuir para o desenvolvimento de novos compostos e pode servir de base 
para o desenvolvimento de novas estratégias terapêuticas para combater a tuberculose e 






The main objective of this work was to study the mechanisms underlying the 
development of drug resistance in M. tuberculosis as a route for the development of new 
therapeutic strategies. This thesis is organized so that each chapter can stand on its own 
as follows: 
Chapter I provide a general introductory description on the current knowledge about 
the main aspects of M. tuberculosis biology, epidemiology, diagnosis, drug resistance, 
and the new therapeutic targets. The review presented gathers and summarizes the 
information about the recent advances that have been made in the mycobacteriology 
field that may help us to proper evaluate the important aspects of M. tuberculosis drug 
resistance. This chapter ends with the description of the purpose and objectives of the 
thesis.  
In Chapter II we describe the prevalence and pattern of gene mutations associated with 
resistance to the first and second line antituberculosis drugs, as well as its levels of 
resistance, in a collection of multi-and extensively drug resistant strains isolated from 
patients in the Lisbon metropolitan area. The application of a drug resistance 
quantitative testing allowed us to describe a different mutational pattern associated with 
resistance to isoniazid among the multidrug resistant strains that circulate in Lisbon. 
The detailed characterization of the genetic mechanism of resistance to the main 
antituberculosis drugs for these strains was the basis for the work presented in chapter 
IV.    
In Chapter III we assess the contribution of efflux to the emergence of isoniazid and 
multidrug resistance in M. tuberculosis. Here we focus on the understanding of the 
chain of events leading to the development of resistance during therapy, with specially 
attention to the differential activity of genes that code for the main M. tuberculosis 
efflux pumps prior to, during and after the establishment of the resistant phenotype and 
their interaction with the genetically based resistance. The role of efflux inhibitors as 
adjuvants in tuberculosis therapy for preventing the emergence of drug resistance was 
also assessed. The identification of the efflux pumps involved in the adaptative response 




allow us to describe the mechanism of action of these compounds in M. tuberculosis 
clinical strains which is presented in chapter IV.  
In Chapter IV we investigate the antimycobacterial properties and the mechanism of 
action of the putative efflux inhibitors verapamil, thioridazine, chlorpromazine, 
flupenthixol and haloperidol against M. tuberculosis, in vitro and in human monocyte-
derived macrophages. This study provides a description of the molecular mechanisms 
by which these agents act in M. tuberculosis and the results obtained lead us to rename 
these compounds from efflux inhibitors to ion channel blockers. This chapter 
contributes with scientific guidance for future research on the improvement and reuse or 
repurpose of known drugs, on the design and development of new ones, and on their 
inclusion in future therapeutic regimens against infections caused by drug susceptible or 
resistant M. tuberculosis. The different experimental procedures designed for this work 
can be applied to characterize and evaluate the bactericidal activity and efficacy of any 
combination of compounds and antibiotics to be used for this purpose. 
In Chapter V, the collection of data provided along this thesis is summarized and 
contextualized in the current context of drug resistance in tuberculosis, the development 
novel antituberculosis drugs and the description of their mechanism of action for their 
future therapeutic usage. The results and the conclusions obtained in this work are 
discussed in light of a mechanistic model that intends to congregate all the findings that 
drove us to the final conclusion that the compounds studied in this thesis can be useful 
adjuvants for antituberculosis therapy, preventing the emergence of drug resistance and 
contributing to the fight against drug resistant tuberculosis. Finally, we propose a 
number of new scientific approaches for further research and future perspectives on the 
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Preface to Chapter I. 
 
Phthisis; scrofula; consumption; wasting; white plague; Pott’s disease; king’s evil; 
among others. Tuberculosis is one of the oldest and most studied diseases in the world. 
Known by several names, and being the bearer of a notorious reputation, tuberculosis 
remains one of the most feared diseases. The causative agent of tuberculosis, 
Mycobacterium tuberculosis, has claimed millions of human lives throughout its 
history. Today, despite the availability of an effective therapy, tuberculosis remains a 
global health problem. With the introduction of tuberculosis chemotherapy and 
implementation of the standardized treatment, it was believed that tuberculosis would 
decline. However, tuberculosis is still a leading cause of morbidity and mortality in 
developing countries. In 2012 were estimated that 8.6 million people developed 
tuberculosis and 1.3 million died from the disease. A further concern is the emergence 
and spread of multidrug resistant strains of M. tuberculosis. In 2012, there were an 
estimated 450 000 new cases of multidrug resistant tuberculosis worldwide, that 
resulted in 170 000 deaths. Due to the emergence of drug resistance, tuberculosis has 
been viewed with a renewed and intense interest. Further research is necessary to 
improve diagnostics, to develop new drugs and vaccines, implement simple and 
effective treatment programs, and understand the interaction between the pathogen and 
the host. This chapter reviews the history, microbiology, pathogenicity, ecology, 
molecular typing, evolution, epidemiology, laboratory diagnostics, treatment, drug 
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Tuberculosis is one of the most ancient infectious diseases. With records dating back 
from the Neolithic revolution (8000-6000 BC) (187), his etiologic agent, 
Mycobacterium tuberculosis, is responsible for one of the highest mortalities rates due 
to only one agent (503). Designated by Hippocrates as phthisis¸ consumption, name by 
which was known until the beginning of the 20th century, tuberculosis reaches 
pandemics proportions in Europe and North America by the end of the 18th century and 
first half of the 19th century, being responsible for the death of millions of people. 
During the 19th century and beginning of the 20th century, M. tuberculosis continued to 
cause several epidemics of tuberculosis. The improvement of sanitation and housing 
conditions and the implementation of antituberculosis therapy have led, in the mid-
twentieth century, to a decrease in the incidence of tuberculosis in developing countries 
(104; 187). However, by the end of the 20th century, the incidence of tuberculosis raises 
again, being declared by the World Health Organization (WHO), in 1993, as a global 
emergence, recognizing by this manner its importance as a menace for public health 
(496). Nowadays, according to the WHO, approximately one third of the world's 
population is infected with M. tuberculosis. In 2012, were reported 8.6 million new 
tuberculosis cases and 1.3 million deaths (506). The re-emergence of tuberculosis is 
related not only with poverty, migration, overcrowding, and increasing of HIV 
incidence in some regions of the world, but also with the emergence of drug resistant 
strains, particularly multi- and extensively drug resistant M. tuberculosis strains (498). 
Tuberculosis remains a major public health problem and the emergence of multidrug 
resistant tuberculosis strongly contributes to this reality. Here, we summarize 
predominantly the history, epidemiology, biology, pathogenesis, clinical features, 
laboratory diagnosis, treatment, drug resistance and the new therapeutic strategies 





A brief history  
Tuberculosis has plagued humanity since prehistory and evidences came from both the 
Old and New Worlds. Characteristic skeletal abnormalities such as Pott’s disease and 
changes in the hip and knee joints are the most frequent forms of tuberculosis found in 
archaeological remains (25). Spinal tuberculosis is frequently associated with bones 
deformities due to vertebral body collapse causing angular kyphosis (199). The 
recognition of such deformities in skeletons indicated that, probably, these people have 
been affected by tuberculosis. Nowadays, conclusive identification of tuberculosis 
infection can be achieved by using a combination of ancient DNA analysis and lipid 
biomarkers (287).  
The support of the antiquity of tuberculosis comes from skeletal evidences, mainly from 
Europe and Africa. There are several cases described in the literature, from a variety of 
sites worldwide (for a more extensive review of tuberculosis in archaeological remains 
see ref. 421). The oldest suggestion of tuberculosis in human fossil bones goes back for 
8000 BC (187). The definitive evidence of tuberculosis has been found in a skeleton, 
dated from 5800 ± 90 BC, recovered from the Neolithic cave of Arma dell’ Aquila in 
Liguria, Italy (69). Also dated from the first half of the fourth millennium BC is 
reported a tuberculosis infection affecting the spine of a Neolithic skeleton discovered 
in the Arene Candide cave, also in Liguria (156). Further evidence of human 
tuberculosis dates from 5000 BC with the discovery of a skeleton of a young man 
showing destruction and fusion of the third and fourth thoracic vertebra in a Neolithic 
grave near Heidelberg, Germany (314). The earliest case of tuberculosis in Britain was 
identified during excavations at Tarrant Hinton, Dorset, England, and was dated from 
the Iron Age, 400-230 BC (273). One of the oldest evidences of typical spinal 
tuberculosis came from the Late Neolithic-Early Copper Age (fifth millennium BC) site 
of Alsónyék-Bátaszék, Hungary (219) and recently, Masson et al. (262) describes a case 
of hypertrophic pulmonary osteopathy in a 7000-year-old skeletal from a person who 
died from tuberculosis, at the Neolithic tell settlement of Hódmezővásárhely-Gorzsa, 
South of Hungary. This is one of the oldest tuberculosis cases identified to date. 
Plausible evidence of tuberculosis has also been identified in one adolescent male spine 




Early Bronze Age of Bab edh-Dhra’, Jordan (313). Evidence for tuberculosis in 
skeletons, dated from 600 AD, was recovered from a mass grave in the monastery of 
John the Baptist near the Jordan River in the Judean desert (524). El-Naijar et al. (142) 
has also reported three potential tuberculosis cases dated from 8100-7600 BP from the 
Neolithic village 'Ain Ghazal, in the city of Amman, Jordan. In 1998, during the 
excavation of a Byzantine basilica in the Negev desert at Karkur, Israel, was discovered 
a calcified fragment of pleura, dating from approximately 600 AD. This was the first 
demonstration of tuberculosis in non-mummified archaeological tissue other than bone 
(132). There is no evidence of skeletal remains from sub-Saharan Africa and the 
majority of archaeological evidences of tuberculosis came from Egypt and Sudan (421). 
The most convincing case of tuberculosis in Egypt occurred with the discovery of the 
mummy of the Amun´s priest Nespherehan from the 21st dynasty, in Thebes, that not 
only exhibits Pott’s disease but also a psoas abscess. After this, several other Egyptian 
mummies have been found that possess evidences of skeletal tuberculosis some of them 
dating from 4500 BC (526).  
In Portugal, the earliest cases of tuberculosis date from the medieval period. The first 
evidence of tuberculosis was found in a skeleton, dated from 12th/14th centuries, 
exhumed from S. João de Almedina Church, Coimbra (101; 377). Another two cases 
found in medieval individuals were described, one from Granja de Serrões, Sintra (376; 
377) and the second from Corroios (244; 377). Tuberculosis was the main cause of 
death at the beginning of the 20th century and several studies indicated that new bone 
formation on the visceral surfaces of the ribs can be used for the diagnosis of pulmonary 
tuberculosis in human remains (378). Portugal has rich skeletal collections and the 
analysis of the skeletons dated from the first half of the 20th century of the collection 
curated in the Anthropological Museum at the University of Coimbra, by Santos and 
Roberts (377) allowed the discovery of eighteen skeletons from juvenile individuals 
who died from tuberculosis affecting different parts of the body. Assis et al. (23) when 
analysed the Coimbra Identified Skeletal Collection described a strong association 
between hypertrophic pulmonary osteopathy and pulmonary tuberculosis in the skeleton 
remains. Matos and Santos (266) conducted a research on the Human Identified Skeletal 
Collection from the Museu Bocage (Lisbon) which represents a Portuguese population 




pulmonary tuberculosis and rib lesions in 76 individuals with tuberculosis as probable 
cause of death. Recently, Matos et al. (265) describes the discovery of a skeleton from a 
12-year-old individual exhumed at the necropolis (13th/14th-19th centuries) adjacent to 
the church of São Miguel, Castelo Branco. This case can be the earliest skeletal 
evidence of tuberculosis in Portugal.  
Pulmonary tuberculosis was described in the ancient Greek medical literature, by 
Hippocrates, as phthisis, which is derived from the Greek “wasting away”. Galen 
provides a remarkable description of the disease due to the extreme emaciation and 
ulcerated state of the lungs (323). Soranus of Ephesus described the symptoms of 
phthisis as follows: latent fever, coughing blood, sanious sputa, coarse breathing, 
emaciation, flushed cheeks and loss of appetite (206). Over time, the disease has been 
known by several different names, namely schachepheth (ancient Hebrew), yaksma, 
consumption, scrofula, Pott’s disease, white plague, king’s evil, and so on. Scrofula, a 
rare manifestation of tuberculosis that affects the lymph nodes, was well documented 
during the middle age in Europe, when it was believed that the cure resulted from the 
power of the divine touch of the kings (31). Pott´s disease was characterized by typical 
skeletal abnormalities, as mentioned before (63). All these several clinical 
manifestations were assumed to be forms of the same disease as consequence of the 
studies of Franciscus Sylvius where he described the characteristic lung nodules as 
"tubercula" (small knots), observing their evolution to cavities (lung ulcers) (55). The 
first credible hypothesis on the infectious nature of tuberculosis was made by Benjamin 
Marten in 1722, who proposed that tuberculosis could be transmitted through the breath 
of a sick person (130). In 1694, the English Doctor Richard Morton used the term 
consumption to designate tuberculosis (55), and finally, in 1819, René Laennec, the 
discoverer of the stethoscope, described for the first time the pathogenesis of 
tuberculosis (45). In 1838, J.L. Schönlein named the disease as tuberculosis due to the 
presence of tubercles in all manifestations of the disease (187). In 1865, Jean-Antoine 
Villemin demonstrated formally that tuberculosis is a contagious disease when he 
successfully transferred pus and fluid from human and bovine lesions to rabbits that 
then developed tuberculosis (465). In 1882, the German Physician Robert Koch 
demonstrated for the first time the etiological agent of tuberculosis from crushed 




Koch's Postulates: "To prove that tuberculosis . . , is caused by the invasion of bacilli 
and conditioned by the growth and multiplication of bacilli it was necessary: (i) to 
isolate the bacilli from the body; (ii) grow them in pure culture; and (iii) by 
administering the isolated bacilli to animals, reproduce the same morbid condition.” 
(47). Robert Koch was awarded with the Noble Prize in Medicine or Physiology in 1905 
for his discovery. In August of 1890, during The First Ordinary Session of the 
International Medical Congress, in Berlin, he announced the discovery of an 
antituberculosis drug, which was called as tuberculin (218). Tuberculin turned to be 
useless and is nowadays used as a diagnosis tool. 
During the 18th century, tuberculosis was known as the White Plague opposite to the 
Black Death that decimate about one third of the population in Europe from 1346 to the 
1800s. At this time the disease became the principal cause of death which leads to its 
romanticization. Tuberculosis arises with more frequency among young adults between 
the ages of 18 and 35. In the literature it was named as the “Captain of Death,” and is 
presented as a romantic ideal way to die (140). Tuberculosis was a disease not just of 
the body, but also of mind and spirit. During the Romantic period, consumption was 
thought to be the disease of poets and talented people and associated with an aesthetic 
image, a kind of beauty and melancholy. The pale, slender figure and rosy cheeks due to 
the disease were highly desirable features among women (140). Prominent people who 
died of tuberculosis included the English poet John Keats, the Polish composer Frédéric 
Chopin, all the Brontë sisters (Charlotte, Emily, and Anne), the Russian dramaturge 
Anton Chekhov, the Italian painter Amedeo Modigliani, and the German writer Franz 
Kafka, among others (140). As the knowledge about the disease increases and with the 
discovery of its etiological agent, the social perception of tuberculosis changed from a 
poetic and aesthetic image to the reality of an infectious disease. In addition, during the 
18th-19th centuries tuberculosis was often associated with vampires. The New England 
folk belief in vampires is based on the capacity of a deceased tuberculosis victim to 
return from the dead as a vampire and cause the “wasting away” of the surviving 
relatives (406). The treatment required exhuming the bodies of deceased relatives and 
checking them for “unnatural” signs, such as “fresh” blood in the heart. Afterwards, the 




Despite the development in diagnosis and medicine it was not possible to find an 
effective cure for tuberculosis until the discovery of streptomycin in 1944. The most 
popular treatment for tuberculosis in the epoch was based on “open-air treatment”. 
People were often advised to move to warm and humid climates as mountains close to 
the sea, to get fresh air, sunlight, and do some exercise. With the belief that tuberculosis 
could be cured by a change of climate quality, in 1859, Hermann Brehmer opened the 
first tuberculosis sanatorium in Gobersdorf, Germany (477). After this, several other 
sanatoriums were followed. By the time of Brehmer’s death in 1899, there were more 
than 300 sanatoriums in Germany alone (112). In 1860, Albert Robin postulates that the 
treatment of tuberculosis had to be not only based on hygienic measures but also 
requires drug therapy and a proper diet (360). Sanatoriums were able to improve the 
health of tuberculosis patients and render them less contagious to the community. The 
contagious nature of the disease makes tuberculosis a matter of public health concern. 
The Decree of Lucca promulgates in Italy in 1699, for the first time, the notification of 
the names of patients with phthisis and burning of their belongings after death (47). The 
advent of antibiotic therapy resulted in a gradual sanatorium close down as the belief 
among the health authorities was that the fight against tuberculosis was over. 
Tuberculosis is by no means a disease of the past. Currently it represents a global threat, 
as it stands as the leading cause of death due to an infectious bacterial agent worldwide. 
Tuberculosis was amongst the diseases that most afflicted the Portuguese population in 
the late 19th century and first half of the 20th century. Tuberculosis originated thousands 
of victims annually, due to the lack of medical knowledge and impotence of the health 
authorities. These numbers were aggravated due to unhygienic general practices and 
overcrowding and industrialization (462). At that epoch, tuberculosis was considered a 
social disease. According to António de Almeida Garrett, tuberculosis was a disease of 
the poor (159). The great majority of the diseased people lived with poor social-
economic conditions, a factor that contributes to the dissemination of the disease. 
However, tuberculosis was not restricted to the anonymous and poor population that 
lived in urban areas, but also extended its arms to prominent people as the King D. 
Pedro IV and his daughter D. Amélia, the writer Julio Dinis, the poets António Nobre 
and Cesário Verde, among others (258). By the end of the 19th century the fight against 




construction of dispensaries, preventoriums and sanatoriums (379). In 1853, was funded 
in Madeira (Funchal) the first Portuguese sanatorium for the treatment of tuberculous 
patients, by the Empress of Brazil Amélia de Beauharnais, widow of D. Pedro IV, in 
memory his daughter, the Princess D. Maria Amélia, who died victim of tuberculosis 
(379; 462). The sanatorium received the name Princess D. Maria Amélia and in 1862 
received the first’s patients. Around 1880, Dr. Sousa Martins conducted two expeditions 
to Serra da Estrela to study the climatic conditions on the mountains in order to begin 
the construction of a sanatorium (462). In 1881, was opened the sanatorium Hospital 
Príncipe da Beira, Guarda (379). The identification of M. tuberculosis, as the causal 
agent of tuberculosis, totally changed the social concept of the disease. Tuberculosis 
was no longer seen as a hereditary disease, but as a contagious infectious disease that 
could be preventable. Based on the preventable condition of the disease it was 
established prophylactic actions against tuberculosis. In 1895 was held in Coimbra the 
first National Congress of tuberculosis (462). Following this, other initiatives were 
created. This included the creation of isolation rooms for the afflicted in the Hospital de 
Santo António and the Hospital da Marinha in 1896 (462). Regarding charity, the 
Duchess of Palmela and her assistants dedicated themselves to serve meals to the poorer 
(379; 462). Several physicians rose against the social problem of tuberculosis with the 
desire to disseminate concepts of hygiene among the population. In 1897, the Society of 
Medical Sciences of Lisbon in collaboration with Dr. Miguel Bombarda initiates a 
campaign against tuberculosis, which led to the creation, in 1899, of the National 
League against tuberculosis (379; 462). The National League against tuberculosis was 
constituted by several commissions whose actions gradually took the form of campaigns 
conducted through national congresses on tuberculosis (1901, 1902, 1904 and 1907) 
(462). In 1899 was born the National Assistance to tuberculosis patients, a private 
Foundation directed by the Queen D. Amélia (379, 462). The foundation became a 
public institution in 1946 (19). The fight against tuberculosis enjoyed political, social, 
and public acceptance and generous funding, with all services, being provided free of 
charge; the epidemiological surveillance began in 1951; the prevention program was 
formally integrated into the primary health care system in 1984; and annual reports have 
been published since 1988 (19). However, tuberculosis remains a public health problem 




Mycobacteria and the tubercle bacillus  
Mycobacteria are acid-fast bacilli belonging to the genus Mycobacterium, family 
Mycobacteriaceae, suborder Corynebacteriaceae, and order Actinomycetales (144). The 
name Mycobacterium results from the junction of myces (fungus) and bakterion (small 
rods) and refers to the fungus-like pellicles that are formed when mycobacteria are 
grown on liquid media (Figure I.1-I). Presently, the genus Mycobacterium comprises 
169 species and 13 sub-species (144). It contains the obligate pathogens responsible for 
tuberculosis, leprosy and Buruli ulcer, whose etiologic agents are M. tuberculosis, 
Mycobacterium leprae and Mycobacterium ulcerans, respectively. However, the great 
majority of mycobacterial species are environmental, as they inhabit mainly in grass, 
soil, marshes, rivers and piped water systems (145). Environmental mycobacteria can 
cause opportunist diseases in those individuals whose immune systems are debilitated. 
Until 1950, all acid-fast bacilli other than the tuberculous bacilli were named just as 
atypical tubercle bacilli (141; 166). The classification of mycobacteria was established 
in 1959 when Ernest Runyon assigned them to four groups according to their capacity 
to produce pigment and growth rate on solid media (367). The first three groups include 
the slow-growing species (colonies in more than seven days) that can be distinguished 
among them by the production of pigment: Group I: photochromogens (pigment 
production in the presence of light); II: scotochromogens (constitutive pigment 
production); and III: nonchromogens. Group IV includes the fast-growing species 
(colonies in less than seven days). Attending to the optimal growth temperatures, they 
range from 20ºC to 52ºC depending on the species (446). The morphology of the 
colonies varies among the species, from rough to smooth. Depending on the conditions 
of growth and age of cultures, cells may vary in size and morphology, from small 
cocobacilli to slightly curved rods, which may be dispersed or presented in small 
clumps. Mycobacteria are aerobic, non-motile, non-sporing, and non-flagellate, with 2-5 
μm in length and 0.2-0.5 μm in width. The presence of lipid storage granules may give a 
distinct banded or beaded appearance to the cells (165). Mycobacteria are called acid-
fast bacilli. They do not strain or stain poorly by the Gram staining, and for that they are 
called Gram-ghosts (448). Due to their almost unique acid-fast property, they can be 
visualized by using an acid-fast staining technique. The original acid-fast staining was 








Figure I.1. Macroscopic and microscopic observation of Mycobacterium tuberculosis. (I) 
Formation of a fungus-like pellicle at the surface of MB7H9; (II) development of rough 
colonies on solid media; and (III) Ziehl-Neelsen staining showing cording formation 
(DMachado, Grupo de Micobactérias, IHMT). 
 
The tubercle bacillus 
‘Tuberkelbazillus’ (tubercle bacillus) was the name by which M. tuberculosis was 
known at the time of its discovery (263). M. tuberculosis was identified in 24 March 
1882 by Robert Koch which not only isolated the bacteria but through its postulates 
established it as the definitive cause of tuberculosis (47; 217). M. tuberculosis complex 
is composed by closely related species that share 99.9% genomic similarity and 
identical 16S rRNA sequences (50). Nevertheless, species from M. tuberculosis 
complex differ among them with regards to their morphological and biochemical 
characteristics, host range, pathogenicity and epidemiological behavior. Nowadays, M. 
tuberculosis complex includes nine species: M. tuberculosis, Mycobacterium bovis, 
Mycobacterium africanum, Mycobacterium caprae, Mycobacterium microti, 
Mycobacterium pinnipedii, Mycobacterium orygis, Mycobacterium mungi, and 
Mycobacterium canettii (10; 20; 94; 457; 458). M. tuberculosis strains produce rough 
colonies on solid media that look like breadcrumbs or cauliflowers (Figure I.1-II). M. 
cannettii is an exception since it forms smooth colonies and is considered an ancestral 
of M. tuberculosis (430; 458). M. bovis and M. caprae possess a wide host range, from 
man to domestic animals. M. africanum is an important pathogen that is isolated from 




M. bovis in regard to the geographical area and biochemical characteristics. M. 
africanum type I is found mainly in West Africa, and presents characteristics similar to 
M. bovis; M. africanum type II, is found mainly in East Africa, and presents similarities 
resembling M. tuberculosis (107; 305). M. microti was first isolated from the vole 
Microtus agrestis (485), and M. pinnipedii was first isolated from seals and sea lions in 
Australia, New Zealand and South America (94), and in an Australian seal trainer (213). 
M. orygis, the oryx bacilli, have been isolated from members of the Bovidae family, i.e., 
oryxes, gazelles, deer, antelope, and waterbucks (457). The mongoose bacillus or M. 
mungus was isolated from banded mongooses (Mungos mungo) in Botswana (10).  
 
The mycobacterial cell wall 
The most distinct characteristic of mycobacteria is their complex and lipid-rich cell 
wall. The mycobacterial cell wall consists of an inner membrane and an outer 
membrane that surround the plasma membrane (57). The outer membrane consists of 
lipids, proteins and polysaccharides. The lipids are often freely associated with the cell 
wall, with some long- and short-chain fatty acids complementing the short and long 
chains found in the inner layer. The lipid-linked polysaccharides associated with the 
outer membrane consist of lipoarabinomannan, lipomannan, phthiocerol-containing 
lipids such as phthiocerol dimycocerosate, dimycolyl trehalose, sulfolipids, and the 
phosphatidylinositol mannosides (PIMs) (56). Lipoarabinomannan (LAM) is a branched 
polysaccharide of the mycobacterial cell wall. In slow-growing, pathogenic 
mycobacteria, such as M. tuberculosis and M. leprae, lipoarabinomannan are coated at 
the terminal β-Ara (arabinose) residue with mannose residues designated as ManLAMs 
(73; 74). The inner membrane is composed of three covalently attached 
macromolecules, the peptidoglycan, arabinogalactan, and mycolic acids (57) and known 
as the peptidoglycan-arabinogalactan-mycolic acids complex. Peptidoglycan, or murein, 
is composed by peptides and glycan strands. The glycan strand consists of alternating 
units of N-acetylglucosamines linked to modified N-acetylmuramic acid (96). Next to 
the peptidoglycan is the arabinogalactan, a branched polysaccharide consisting of 
arabinan and galactan (275). Arabinogalactan is the major polysaccharide of the 




in the furanose configuration (275). The galactose residues are arranged in alternating 
1→5, 1→6 linkages of approximately 30 residues, with the arabinan attached to the 
position 5 of the galactan in 1→5 linkages (102). Arabinogalactan is covalently attached 
to the peptidoglycan by a phosphoryl-N-acetylglucosaminosyl-rhamnosyl linkage (276). 
Next to the arabinogalactan is one of the principal components of the mycobacterial cell 
wall – the mycolic acids, which are long-chained α-alquil branched -β-hidroxilated fatty 
acids that contain up to 90 carbon atoms (56). The aliphatic chains of the mycolic acids 
contain methyl branches, methoxymycolates, unsaturated bonds and cyclopropane rings 
(33). External to mycolic acid is a layer composed by trehalose dimycolates and 
sulpholipids (75). Trehalose dimycolates, or cord factor, are thought to be responsible 
for the characteristic serpentine cording arrangement of M. tuberculosis (Figure I.1-III). 
On the surface of the mycobacterial cell wall can also be found complex molecules as 
the mycosides. The majority of mycosides are peptidoglycolipids, consisting of 
peptides, lipids (mycoserosic acids) and carbohydrates (56). The mycobacterial cell wall 
differs from that of most other bacteria and forms a diffusion barrier which is 100- to 
1000-fold less permeable to hydrophilic molecules. The permeability properties are 
facilitated by channel-forming proteins also designated as porins (Figure I.2). 
 
Figure I.2. Simplified schematic representation of the mycobacterial cell wall . 1, Cellular 
lipidic bilayer with internal porins embebed; 2, peptidoglycan layer; 3, arabinogalactan layer; 4, 
mycolic acid layer; 5, external porins; 6, lipoarabinomannan (LAM); 7, external lipids and 
glycolipids embebed in the external face of the mycolic acid layer (trehalose dimycolates and 





Recently, the basic structural model of the mycobacterial cell wall described above was 
revised and updated according to the ultrastructure findings where a structure more 
close to the Gram-negative bacteria was described including a periplasmic space with an 
outer and inner membrane (303; 527). Both the classical and modern models converge 
in its high complexity and diversity of molecules that contributes to the mycobacterial 
impermeability to the outer environment and drug resistance (56; 303). 
 
The genome of M. tuberculosis  
M. tuberculosis H37Rv was isolated in 1905 and classified as type-strain by Kubica et 
al. (226). It has remained pathogenic and because of this is the most widely used strain 
in tuberculosis research. The complete genome sequence of M. tuberculosis H37Rv was 
obtained in 1998 (89) and re-annotated in 2002 (68). M. tuberculosis genome comprises 
4 411 532 bp, with a G+C content of 65.9% (68; 89; 242). This includes 4018 genes 
encoding proteins (more 94 than the original sequence), 13 pseudogenes, 45 tRNA 
genes, three rRNA genes, 30 ncRNA genes and two miscRNA genes (242). The 
functional classification of M. tuberculosis genes is shown in Table I.1.  
 
Table I.1. Functional classification of M. tuberculosis genes (242*). 
Class  Function  Number of genes 
0  Virulence, detoxification and adaptation  239 
1  Lipid metabolism  272 
2  Information pathways  242 
3  Cell wall and cell processes  772 
4  Stable RNAs  80 
5  Insertion sequences and phages  147 
6  PE and PPE proteins  168 
7  Intermediary metabolism and respiration  936 
8  Proteins of unknown function  15 
9  Regulatory proteins  198 
10  Conserved hypothetical proteins  1042 
*Last access May 2014. 
 
The number of sequencing projects and related databases has increased in the last years 




benefit for the field of mycobacteriology since it can increase our knowledge regarding 
the functions of several gene products. This improvement is reflected on the reduced 
number of proteins with unknown function on M. tuberculosis genome at the present. It 
is expected that this number continues to decrease in the coming years with the results 
from the above mentioned projects. 
 
M. tuberculosis ‘devolve’ to evolve 
Progressive genome downsizing is a hallmark of mycobacterial evolution (Figure I.3). 
When compared with nontuberculous mycobacteria it is observed that M. tuberculosis 
complex has been evolved by reductive evolution. The genome of the non-pathogenic 
M. smegmatis has 7 Mb in size; the genomes of the pathogenic M. tuberculosis and M. 
leprae are 4.41 Mb and 3.3 Mb in size, respectively. This suggests that pathogenic 
mycobacteria have evolving towards pathogenicity by the loss of its genetic material. 
The adaptation to a pathogenic life style and permanent association with a host has led 
to the loss of genes indicating that a minimal gene set is needed for a successful obligate 






Figure I.3. The devolution of mycobacteria. Diagram shows the reduction of genome size 
among some environmental non-pathogenic and pathogenic mycobacteria, and obligate 
pathogens. In the Figure were not considered the time and genetic events preceding speciation. 
Based on 461a. Genome sizes were obtained from National Center for Biotechnology 
Information (NCBI) (http://www.ncbi.nlm.nih.gov/, last access May, 2014).   
 
Due to the high degree of conservation among M. tuberculosis complex species it has 
been suggested that they underwent an evolutionary bottleneck at the time of speciation 
(59). The second suggestion state that the ancestral form of M. tuberculosis was M. 
bovis (418) and that the evolution of M. tuberculosis from M. bovis results in a more 
restricted host range, from an animal to a human pathogen. However, both hypotheses 
came before the revolution brought by the characterization of the M. tuberculosis 
genome and also before the comparative genomics uncovered several variable genomic 
regions in the members of the M. tuberculosis complex (59). The differentiation 
between the various species belonging to the M. tuberculosis complex can be made by 
the analysis of the presence or absence of 20 regions of difference on their genome 
(Figure I.4). M. tuberculosis complex RDs comprise the RD1 to RD14, ranging from 




RvD1 to RvD5 and a M. tuberculosis specific deletion, TbD1, that is absent from the 
strain H37Rv. M. canettii possess all RDs, RvDs and TbD1; additionally it have a 
specific deletion that partially overlaps RD12, RDcan (59). M. africanum strains possess 
the six regions absent in H37Rv, but lack RD9 (M. africanum type I) and RD9 plus 
RD7, RD8 and RD10 (M. africanum type II); M. microti lacks RD7, RD8, RD9 and 
RD10 and possess a specific deletion, RD1mic, that partially overlaps RD1. M. mungi do 
not possess the RD7, RD8, RD9 and RD10 and have a specific deletion, RDmun. M. 
orygis, unlike M. microti, the dassie bacillus, and M. mungi, has an intact RD1 and a 
specific deletion of RD12 (457). M. pinipedii like M. orygis, M. microti, the dassie 
bacillus, and M. mungi, do not have the RD7, RD8, RD9 and RD10 but shows a specific 
deletion, RDseal. M. caprae shows the deletion of RD7, RD8, RD9, RD10, RD12 and 
RD13, and M. bovis additionally presents the deletion of RD4. M. bovis BCG strains 
display a large number of deletions, from RD1 to RD14. The dassie bacillus is a rare 






Figure I.4. RD deletion based phylogeny of the M. tuberculosis complex. Simplified 
evolutionary pathway of M. tuberculosis complex based on the works of Brosch et al. (59) and 
van Ingen et al. (457). 
 
Molecular typing  
In the last decades, several genotyping methods have been developed for the 
differentiation of M. tuberculosis strains. The majority of the methods used for 
molecular typing target repetitive units in the mycobacterial genome, either interspersed 
repeats (direct repeats or insertion sequence) or tandem repeat (264). The most widely 
used molecular typing method for M. tuberculosis complex isolates is the IS6110 
restriction fragment length polymorphism (IS6110-RFLP). The IS6110-RFLP typing is 




insertion element with 1361 bp that is randomly dispersed in the M. tuberculosis 
genome (443; 455). The IS6110 insertion sequence was first described by Thierry et al. 
(444) and until recently was thought to be exclusive to the M. tuberculosis complex. 
The IS6110 was found in the genome of M. smegmatis and named ISMs6110 (91). The 
difference between the ISMt6110 and ISMs6110 is that the later lacks one inverted 
repeat. These transposable elements have been shown to be involved in gene disruption 
(374). The IS6110 insertion sequence varies in number (0 to ≈25) and position within 
the genome generating a high level of DNA polymorphism among strains (459). It is 
also known that the insertion of IS6110 can alter bacterial gene expression. Depending 
on the location, the IS6110 insertion sequence may upregulate the expression of 
downstream genes by acting as a promoter (13; 35). This activity has been demonstrated 
for upregulation of the two-component regulatory system PhoP/PhoR (410). The 
IS6110-RFLP has been used to infer genetic relationships between M. tuberculosis 
strains with high (≥6) IS6110 copy number. It has low sensitivity for the 
epidemiological study of strains with low (<6) copy number (97). The IS6110-RFLP 
analysis requires (i) restriction endonucleases (PvuII) to cleave the genomic DNA, 
originating DNA restriction fragments of different sizes that can be visualized by gel 
electrophoresis, (ii) hybridization with a labelled DNA probe complementary to the 
IS6110 sequence, and (iv) detection of the labelled probes by autoradiography (459). 
The resulting banding pattern is characteristic of a M. tuberculosis strain. Despite its 
widespread use, this method has several limitations: (i) it can only be applied to cultures 
since requires large amounts of DNA; (ii) is time consuming and labour intensive; (iii) 
it cannot accurately differentiate low copy number strains; (iv) is expensive; (v) and 
does not allow to perform inter-laboratory comparisons with confidence due to the 
complexity on the interpretation of the results obtained. Nevertheless, this methodology 
was the basis for the current knowledge about the transmission dynamics of M. 
tuberculosis strains in different regions of the world. Besides, it has the capacity to 
evaluate (i) exogenous reinfection and mixed infections; (ii) the impact of drug 
resistance on transmission and pathogenesis; (iii) the geographical distribution and 
global dissemination of M. tuberculosis strains; detect outbreaks and laboratory 
contamination; and track contacts, among others. To bypass the several limitations 




namely spoligotyping (204) and mycobacterial interspersed repetitive units-variable 
number tandem-repeats (MIRU-VNTR) typing (427). 
Spoligotyping (for spacer oligotyping) is based on the polymorphisms of the 
chromosomal direct repeat (DR) locus of the M. tuberculosis complex genome, that 
contains a variable number of copies of direct repeats of 36 bp interspersed with unique 
nonrepetitive sequences (34 to 41 bp) (204), which together are termed direct variable 
repeat (DVR) sequences. Isolates of M. tuberculosis complex generally differ in the 
presence or absence of one or more spacers and adjacent DRs (456). The DR region of 
M. tuberculosis is also a hotspot region for the integration of the IS6110 (146; 204; 
478). The presence or absence of the DRVs is evaluated through polymerase chain 
amplification (PCR) of the DVRs with the standard set of primers (DRb and DRa-5′-
biotinylated) and subsequent hybridization in a membrane containing 43 different DVR 
sequences. Following the hybridization, the membrane is incubated with streptavidin-
peroxidase and the hybridization signals visualized by chemiluminescence (164). This 
technique is faster and easier to perform than the IS6110-RFLP typing and requires 
smaller amounts of DNA. Spoligotyping presents high sensitivity to detect and 
discriminate among isolates with low IS6110 copy number (164). However, the 
observation that the DRVs may undergo convergent evolution, leading to 
epidemiologically unrelated strains sharing identical spoligotype patterns (479) is the 
main limitation of this molecular typing method. Nevertheless, spoligotyping can be 
useful to study population structure of M. tuberculosis strains in several geographical 
areas, since the evolution of the DRs created unique spoligotype signatures. The strains 
that evolved from a common ancestral can be grouped into evolutionary lineages 
according to unique spoligotype signatures (423). The simplicity of this method has 
allowed the establishment of an international spoligotype database, originally named as 
SpolDB (version 1 to 4) (61) and now updated to SITVITWEB, which describes 62 582 
clinical isolates from 153 countries (119). 
Mycobacterial interspersed repetitive units (MIRU) typing has become the most 
important method for M. tuberculosis complex typing, as it allows high-throughput, 
discriminatory and reproducible analysis of M. tuberculosis clinical isolates. MIRU is a 
M. tuberculosis complex specific name (428; 429), for a multiple locus VNTR (variable 




VNTRs, corresponds to a location in a genome where a short nucleotide sequence is 
organized as a tandem repeat (clustered together and oriented in the same direction) 
(472). VNTR typing relies on multiplex PCR amplification using specific primers for 
the flanking regions of the VNTRs. The determination of the sizes of the amplicons is 
done by electrophoresis. As the length of the repeat units is known, the number of 
VNTR copies is given by the sizes of the bands obtained (204). The final result is a 
numerical code, corresponding to the repeat number in each VNTR locus (Figure I.5). 
VNTRs sequences comprises exact tandem repeats (ETR) (157), MIRUs and QUB 
(Queen's University Belfast)-VNTRs (364; 405). MIRUs are minisatellite-like structures 
with 40±100 bp found as tandem repeats and scattered in 41 intergenic regions of the M. 
tuberculosis genome (429). A collection of 186 strains representing the major M. 




Figure I.5. MIRU-VNTRplus data table. For each strain is shown the identification, the 
species and lineage followed by the MIRU-VNTR pattern, in blue, and the spoligotyping 
pattern. An UPGMA tree is used for cluster the strains (MIRU-VNTRplus web page at 
http://www.miru-vntrplus.org/, last access May 2014).  
 
The MIRU-VNTR application allows the input of copy numbers for 24 MIRU-VNTR 
loci, a highly discriminatory subset of 15 loci or the original 12 loci (427; 429), 
spoligotyping patterns, regions of difference profiles, single nucleotide polymorphisms 
(SNPs), susceptibility data, and IS6110 RFLP fingerprint images (12; 427; 487). As a 
basis for standardized MIRU-VNTR typing of M. tuberculosis, the 15 MIRU-VNTR is 
proposed to be applied to epidemiological studies and the 24 loci for phylogenetic 




several advantages such as rapidness, it’s easier to perform, cheap, appropriate for all 
M. tuberculosis isolates, even for IS6110 low-copy strains and allows easy and rapid 
inter-laboratory comparison of the results. Several studies show that MIRU-VNTR-
based typing possess a discriminatory power similar to that of IS6110-RFLP typing 
which could be further enhanced when combined with spoligotyping (139; 407; 425). 
 
M. tuberculosis complex molecular epidemiology and lineages 
The development of molecular techniques for genomic analysis, such as those referred 
in the previous section, has revealed that species belonging to M. tuberculosis complex 
can be divided into lineages, sub-lineages, clusters or families (92). However, the 
markers upon which these techniques are based change quite rapidly, making it hard to 
describe deep phylogenetic relationships (158). The large sequence polymorphisms 
(LSPs) represent unique event polymorphisms and this analysis can be used to establish 
M. tuberculosis phylogenies (192). Gagneux et al. (158) used the LSPs and the regions 
of difference TbD1, RD7, RD8, RD9, RD10 and RDcan plus the 7-bp deletion in the 
pks15/1 locus to describe the six main lineages of M. tuberculosis complex (Figure I.6) 
which are associated with particular populations. Lineage 1 corresponds to the Indo 
Oceanic; lineage 2, East Asia; lineage 3, East African Indian; lineage 4 comprises Euro-
American, West Africa, South Africa, and Central Africa; lineage 5, West African-1; 
and lineage 6, West African-2. With the application of spoligotyping, a total of six 
lineages and several sub-lineages within the M. tuberculosis complex have been defined 
(119; 151). These lineages correspond to the previously ones identified in the work by 
Gagneux et al. (158) (Figure I.6). Spoligotyping based lineage East African-Indian and 
Manu corresponds to the previous lineage 1; Beijing lineage, lineage 2; Central Asian 
(CAS), lineage 3; X, Haarlem, LAM (Latin American Mediterranean) and Uganda, 
lineage 4; AFRI1 (africanum type 1), lineage 5; AFRI2 (africanum type 2), and BOV, 
M. bovis lineage (151). Demay et al. (119) defined the spoligotyping based lineage 
PINI, which corresponds to M. pinnipedii strains. Recently was identified the M. 
tuberculosis lineage 7 which seems to be, so far, associated strictly with the Horn of 
Africa (154). Other studies have used single nucleotide polymorphisms (SNPs) for the 




Figure I.6. M. tuberculosis phylogenies and the geographic regions associated. At the right it 
is presented the M. tuberculosis phylogenies defined by the analysis of LSPs as defined by 
Gagneux et al. (158) except for lineage 7 that was defined by Fridessa et al. (154). Region of 
difference are shown in rectangles. At the left is shown the spoligotyping based lineages as 
defined by the work of Filliol et al. (151). The spoligotyping based BOV lineage was defined in 
the work by Demay et al. (119).  
 
Spoligotyping, single nucleotide polymorphisms, and large sequence polymorphisms 
presents with different discriminatory power and not always coincide. Therefore, it 
becomes challenging to establish M. tuberculosis complex lineages. MIRU-VNTR 
typing has allowed achieving not only a significantly higher discrimination, but also 
provided with a new insight on M. tuberculosis complex evolution (119). This 
methodology can be used to classify M. tuberculosis complex isolates; however, it is 
needed further analyses to study all the 24 loci individually and search for the 







































































Molecular epidemiology of M. tuberculosis strains in Portugal 
According to the World Health Organization, there were an estimated 8.6 million 
incident cases of tuberculosis in 2012 and 1.3 million deaths were attributed to the 
disease. The emergence and spread of drug resistant strains of M. tuberculosis is 
becoming dramatically worse every year. An estimated 450 000 new cases of multidrug 
resistant tuberculosis with 170 000 deaths associated occurred globally in 2012 (506). 
Only about 84 000 (19%) of these were laboratory confirmed, in part, because of the 
lack of laboratory capacity in many resource-limited settings. Conventional drug 
susceptibility testing involves culturing the bacteria from a clinical specimen and 
determining if the bacteria can grow in media containing the antituberculosis drugs and 
that requires an operational and quality assured network of tuberculosis laboratories. 
The lack of such support associated with tuberculosis control and drug observed 
therapies programs inadequately implemented are nowadays favoring the selection and 
spread of drug resistant forms of M. tuberculosis. Although theoretically any M. 
tuberculosis strain can develop drug resistance, there are a number of strains into 
distinct lineages that have demonstrated a particular tendency to become multidrug 
resistant. It had been shown that strain type plays a role not only in disease outcome, 
variation in vaccine efficacy but also in the emergence of drug resistance (155). Strain 
type also influences disease epidemiology as in some settings it is associated with the 
presence or absence of clustering due to recent transmission (210; 328). Lineage-
specific traits in the virulence and predisposition to acquire drug resistance of clinical 
isolates have been reported within modern lineages, such as Beijing and Euro-American 
Haarlem strains that are believed to exhibit more virulent phenotypes compared to 
ancient lineages, such as East African Indian and M. africanum strains (155; 355). The 
molecular mechanisms and genetic factors responsible for the described differences in 
pathogenesis, virulence and ability to acquire resistance remain largely unknown and it 
is expected that the recent efforts with the whole-genome sequencing projects will shed 
some light to this. 
In 2002, the Portuguese National Health Authorities recorded a tuberculosis incidence 
of 41 new cases per 100 000 inhabitants, with 12.7% cases of multidrug resistant 




number of cases decreased to 20.4 new cases per 100 000 inhabitants with an average of 
0.87% cases of multidrug resistant tuberculosis (129). However, despite the significant 
decline in tuberculosis incidence in the recent years, Portugal hasn't reached, yet, the 
goal of the < 20 cases/ 100 000 inhabitants to be considered a low incidence country. 
The main problem is prevalence of multidrug drug resistant tuberculosis and, in 
particular, extensively drug resistant tuberculosis. From the 0.56% cases of multidrug 
resistant tuberculosis reported in 2012, 20% corresponded to extensively drug resistant 
tuberculosis (128). Multi- and extensively drug resistant tuberculosis constitutes a major 
preoccupation mainly in the three main urban centres, Lisbon, Porto and Setubal (129).  
The study of the genetic diversity of the M. tuberculosis strains circulating in Lisbon 
over these years allows us to observe that the majority of the multidrug resistant M. 
tuberculosis strains circulating in Lisbon belong to a genetically related group (324; 
326, 327). It was found that the prevalence of this group of strains among multidrug 
resistant M. tuberculosis strains was almost 90% (324; 326). Furthermore, it is now 
recognized that approximately 20% of all multidrug resistant strains circulating in 
Lisbon are extensively drug resistant (128). This group of strains was identified in 1998 
by IS6110-RFLP in a study comprising the characterization of 99 multidrug resistant 
strains from 14 hospitals of Lisbon (339). It was found that 88.9% of the strains were in 
cluster. Four clusters were identified, the cluster A, B, C and D, each one harbouring a 
distinct IS6110-RFLP profile. From the four clusters, cluster A was the predominant 
comprising 75% of the strains. This cluster was at the time associated with an outbreak 
of multidrug resistant tuberculosis among a majority of HIV-positive patients and drug 
abusers (340). Strains from cluster A display similar RFLP patterns being characterized 
by the presence of 11 to 13 IS6110 bands. Because of this, cluster A was divided in 
three sub-clusters, A1, A2, and A3. Cluster A is now designated by Lisboa Family 
(342). So far, were reported 11 different clusters belonging to Lisboa Family (324; 326; 
342). Among these, cluster Lisboa3 is the most prevalent. Cluster Lisboa3 can be 
divided in Lisboa3A and Lisboa3B based on IS6110-RFLP patterns; cluster Lisboa3A 
comprises an extra IS6110 copy whereas cluster Lisboa3B comprises 3 extra copies of 
IS6110 (329). These strains are divided in two related clusters as defined by MIRU-
VNTR. The two main genetic clusters correspond to the clusters Lisboa3 and Q1 (329). 




(110; 324). Lisboa3 can be assigned to LAM1 sublineage and Q1 to LAM4 sublineage 
(329). Cluster Q1 is genetically similar to the Lisboa family, although it presents less 
mutational diversity than the Lisboa3 cluster (324; 326). Cluster Q1 corresponds to the 
original cluster B determined by RFLP. The exact phylogenetic origin of cluster Q1 
with respect to the Lisboa family is still under study (Perdigão et al., unpublished). 
Lisboa Family has been associated mostly with multi- and extensively drug resistant 
tuberculosis; however, it also includes susceptible strains (342). Until now, no 
correlation has been established between the different clusters and drug resistance, i.e., 
among the same cluster there are strains with different susceptibility patterns (324; 326; 
327).  
These clusters of strains, mainly detected in the Lisbon region have been disseminated 
to other regions of the Portugal. The Lisboa Family is a threat to the control of 
tuberculosis since its prevalence over the years suggests that these strains may possess 
selective advantages over other strains with different genetic backgrounds (469). 
 
Pathogenesis of tuberculosis  
M. tuberculosis infects about one third of the world’s population. However, only less 
than 10% will developed the disease. The majority of the infected individuals 
successfully contain the infection due to an efficient immune system (451). These 
individuals are non-infectious and do not present symptoms of the disease. This status is 
called clinical latency - or latent infection - and can endure through the individual life 
time. Nonetheless, a perturbation of the host immune system response can lead to the 
reactivation of the infection (450). The consequences of M. tuberculosis infection are 
dependent on the virulence of the infecting strain as well as the resistance of the 
infected host.  
M. tuberculosis is disseminated by airborne droplet nuclei, which can be transmitted 
from of a person to another. When an infected individual coughs, the dispersed droplets 
can be inhaled by a new host (451). The exhaled droplets can remain in the air during 
several hours and the infectious dose is estimated to one bacterium (368). When the 




macrophages and transported across the alveolar epithelium into the lungs (106; 450). 
The entry of M. tuberculosis into the macrophage is mediated by several receptors, 
including, scavenger receptors, complement receptors, and the mannose receptor (311). 
In response to the presence of mycobacteria, and at least partly through interactions of 
mycobacterial components with Toll-like receptors, the macrophages induce a localized 
pro-inflammatory response that leads to the recruitment of mononuclear cells from 
neighbouring blood vessels (368; 451). Production of tumour necrosis factor (TNF-α) 
and inflammatory chemokines from the infected macrophages serves as signals for the 
recruitment of additional cells (278; 368; 451). These includes neutrophils, natural killer 
T cells, CD4+ and CD8+ T cells, each of which produce their own set of chemokines and 
cytokines that increase cellular recruitment and modification of the infection site (368). 
The migration of macrophages and T and B cells to the site of infection culminates in 
formation of a localized nodular inflammation, the granuloma, or tubercle, which is the 
pathological hallmark of tuberculosis (452). The primary parenchymal focus is called as 
Ghon focus and usually drains via local lymphatics to the regional lymph nodes. The 
combination of the Ghon focus, local lymphangitis and regional lymph node 
involvement is known as the Ranke complex (114) and is often morphologically 
observed as a calcified granulomatous lesion. 
Granulomas are organized and dynamic structures composed by infected macrophages 
surrounded by foamy macrophages, dendritic cells, multinucleated Langhans giant cells, 
endothelial cells, and a mantle of lymphocytes in association with a fibrous cuff of 
collagen and other extracellular matrix components that delineates the periphery of the 
granuloma (106; 368; 452). During infection the granuloma evolves from cellular 
granulomas to necrotizing granulomas (Figure I.7) (106; 368). The necrotic core, or the 
caseum, due to its cheese-like appearance, results from both host and bacterial cell lysis. 
The caseum initially forms in the center of the granuloma and spreads outwards (Figure 
I.7-II). As the granuloma matures, it often develops several layers of fibroblasts (fibrous 
cuff), limiting the spread of the infection. A cavity is formed when the granuloma 
comes into contact with an airway, which involves transformation of the granuloma into 
a cavity made of a fibrotic wall filled with liquefied caseum that is directly connected to 




contributes to the accumulation of infectious necrotic material in the lumen that can be 
coughed up to spread mycobacteria to other individuals (86).  
 
 
Figure I.7. Maturation of the granuloma. (I) Cellular granuloma where the bacilli reside 
extracellularly and in activated and foamy macrophages; (II) Necrotic granuloma, bacilli can be 
found extracellularly in the necrotic caseum and in immune cells; (III) Cavity formation, bacilli 
are found extracellularly in the cavity caseum and intracellularly in macrophages, foamy 
macrophages and neutrophils. Both intracellular and extracellular bacteria are released at the 
luminal side of the cavity and later appear in sputum. Reproduced with permission from 
Macmillan Publishers Ltd (106).  
 
Although granuloma formation is regarded as an attempt to contain the spread of the 
bacilli, several studies have shown that pathogenic mycobacteria use granuloma cells to 
expand, disseminate and colonize nascent granulomas (113; 288). Infection of 
macrophages with M. tuberculosis can results in necrosis, defined by cell lysis, which 
allows their escape from macrophages and their spread to the surrounding macrophages 
(36; 311).  
In addition, the granuloma functions as an immune microenvironment to facilitate the 
interaction between T cells and macrophages and cytokines (368). CD4+ and CD8+ T 
cells are important producers of Th1-type cytokines, such as IFN-γ (interferon gamma) 
and TNF-α which act synergistically to activate M. tuberculosis-infected macrophages. 
The activation of infected macrophages will lead to the upregulation of the inducible 
nitric oxide synthase, resulting in the production of reactive nitrogen intermediates, such 
as nitric oxide. Reactive nitrogen intermediates, together with reactive oxygen 
intermediates, exerts antimycobacterial effects, which lead to the reduction of bacterial 
burden (232). However, this structure can also provide a house for M. tuberculosis for a 





events that results in the formation of a phagosome around the phagocytosed bacteria. 
Usually the phagocytosed material is degraded in lysosomes, a process called autophagy 
(122). Phagocytosis of pathogenic microorganisms by macrophages and neutrophils 
consist in the first step for their eventual degradation, as the phagosome eventually 
matures into a phagolysosome rich in acid hydrolases with degradative and microbicidal 
activity (450). However, M. tuberculosis inhibits phagolysosomal fusion and persists in 
the phagosome, preventing acidification of the phagosomal compartment (21; 175). 
Subsequent studies demonstrate that the vacuoles containing mycobacteria are not 
acidic (98). The basis for the acidification defect was provided by studies showing that 
mycobacterium-containing phagosomes exclude the vesicular proton ATPases (424). 
The presence of the bacillus within the granulomas hinders drug delivery and represents 
a further concern to the control of the disease. To reach the center of necrotic 
granulomas, where quiescent extracellular bacilli are found (39), drugs must diffuse 
from the periphery to the necrotic center and penetrate in the caseous region (106). The 
presence of intracellular bacteria creates an additional obstacle since the drugs must 
permeate the cell in which the bacterium resides. To circumvent this problem, some of 
the innovating approaches rely on liposomes (211; 474) and nano-based drug delivery 
systems for encapsulation and release of antituberculosis drugs (161; 167; 409). 
Targeted drug delivery into macrophages can reduce toxicity and increase drug levels 
inside the lesion. Liposomes and nanoparticles function as particulate carriers that target 
the macrophages by taking advantage of their phagocytic properties (106). All these 
drug delivery systems have considerable potential for treatment of tuberculosis. 
 
Macrophages: a central element to control the pathogenesis of tuberculosis  
 
The initial infection of the macrophage results in the production of pro-inflammatory 
cytokines such as interleukins (IL) IL-6, IL-1, IL-12 and TNF-. T-cell responses are 
shaped by interactions with dendritic cells, which depend on the innate immune 
response against M. tuberculosis. Th1 T cells produce IFN- and promote mycobacterial 
killing by infected macrophages. Th17 T cells secrete IL-17 and are important for 
protective vaccine-induced responses. The role of Th2 T cells in host defence against M. 




demonstrated that the key cells and factors for the control of tuberculosis reside in the 
combination of innate and adaptive responses that influence the macrophage response 
against M. tuberculosis infection as well as the clinical outcome (106; 368; 452). 
Macrophages are phagocytes with innate immunity functions in non-specific defence 
but are also the cells that initiate the host specific defence mechanisms (adaptive 
immunity). Their role is to phagocytose - engulf and then digest - cellular debris and 
pathogens and also stimulates lymphocytes and other immune cells to respond to 
pathogens. When a macrophage ingests a pathogen like M. tuberculosis, he becomes 
confined inside the phagosome, which then fuses with a lysosome. Within the 
phagolysosome, enzymes and toxic peroxides are supposed to promote the acidic 
digestion of the bacteria. However, M. tuberculosis, resist to this programmed 
elimination in the phagolysosome releasing a number of inhibitors of the 
antimycobacterial effector functions of the macrophages, such as generation of reactive 
oxygen intermediates (H2O2), the release of reactive nitrogen intermediates (e.g. nitric 
oxide) that prevents the acidification of the phagolysosome, as well promotes the 
slowdown of the pro-inflammatory response by decreasing the secretion of the above 
mentioned cytokines (368; 452). The result of this concerted action allows M. 
tuberculosis to survive within the macrophages maintaining a vicious circle of (i) 
preventing fusion of phagosomes with lysosomes; (ii) avoiding hydrolysis within the 
acidic phagolysosomes of the activated macrophages; (iii) promoting their replication 
inside the macrophage until the burst of the infected macrophage and the release of new 
bacilli to the surrounding. This circle of phagocytosis-apoptosis-necrosis runs 
uncontrolled until the granuloma emerges and contains the spread or, under 
immunosuppression, contention is not possible and active disease will outcome (106). 
At this time, the infection is in the lungs, and with severe cavitary disease the bacteria 
will, via lymphatic and capillaries, reach and infect other organs (disseminated 
tuberculosis). In more than 90% of the infected individuals the mycobacterium is 
contained inside the granuloma with no presentation of clinical symptoms (latent 
tuberculosis). Up to 10% percent of those with latent M. tuberculosis infection will 
eventually develop clinically active disease that manifests as localized pulmonary 




The clinical diagnosis of tuberculosis is a paradigmatic example of how the clinician 
needs the support of complementary exams to confirm the clinical suspicion. From the 
anamnesis to the physical exam, the gathering of cardinal signs of tuberculosis (cough, 
weight loss, fever, night sweats, and asthenia) needs to be complemented with strong 
evidences coming from lung radiology and the immune based tests, the tuberculin skin 
test (TST) and the interferon gamma release assays (IGRA). Both measure a person’s 
immune reactivity to M. tuberculosis. In the TST or Mantoux test (the intradermal 
injection is termed the Mantoux technique) a standard dose of purified protein 
derivative (PPD), usually 5 tuberculin units, is injected intradermally and the induration 
caused read 48 to 72 hours later. A person who has been exposed to M. tuberculosis is 
expected to mount an immune response in the skin, measured by the diameter of the 
induration raised, proportional to how recent this contact was (334). In the IGRA tests, 
white blood cells from individuals that have been infected with M. tuberculosis will 
release IFN- when mixed with purified antigens derived from M. tuberculosis (mainly 
CPD-10 and ESAT-6) (229). The lymphocytes of a person who has been exposed to M. 
tuberculosis is expected to release IFN- at a level proportional to how recent this 
contact was. Complementary and essential to this diagnostic procedure is the mandatory 
request of support from the mycobacteriology laboratory for the detection, isolation and 
characterization of the bacilli causing the disease, the final confirmation that the patient 
has active tuberculosis. Global efforts to combat tuberculosis continue to be hampered 
by a lack of readily accessible and rapid laboratory services to establish the diagnosis of 
tuberculosis and monitor response to therapy. Of particular importance for the clinician 
or to any health system, is to obtain timely information on the drug susceptibility pattern 
of the infecting bacilli, with particular importance in countries such as Portugal, where 
high rates of multi- and extensively drug resistant tuberculosis are noticed, in order to 
optimize and adapt the multiple drug regimens to the most adequate and effective 
therapeutic combination. 
 
Laboratory diagnosis of tuberculosis 
The main priority of tuberculosis control programs is the rapid and accurate diagnosis 




intended to interrupt the chain of transmission of the bacillus and provide appropriate 
treatment to the patient. Therefore, the mycobacteriology laboratory has a major role in 
the diagnosis and management of tuberculosis. Diagnosis of active tuberculosis is 
mainly based on clinical suspicion, chest radiographs, microscopy, culture on solid and 
liquid media, and molecular identification. 
 
Isolation and identification of M. tuberculosis complex – conventional methods 
The conventional methods employed for the diagnosis of tuberculosis rely on acid fast 
staining, culture and phenotypic characterization. M. tuberculosis can be isolated from a 
wide variety of biological samples such as bronchial secretions, sputum, 
bronchoalveolar lavage fluid, gastric lavage, blood, bone marrow, urine, pleural fluid, 
cephaloraquidian liquid, biopsies, among others. The detection of acid-fast bacilli is the 
oldest diagnostic method used for the diagnosis of tuberculosis. Microscopic 
examination of smears for the detection of acid-fast bacilli by the Ziehl-Neelsen staining 
is simple, rapid, and inexpensive. In this procedure, the smears are stained with hot 
carbol fuchsine, decolorized with 25% sulphuric acid and ethanol, and counterstained 
with methylene blue. Mycobacteria will appear as red cells against a blue background. 
In spite of the high specificity of the procedure, its sensitivity has been reported to vary 
from 20 to 80% (419; 420) and frequently negative among HIV-infected patients due to 
its atypical presentation (320). Other staining methods have been developed to improve 
the sensitivity and specificity of the detection, which includes the fluorescent auramine-
rhodamine staining (419). This technique is more rapid than the Ziehl-Neelsen staining 
and increases the sensitivity by almost 10% (419). This increased sensitivity allows the 
reduction in the number of samples analysed, thereby decreasing workload and speeding 
up diagnosis (449). However, is more expensive due the maintenance of the 
fluorescence microscope. Besides, these methodologies do not distinguish between M. 
tuberculosis and nontuberculous mycobacteria. The identification of smear-positive 
patients is of major importance since it is directly related with the degree of the 
infection and the severity of the disease. As such, culture remains the gold standard for 




Mycobacterial culture allows species identification, drug susceptibility testing, 
monitoring the response to drug therapy and epidemiological studies. Culture is an 
expensive method, since the majority of these microorganisms do not grow in common 
culture media, requiring the employment of specific media (for a more detailed 
description see ref. 471). Besides, M. tuberculosis slow growth rate complicates its 
detection. For isolation of M. tuberculosis and other mycobacterial species from 
biological samples, three main types of media can be employed: egg-based medium 
(Löwenstein-Jensen), medium with agar (Middlebrook 7H10 and 7H11) and liquid 
medium (Middlebrook 7H9, 7H12 and 7H13). Among the solid media, the Löwenstein-
Jensen medium is the most widely used. Growth detection takes approximately two to 
six weeks depending on the media used and the species of mycobacteria. Growth of M. 
tuberculosis on Löwenstein-Jensen medium is regarded as rapid and luxurious or 
eugonic. Contrary, M. bovis grows poorly on normal Löwenstein-Jensen medium with 
small and flat dysgonic colonies (481). The development and implementation of liquid 
culture media allowed the reduction of the time to detection of positive cultures 
providing a more rapid diagnosis. The commercial liquid-based culture systems can be 
manual, semi-automated or automated using radiometric, colorimetric or fluorometric 
detection methods. The liquid media generally used is the Middlebrook 7H9 or the 
Middlebrook 7H12/7H13, depending on the system and the source of the specimen. 
Examples of these systems include the BACTEC®460TB, BACTEC®MB9000, 
BACTEC®MGIT®960 or 320 and the manual MGIT, the Septi-Chek AFB® systems 
(Becton Dickinson Instrument systems, Sparks, MD, USA), the ESP® (Extra Sensing 
Power) Myco-ESPculture System II® (Trek Diagnostic Systems, USA), and the 
BacT/ALERT MB® (bioMérieux, S.A. Marcy-l’Etoile, France). The most widely used 
is the BACTEC system, in its two versions: (i) the BACTEC-460TB semi-automated 
radiometric system based on the works performed by Cummings et al. and Middlebrook 
et al. (100; 395). This system uses Middlebrook 7H12 media that contains a radioactive 
substrate, palmitic acid labelled with 14C, which is metabolized by the mycobacteria. 
Mycobacterial growth is detected by measuring the release of radioactive CO2 with the 
aid of a gas flow radio counter (395, 396). The BACTEC 460-TB system converts the 
radioactivity released into a growth index (GI), ranging from 0 to 999; (ii) the BACTEC 




widely used for the isolation of mycobacteria. For mycobacterial growth, is used 
growth-indicator tubes (MGIT; Mycobacteria Growth Indicator Tube) containing 7 ml 
of modified Middlebrook 7H9 media and a gel with a fluorochrome (ruthenium) 
impregnated at the bottom of the tube. The increase in the fluorescence due to oxygen 
consumption, as a consequence of mycobacterial metabolism, is measured automatically 
by the system and converted into growth units (GU). Mycobacterial cultures, in 
combination with smear microscopy, have the potential to increase the sensitivity of the 
diagnosis of mycobacterial infections and constitute the basis of further testing, which 
includes drug susceptibility testing and mycobacterial species identification. Classically, 
the identification of M. tuberculosis complex is based on the observation of phenotypic 
characteristics and a battery of biochemical tests - growth rate, growth at different 
temperatures, colony morphology, pigment production, niacin production, catalase 
activity, nitrate reduction, susceptibility to thiophene-2-carboxylic acid hidrazide 
(TCH), among others (109). In spite of their standardization and application in several 
reference laboratories, these methods can give false-results, require trained personnel, 
are time consuming and extremely laborious, resulting in the delay of a result by several 
weeks. During the last decades, has been developed several molecular methods for the 
identification of M. tuberculosis from cultures or directly from clinical samples thus 
reducing the time to diagnosis.  
 
Molecular methods for the diagnosis of tuberculosis and drug resistance 
Molecular tools for the diagnosis tuberculosis have evolved quickly during the last 
years. The development of rapid, sensitive and specific molecular techniques for the 
detection and identification of M. tuberculosis and other mycobacterial species 
constitutes a great advance in the diagnosis of tuberculosis and other mycobacterial 
diseases. These methods are based on the detection of specific fragments of DNA (or 
RNA) of the mycobacteria by PCR and includes, among others, RFLP analysis, real-
time PCR, DNA sequencing, and nucleic acid hybridization (135; 439). Presently, 
nucleic acid amplification-based techniques have become widely used for the detection 
of M. tuberculosis. The identification of bacteria by the analysis of gene sequence is 




directly from specimens. Sequencing is considered the gold standard for the 
identification of mycobacteria and the ribosomal 16S rRNA is the most common target 
(446). The 16S rRNA is highly conserved among different species, however, it contains 
hypervariable regions that are species-specific and that can be used for a proper 
identification at species level (174). When the analysis of the 16S rDNA is not enough 
for species identification, other genes such as the 16S-23S rRNA intragenic region, 
rpoB, gyrB, hsp65, recA and sodA can be used (3; 365). 
Among the commercially available methods for the direct detention of M. tuberculosis 
complex isolates are the enhanced amplified M. tuberculosis direct test (EMTD; Gen-
Probe, Inc., San Diego, Ca) and the Amplicor Mycobacterium tuberculosis test 
(Amplicor, Roche Diagnostic Systems Inc., Branchburg, NJ). Both tests are certified for 
the direct detection of M. tuberculosis in clinical specimens (71). The EMTD is an 
isothermal transcriptase-mediated amplification system and is the first FDA-approved 
direct test for helping to diagnose smear-positive and negative specimens (72; 76), 
whereas the Amplicor assay, which uses PCR amplification of the 16S rDNA with 
biotinilated primers and automatic colorimetric detection with the Cobas Amplicor 
system, is only validated for the use on respiratory samples with smear-positive acid-
fast bacilli (72; 103). 
The identification of mycobacterial isolates from cultures was, for many decades, based 
on biochemical tests and phenotypic characteristics, which are time-consuming, slow, 
dangerous for the operator due to the high load of bacilli needed to be manipulated, and 
frequently gives ambiguous results. Several molecular systems were developed to 
overcome these limitations and are now being used for the identification of 
mycobacterial isolates from cultures. The AccuProbe (Gen-Probe) uses DNA probes for 
the identification of M. tuberculosis complex, M. avium complex, M. avium, M. 
intracellulare, M. kansasii, and M. gordonae from cultures (233). This method is based 
on the hybridization protection assay methodology by using DNA probes labelled with 
acridinum ester, a chemiluminescent compound (249). The single-stranded DNA probes 
are complementary to the mycobacterial rRNA. After a step of sonication, the probes 
will form a stable DNA-RNA complex. The hybrids can be detected by light emission 
on a luminometer. The method is safe, easy to perform, highly sensitive and specific 




amplification with biotinylated primers, reverse hybridization with species-specific 
DNA probes that are immobilized on a membrane strip, and colorimetric detection of 
the hybridized probes. Two systems for the identification of M. tuberculosis and other 
mycobacterial species are commercially available: the INNO-LiPA Mycobacteria v2 
and the GenoType Mycobacterium CM/AS. The INNO-LiPA Mycobacteria v2 
(Fujirebio Europe, Ghent, Belgium) is based on the amplification of the 16S-23S rRNA 
intragenic region and allows the identification of 17 mycobacterial species: M. 
tuberculosis complex, M. avium, M. intracellulare, M. scrofulaceum, M. kansasii, M. 
xenopi, M. chelonae, M. gordonae, M. fortuitum complex, M. malmoense, M. 
genavense, M. simiae, M. smegmatis, M. haemophilum, M. marinum/M. ulcerans and 
M. celatum. Besides, it can differentiate subspecies within M. kansasii and M. chelonae 
(INNOLiPA V2 package insert, 2005). The GenoType Mycobacterium (Hain 
Lifescience, Nehren, Germany) includes a multiplex PCR, followed by reverse 
hybridization on a membrane strip and colorimetric detection of the hybridized probes. 
There are available three identification systems: (i) the GenoType MTBC for the 
differentiation within M. tuberculosis complex; (ii) the GenoType Mycobacterium CM 
(common mycobacteria), and (iii) the GenoType Mycobacterium AS (additional 
species). The GenoType MTBC uses specific fragments of gyrB gene, 23S rDNA and 
the RD1. The analysis of gyrB polymorphisms allows the differentiation within M. 
tuberculosis complex (304). M. bovis BCG can be detected by the absence of the RD1 
(436). The amplification of the 23S rDNA covers the Gram-positive bacteria with a 
high content of G+C (amplification control) and all members of the M. tuberculosis 
complex (357). The GenoType CM/AS assays have as target the 23S rDNA gene. 
Combined, the GenoType CM and AS allows the identification of 29 mycobacterial 
species: M. tuberculosis complex, M. avium, M. intracellulare, M. chelonae, M. 
abscessus, M. fortuitum, M. gordonae, M. scrofulaceum, M. interjectum, M. kansasii, 
M. malmoense, M. marinum, M. ulcerans, M. peregrinum, M. xenopi, M. simiae, M. 
mucogenicum, M. goodii, M. celatum, M. smegmatis, M. genavense, M. lentiflavum, M. 
heckeshornense, M. szulgai, M. phlei, M. haemophilum, M. gastri, M. asiaticum and M. 
shimoidei (GenoType Mycobacterium CM/AS, package insert, 2010). The test if rapid, 




Next to the detection of M. tuberculosis complex is the detection of mutations 
associated with resistance to the main first and second line drugs. The methods 
available are based on the evidence that resistance associated mutations occur in 
specific regions of the genes whose products are targeted by these antibiotics (discussed 
in the next section). These include the INNO-LiPA Rif. TB (Fujirebio Europe), 
GenoType MTBDRplus, GenoType MTBDRsl (Hain), and the AID TB Resistance 
assay (GenID, Autoimmun Diagnostika, GmbH, Strassberg, Germany). In 2008, the 
World Health Organization endorsed two line probe assays for rapid screening of 
patients at risk of multidrug resistant tuberculosis in smear-positive samples, namely the 
INNO-LiPA Rif. TB and the Genotype MTBDRplus (502). In 2011, the GeneXpert 
MTB/RIF (Cepheid, Sunnyvale, CA) was endorsed by the World Health Organization 
for the direct detection of M. tuberculosis and resistance to rifampicin in smear-positive 
and negative samples (504). The INNO-LiPA Rif. TB uses a nested PCR for the 
detection of M. tuberculosis and mutations associated with rifampicin resistance, and 
can be used directly from clinical specimens and from cultures (467). The nitrocellulose 
strips contains 10 oligonucleotide probes, from which: one is specific for the detection 
of M. tuberculosis complex strains; five-partially overlapping probes that hybridize with 
wild type sequences (S1-S5), and four resistance probes (R) carrying the mutations 
D516V (R2), H526Y (R4a), H526D (R4b), and S531L (R5). The absence of 
hybridization one or more wild type probes indicates the presence of a mutation that can 
be detected with the hybridization of one of the mutation probes (INNO-LiPA Rif. TB, 
package insert, 2011). The GenoType MTBDRplus assay enables the simultaneous 
detection of the M. tuberculosis complex, the most common mutations in rpoB gene for 
rifampicin resistance and mutations in katG and inhA for isoniazid resistance. It uses a 
multiplex PCR and can be used directly on clinical specimens and cultures (Genotype 
MTBDRplus, package insert, 2009). The GenoType MTBDRsl is based on the same 
principle as the MTBDRplus but for the detection of mutations associated with 
resistance to second line drugs: gyrA gene for fluoroquinolone resistance, rrs for 
aminoglycosides and cyclic peptides, embB for ethambutol (Genotype MTBDRsl, 
package insert, 2009). This assay can be applied to smear-positive and negative 
specimens (191). The test was not approved to date for diagnosis due to the scarce 




AID TB resistance assays are modular line probe assays for the rapid detection of 
mutations associated with resistance to isoniazid and rifampicin (module 1), first and 
second line aminoglycosides and cyclic peptides (module 2), and fluoroquinolones and 
ethambutol (module 3). This is the only molecular assay that detects mutations 
associated with streptomycin resistance. These assays can be used directly in clinical 
specimens and cultures. The evaluation of the three modules for the direct detection of 
M. tuberculosis and mutations associated with resistance on smear positive respiratory 
and non-respiratory samples showed a high specificity, 100%, 97.1%, and 100%, 
respectively (359). 
The equipment required for line probe assays is the basic equipment available in a 
molecular biology laboratory, namely, a thermocycler and a water bath. The procedure 
is divided in four main steps: 1) sample processing; 2) DNA extraction from the 
decontaminated samples; 3) a nested or multiplex PCR (depends on the system used) 
with biotinylated primers followed by 4) reverse hybridization. Usually, they can be 
performed in 48 hours. The GeneXpert MTB/RIF  is a fully automated system and is 
based on a hemi-nested real-time PCR that targets the rifampicin resistance determining 
region (RRDR) of the rpoB gene. It uses plastic cartridges with multiple compartments 
that are supplied preloaded with buffers and lyophilized reagent beads necessary for 
sample processing, DNA extraction and for the heminested PCR. Before the analysis, 
the samples are treated with an inactivation solution (sodium hydroxide plus 
isopropanol) and incubated at room temperature in order to reduce biohazard risk (231). 
The results are automatically generated by the system with no operator intervention. 
The assay can be performed directly from a clinical sample or from decontaminated 
sputum pellet. Generally it can be done within two hours. 
All these molecular methods have been showed to be relatively fast and easy-to-perform 
while presenting high specificity and sensitivity. However they cannot replace the 
phenotypic testing due to their inability to detect all mutations associated with drug 
resistance as well the contribution of the phenotypic traits of the strain of M. 
tuberculosis to the overall resistance level, such as the impermeability of the cell wall 
and the efflux activity. These methods only detect the most frequent mutations 




the prevalence of mutations associated with resistance to the drugs covered by these 
assays, since they vary between different geographical regions (221).  
 
Drug susceptibility testing  
Susceptibility testing to first line antituberculosis drugs is essential for the 
administration of an appropriate therapy. However, if culture is a slow process, drug 
susceptibility testing is even more time consuming. The traditional methods for M. 
tuberculosis drug susceptibility testing consist on: (i) the absolute concentration 
method; (ii) the resistance ratio method; and (iii) the proportion method (70). All these 
methods use agar (MB7H10 or MB7H11) or Löwenstein–Jensen medium. For the 
absolute concentration method, the antibiotics are incorporated in the media as two-fold 
dilutions. This method corresponds to a minimum inhibitory concentration 
determination (MIC) and can be also performed by broth micro- and macrodilution, 
although standardization is easier with solid media. Resistance is defined as the lowest 
concentration of the drug that inhibits growth (<20 colonies). The resistance ratio 
method is very similar to the previous one, however with this method, variations on 
MICs values are controlled with the simultaneous testing of an isolate with different 
batches of the same antibiotic. The resistance ratio is defined as the MIC for the strains 
divided by the MIC for a reference strain. If the ratio is ≤2 the isolate is considered 
susceptible or resistant if ≥8. The proportion method is based on the premise that every 
wild type M. tuberculosis strain is not a homogenous population but instead contains a 
mutant subpopulation resistant to the antimycobacterial drugs together with a 
susceptible subpopulation. The difference between a resistant strain and a susceptible 
strain is that the proportion of resistant bacteria among the population is much higher in 
the resistant strain than in the susceptible one (70). The critical concentration of an 
antituberculosis drug is defined as the concentration that is required to eliminate more 
than 99% of the population of a control strain that never has been in contact with the 
drug. A strain is considered susceptible to a given drug tested at their critical 
concentration if among the population the proportion of resistant cells is less than 1% 
(critical proportion). The strain is considered resistant when the number of drug-




with the drug-free growth control. The proportion method correlates well with an 
effective clinical outcome and is the gold standard for M. tuberculosis drug 
susceptibility testing. However, when performed on solid media these methods provide 
results only after four  to eight weeks of incubation at 37°C. Moreover, the extended 
incubation time can result in degradation of the drugs. Therefore, the determination of 
the antibiotic susceptibility testing for M. tuberculosis requires more rapid and accurate 
procedures. The development of broth-based methods and the optimization of the 
proportion method to be used in these systems reduced significantly the time needed to 
complete the susceptibility test. Nowadays, the BACTEC MGIT 960 is the system of 
choice. Within this system, the susceptibility of a strain to a given antibiotic is 
determined as the ratio of the growth indexes between the tube containing the critical 
proportion of the test strain (1%) in drug free media and the strain in the presence of an 
antibiotic at its critical concentration.  
 
Tuberculosis chemotherapy and the emergence of drug resistance 
M. tuberculosis is a difficult therapeutic target, mostly due to its long generation time 
coupled with its ability to establish persistent infections (482). In addition, the 
localization and the pH of some lesions can limit or inhibit the access of the drugs. The 
drugs used for the treatment of tuberculosis, streptomycin, isoniazid, rifampicin, 
ethambutol and pyrazinamide, are designated as first-line, or essential, antibiotics (497) 
and form the basis of the great majority of drug regimens worldwide. The second-line 
drugs are reserved for the treatment of drug resistant tuberculosis (498). The purpose of 
tuberculosis chemotherapy is not only to cure the patients of the infection and prevent 
the relapse of the disease but also, sterilize the lesions and prevent the emergence of 
drug resistance. During infection a patient presenting with tuberculosis can harbour 
three different populations: (i) the first population corresponds to the actively growing 
extracellular bacteria that are usually present within aerated cavities; ii) the second 
population consists of intermittently growing bacilli; and (iii) the third population 
includes dormant bacilli that are present in lesions characterized by an acidic 
environment and under anaerobic conditions such as in inflammatory lesions or within 




three main properties: bactericidal activity, defined as their ability to kill actively 
growing bacilli rapidly; sterilizing activity, defined as their ability to kill the semi-
dormant bacilli; and capacity to prevent the development of drug resistance (Table I.2) 
(290; 291). In this context, we can make the distinction between agents that are able to 
eliminate the bacilli in vitro (bactericidal) from those drugs that have the capacity to 
sterilize the lesions in vivo. Among the first-line antituberculosis drugs, the most 
effective in the three categories mentioned above are isoniazid, rifampicin and 
pyrazinamide, respectively (290; 291). 
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 Legend: STR, streptomycin; INH, isoniazid; RIF, rifampicin; EMB, ethambutol; PZA, pyrazinamide.  
+++ to +/-: level of activity of antituberculosis drugs.  
 
As mentioned above, M. tuberculosis populations, irrespective of the location, consists 
on a mixture of a mutant subpopulation resistant to the antimycobacterial drugs and a 
drug susceptible subpopulation. Drug therapy can easily lead to the selection of resistant 
bacilli, since it will act only on the susceptible population. Thus, in order to prevent the 
selection of drug resistant mutants, the drug regimen should be based on a multiple 
therapy comprising the three activities simultaneously (bactericidal, sterilizing and 
prevention of emergence of resistance). 
In the past decades, a number of effective drug regimens have been described. Most 
regimens are given for six months, and this corresponds to the shortest duration of 
treatment required. The standard regimen recommended by the World Health 




(WHO/IUATLD) comprises an initial intensive phase with duration of two months with 
four drugs (isoniazid, rifampicin, pyrazinamide, and ethambutol or streptomycin), 
followed by a continuation phase with rifampicin and isoniazid used together during 
four months (498). Together, isoniazid and rifampicin eliminate more than 99% of the 
bacterial population during the first two months (137). During the continuation phase, 
rifampicin eliminates the dormant bacilli and isoniazid eliminates the rifampicin-
resistant mutants when they start growing. 
Drug resistant tuberculosis can be classified as acquired or primary drug resistance 
based on the history of the patient previous treatment. The World Health Organization 
defines acquired drug resistance as the isolation of drug-resistant M. tuberculosis from a 
patient with record of previous treatment. In patients who have not had prior treatment 
with antituberculosis drugs, the bacterial resistance is called primary resistance (499). 
The three main aspects that contribute to the development of drug resistance in M. 
tuberculosis are: the emergence of spontaneous mutations at low frequency, the 
selection of resistant mutants due to poor management of the disease (including 
inappropriate drug regimens and non-compliance) and transmission of drug resistant 
strains. 
Unlike other bacteria, M. tuberculosis harbours no plasmids and his population structure 
is essentially clonal, which suggests a limited role for horizontal gene transfer (298). 
Therefore, M. tuberculosis drug resistance arises through the accumulation of particular 
chromosomal mutations in the genes associated with the resistance to each 
antituberculosis drug individually (202; 347; 522). This indicates that the chromosomal 
loci responsible for the resistance to various drugs are not linked. Hence, the probability 
of development of resistance to more than one drug is the product of the probability of 
emergence of resistance to each one of them. The mutation rate for emergence of 
resistance to isoniazid and rifampicin in M. tuberculosis was estimated to be 10–8 and 
10–9 mutations/bacterium/cell division, respectively (108). Considering that cavitary 
lung lesions contains an average of 108 bacilli and in the solid caseous tuberculous 
lesions the concentration of bacilli reaches 104 to 105 (334), it is expected during 
monotherapy, to occur the selection drug resistant bacteria. For this reason, in order to 
prevent the emergence of resistance, as stressed before, tuberculosis treatment is and 




Molecular genetic basis of drug resistance 
The advances in the molecular biology field and the accessibility to the new information 
generated by M. tuberculosis whole genome sequencing have added significant 
knowledge concerning the resistance mechanisms to the main antituberculosis drugs. In 
this subsection, we will address the resistance mechanism for the first-line drugs, 
isoniazid, rifampicin, ethambutol, pyrazinamide, and streptomycin, and to the mainstay 
drugs for the treatment of multidrug resistant tuberculosis, fluoroquinolones, 
aminoglycosides and cyclic peptides.   
Isoniazid 
In the 1950’s, it was noticed that isonicotinic acid hydrazide (later known as isoniazid) 
had a high bactericidal activity against M. tuberculosis (42), that alongside with 
rifampicin, became the backbone of tuberculosis chemotherapy (498). While other 
mycobacterial species are less susceptible to this drug, M. tuberculosis is highly 
sensitive with minimum inhibitory concentrations ranging from 0.02 to 0.1 µg/ml. 
Isoniazid enters in the cells by passive diffusion and it’s primarily target are the mycolic 
acid biosynthesis (464). Isoniazid is a prodrug that needs to be converted in its active 
form with antituberculosis activity. This is achieved by the multifunctional catalase-
peroxidase enzyme KatG, product of katG gene (189; 517). When activated by KatG, 
isoniazid forms a hypothetical isonicotinic acyl radical that binds to the nicotinamide 
adenine dinucleotide (NAD) originating a ternary complex, the INH-NAD adduct, 
essential for the inactivation of the InhA enzyme (345; 366), which is the target of 
isoniazid (30). The InhA enzyme, encoded by the inhA gene, is an enoil-acil (ACP) 
reductase dependent of the nicotinamide adenine dinucleotide hydrogenase (NADH) 
belonging to the fatty acid synthase type  II system (FAS-II) (123; 259). M. tuberculosis 
has two FAS systems. The FAS-I accounts for the initial synthesis of fatty acids C16 to 
C18 and C24 to C26, used for the production of phospholipids (346). These C16-C18 fatty 
acids are then extended up to C56 by the FAS-II system to make precursors of mycolic 
acids, which are the essential constituents of the M. tuberculosis cell wall (260). KatG-
activated isoniazid leads to the ineffectiveness of InhA with consequent accumulation of 




(432; 464). In addition to its catalase and peroxidase activity, the KatG enzyme serves 
as both peroxinitritase (486) and NADH oxidase (401). It is also important to 
mycobacterial pathogenesis, since KatG enzyme counteracts the phagocyte oxidative 
burst (302). 
Isoniazid resistance is thought to be associated with a multiplicity of mutations affecting 
one or more genes, including the genes katG, inhA, ahpC, kasA, aphC-oxyR intragenic 
region and ndh. The great majority of the mutations responsible for isoniazid resistance 
in clinical isolates of M. tuberculosis occur in the katG gene. The katG region of the M. 
tuberculosis genome is highly variable and due to the presence of repeated sequences it 
becomes unstable. This fact may contribute to the increased likelihood of occurrence of 
mutations in this gene (518). KatG gene mutations can occur in the N-terminal and C-
terminal of the protein. The N-terminal region is associated with the active site of the 
enzyme (190) and most of the mutations that confer high levels of resistance are located 
between codons 138 and 350. The most common mutation on the katG gene is a point 
mutation in codon 315, where a serine is substituted by a threonine (S315T). This 
substitution is responsible for about 50-90% of the isoniazid resistant mutants 
worldwide and is associated with high-level isoniazid resistance (93; 168; 181). The 
most common polymorphism associated with the S315T mutation occurs in codon 463, 
where an arginine residue is replaced by a leucine (168; 190; 202). This substitution is 
not associated with isoniazid resistance as it occurs in the C-terminal of the protein and 
does not affect the activity of the protein (190). Several other mutations in katG have 
been reported. These include missense mutations, nonsense mutations, insertions, 
deletions, truncated regions and, more rarely, the complete deletion of gene (347; 517). 
katG gene mutations may lead to a reduction or the complete loss of the catalase-
peroxidase activity (188; 517) which results in the incapacity to activate isoniazid.  
The link between the synthesis of mycolic acids and isoniazid was done by Banerjee et 
al in 1994 (30) with the discovery that the inhA gene encodes the target of isoniazid, the 
InhA enzyme. The inhA gene is organized in an operon along with mabA gene (349). 
Mutations that occur in inhA promote a decreased affinity of isoniazid for NAD (30). 
Crystallography studies of the complex INH-InhA-NADH shown, that the pyridine ring 
of isoniazid is covalently bound with the NAD+ ring inside the active site of the enzyme 




bond (INH-NAD) that is responsible for the inhibition of InhA (354; 366). At least, 
eight nucleotide substitutions in the local of ligation of INH-NAD to InhA have been 
associated with isoniazid resistance: I16T, I21T, I21V, I47T, V78A, S94A, I95P and 
I194T (123; 202; 239). The mutation S94A (the most frequent) seems to affect directly 
the bond INH-NAD (181; 202), resulting in the incapacity of isoniazid (and 
ethionamide) to inhibit the mycolic acid synthesis (464). This data is consistent with the 
structural interactions between isoniazid and InhA and support the importance of these 
mutations in mechanism of resistance to isoniazid (181). However, mutations in the 
promoter region of the gene occur more frequently, with a higher incidence for the 
mutation C-15T (2; 168; 181). This mutation increases the inhA mRNA level resulting 
in InhA overexpression and an eightfold increase in the resistance to isoniazid (463). 
Mutations in the structural region of the gene can co-exist with mutations in his 
promoter and/or katG, albeit this is a rare event (202; 251). Mutations in inhA gene 
mutations are associated with low and intermediate levels of resistance (202). Overall, 
clinical isolates with mutations in inhA represent approximately 15-30% of the isoniazid 
resistant cases conferring low-levels of resistance (52). Recently, it was shown that the 
presence of a mutation in the inhA promoter region together with a mutation in the inhA 
structural region can lead to the development of high level isoniazid and ethionamide 
resistance (251). 
A reduced percentage of isoniazid resistant M. tuberculosis clinical strains have also 
been associated with a specific mutation in the type II NADH dehydrogenase (ndh 
gene), the substitution R268H (181; 234), which causes a reduction on the enzyme 
activity leading to an increased NADH/NAD+ ratio and coresistance to isoniazid and 
ethionamide (284).  
Several other genes have been implicated in isoniazid resistance, e.g. (i) the ahpC gene 
that encodes the alkyl hydroperoxide reductase enzyme (AhpC). The AhpC protein is 
regulated by the oxyR gene in most mycobacteria and the loss of oxyR in M. 
tuberculosis appears to be linked to the altered expression of the ahpC gene (121). 
Mutations in oxyR-ahpC locus increase the expression of AhpC (121) and compensate 
the loss of catalase activity in katG deficient strains (391); (ii) the kasA gene, which 
encodes β-ketoacyl acyl carrier protein synthase, forms part of a five genes (kasA, kasB, 




extension by FAS-II (43); and (iii) furA, a negative regulator of katG (344; 510). 
However, in each case, the mutations found in these genes were associated with 
mutations in katG and/or in the inhA promoter region or were also present in isoniazid 
susceptible strains.  
 
Rifampicin  
Ansamycin derivatives, such as rifampicin, are antibiotics used in the treatment of 
tuberculosis, leprosy, and diseases caused by Gram-positive bacteria. Ansamycin was 
isolated in 1957 from Amycolatopsis mediterranei (previously known as Streptomyces 
mediterranei and Nocardia mediterranei) (387). The ansamycins antibiotics containing 
an "ansa" chain connecting two nonadjacent carbons of an aromatic nucleus are 
interesting due to their unusual macrocyclic structures and their remarkable biological 
activities. Of the ansamycins which contain a naphthalene moiety, the rifamycins and 
the streptovaricins and their derivatives have received intense study. Ansamycins are 
structurally characterized by a planar naphthoquinone ring in which positions 3 and 4 
have been extensively modified by hemisynthesis to yield commercial antibiotics (318) 
like rifampicin, rifapentine, and rifabutin. 
Rifampicin, a semi-synthetic derivative of rifamycin B, was introduced as 
antituberculosis drug in 1972 (495). Rifampicin has a broad-spectrum activity and is 
particularly active against M. tuberculosis with minimum inhibitory concentrations 
ranging from 0.05 to 1 μg/ml. Rifampicin is active against both growing and stationary 
phase bacilli with low metabolic activity (522). Its rapid bactericidal activity aided to 
shorten the duration of treatment against drug susceptible M. tuberculosis when used in 
combination with pyrazinamide and isoniazid (125). Currently, rifampicin is a 
cornerstone of tuberculosis and leprosy therapy and is classified has as essential drug by 
the World Health Organization (497). 
The mechanism of action of rifampicin was first demonstrated by Hartmann et al. (177; 
178) by using Escherichia coli in which was shown that rifampicin inhibits the RNA 
polymerase. Since then, it was assumed that, in M. tuberculosis, rifampicin possesses 
the same mechanism of action. In 1993, the study performed by Levin and Hatful (240) 




RNA polymerase. The RNA polymerase is an oligomer consisting of a core enzyme 
formed by four chains α2ββ′ in association with the σ subunit to specifically initiate 
transcription (513). The four different subunits (α, β, β’ and σ) are encoded by rpoA, 
rpoB, rpoC and rpoD genes, respectively (286). Rifampicin binds in a pocket of the β-
subunit of RNA polymerase deep within the DNA/RNA channel, but more than 12Å 
away from the active site. It directly blocks the path of RNA elongating when the 
transcript becomes two to three nucleotides in length (66). 
More than 95% of M. tuberculosis clinical strains resistant to rifampicin harbour a 
mutation in an 81 base pair core region of the gene known as the rifampicin resistance 
determining region (RRDR) (440). The RRDR is presumed to be the rifampicin binding 
site (78; 522). All these mutations are comprised between codons 507 and 533 (E. coli 
numbering) of the rpoB gene and are associated with rifampicin resistance as they alter 
the structural conformation of the RNA polymerase thereby decreasing the binding 
affinity between rifampicin and the RNA polymerase (66). The RRDR is also known as 
cluster I (358). Several studies identified a variety of mutations, deletions and insertions 
in the rpoB gene among rifampicin resistant M. tuberculosis strains. The level of 
resistance to rifampicin in M. tuberculosis is dependent on the position of the mutation 
in the rpoB gene. Generally mutations in the RRDR convey high-level resistance. 
Mutations at positions 531 and 526 are among the most frequent mutations found in 
rifampicin resistant strains and are associated with high-level resistance (>32 µg/ml) 
and cross-resistance to all rifamycins (186; 202; 347; 467; 522). These mutational 
hotspots have being used for the prompt identification of rifampicin resistant isolates by 
molecular methods (52; 202; 347). Conversely, mutations in codons 511, 516, 518 and 
522 are associated with low-level resistance to rifampicin (195, 202). Several other 
mutations along the RRDR have been rarely reported which were shown to be 
associated with variable levels of resistance (205; 254; 333; 440). Furthermore, it have 
been described the occurrence of mutations outside RRDR (49; 182; 186; 267; 343; 
358; 404). 
Recently, Comas et al. (90) showed that rifampicin-resistant M. tuberculosis strains can 
acquired, over the time, particular compensatory mutations in rpoA and rpoC genes that 
lead to the emergence of multidrug resistant strains presenting a high competitive 





In 1945 was demonstrated that nicotinamide (nicotinic acid, a vitamin B3 precursor) 
had inhibitory activity against M. tuberculosis (82). The synthesis of nicotinamide 
analogues led to the identification of pyrazinamide as the most active compound in a 
murine model of tuberculosis (521). Pyrazinamide was first synthesized by Dalmer and 
Walter in 1936 but its tuberculostatic activity was only established in 1952 (228). 
Pyrazinamide is a crucial component of tuberculosis therapy due to its unique ability to 
shorten the duration of tuberculosis treatment from nine months to six months when 
used in combination with isoniazid and rifampicin (521). It has an excellent sterilising 
effect on semidormant M. tuberculosis under acidic conditions (183) but has no activity 
against M. tuberculosis under normal pH environments (438). Besides, pyrazinamide 
lacks bactericidal activity during the first two days of treatment (521). Pyrazinamide is 
exclusively active against M. tuberculosis complex members, with the exception of M. 
bovis and M. canettii that are intrinsically resistant (150; 521). The in vitro 
antimycobacterial activity of pyrazinamide is dependent on the pH of the media. 
Acidification of the culture media to pH 5.5 enhances the activity of pyrazinamide 
against M. tuberculosis. However, even under such conditions, pyrazinamide exert only 
bacteriostatic activity with minimum inhibitory concentrations ranging from 6-50 
µg/ml. Moreover, its minimal bactericidal concentration is more than 1000 µg/ml (521). 
Pyrazinamide is a pro-drug that enters in the cell by passive diffusion (519) where it 
will be converted into its active form, pyrazinoic acid (POA), by the mycobacterial 
nicotinamidase/pyrazinamidase enzyme (PZAse) (220). The loss of PZAse activity is 
observed in M. tuberculosis strains that are resistant to pyrazinamide (220). PZAse 
enzyme is encoded by the pncA gene (385) and single mutations in this gene are 
considered the major cause for pyrazinamide resistance. Approximately 72% to 97% of 
all clinical isolates resistant to pyrazinamide carry a mutation in the structural gene or in 
the putative promoter region of the pncA gene, which includes missense mutations, 
insertions and deletions (237; 246; 283; 341; 362; 385). Pyrazinamide resistance has 
been shown to be strongly associated with multidrug resistance. Mutations in pncA are 
scattered throughout its sequence, however, there is some degree of clustering to the 




comprise the active site (D8, K96, A134 and C138), and the metal-binding site (D49, 
H51 and H71) (138). Mutations affecting the metal-binding residues or the active site 
are a cause a major reduction of the enzymatic activity and appear to be associated with 
high-level pyrazinamide resistance (389). However, the involvement of other resistance 
mechanisms is suggested by the existence of isolates that exhibit a high-level of 
pyrazinamide resistance without mutations in the pncA gene. For instance, M. bovis is 
intrinsically resistant to pyrazinamide due to a single point mutation (C→G) in pncA 
gene at position 169 that produces a non-effective PZAse (385), whereas M. canettii is 
also resistant to pyrazinamide but lacks pncA mutations (150). 
PZAse is located in the cytoplasm and is constitutively expressed (426; 519). As 
referred above, pyrazinamide enters the cells by passive diffusion where it will be 
hydrolysed by PZase to the active bactericidal compound POA. The POA produced 
intracellularly reaches the cell surface through passive diffusion and a defective POA 
efflux pump (519). The extracellular acidic pH facilitates the formation of uncharged 
protonated POA, which then diffuses through the membrane, leading to the 
accumulation of POA and disruption of the membrane potential. The protonated POA 
brings protons into the cell and cause cytoplasmic acidification and de-energize the 
membrane by collapsing the proton motive force (PMF), which affects membrane 
transport (521). In M. tuberculosis, at an acidic external pH, the rate of passive 
transmembrane equilibrium of POA seems to overwhelm that of active efflux, resulting 
in the accumulation of POA within the cells (519). Moreover, the decrease of the 
intracellular pH due to the accumulation of POA was initially thought to cause the 
inactivation of the fatty acid synthase I (fasI) (525). This hypothesis was denied in the 
study by Boshoff et al. (51) where was shown that FAS-I is the target of 5-Cl-PZA and 
not of pyrazinamide or POA. Therefore, the molecular target of pyrazinamide remains 
unknown. To clarify this subject, Shi et al. (393) identified four proteins as potential 
targets of POA. Among these, the authors identified the ribosomal protein S1 (RspA, 
Rv1630) as a target for POA. RpsA is involved in translation and ribosome-sparing 
process of trans-translation (393). Shi et al. elegantly demonstrated that POA binds to 
RpsA and inhibits trans-translation and not translation. When POA binds to RpsA, it 
prevents the binding of tmRNA, which therefore cannot rescue stalled ribosomes. 




handling stalled ribosomes or damaged mRNA and proteins under stressful conditions 
(300; 442). This finding helps to explain how different stress conditions, such as 
starvation, acid pH, hypoxia, and energy inhibitors and other drugs could potentiate 
pyrazinamide activity (521). Mutations in rpsA have been found in some pyrazinamide 
resistant isolates without mutations in pncA gene (150; 400). However, they are present 
only in a minority of strains indicating that the analysis rpsA mutations lacks sensitivity 
restricting its use for the routine testing of pyrazinamide susceptibility testing 
exclusively by molecular means (9; 400). Furthermore, it was shown that not all 
mutations in rpsA are associated with pyrazinamide resistance (150). Nevertheless, it 
can be a useful tool for the study of pyrazinamide resistance in strains presenting 
positive pyrazinamidase activity without detectable mutations in pncA. Curiously, 
Feuerriegel et al. (150) found that M. canettii strains possess mutations in the rpsA 
gene. The authors suggest that altered trans-translation might be the mechanistic basis 
for the intrinsic pyrazinamide resistance of this species. Furthermore, the quest for a 
new target associated with pyrazinamide resistance leads to the identification of PanD 
as a possible new mechanism of pyrazinamide resistance (516). PanD encodes an 
aspartate decarboxylase, which is involved in synthesis of β-alanine, a precursor of 
pantothenate and co-enzyme A biosynthesis (81). Zhang et al. (516) identified different 
mutations occurring in panD gene in 5 pyrazinamide resistant mutants generated in 
vitro. The authors also identified a panD mutation in a M. canettii strain and in a 
pyrazinamide resistant clinical isolate. More studies are needed to address the role of 
rpsA and panD mutations on pyrazinamide resistance. 
Pyrazinamide susceptibility testing is complicated by the fact that pyrazinamide is only 
active in an acidic media. Among the conditions that can affect the results of 
susceptibility testing to pyrazinamide are (i) the effect of the inoculum size: large 
inoculum (107-8 bacilli/ml) can increase the pH of the media and originate false 
resistance; (ii) the effect of bovine serum albumin (BSA): susceptibility of the bacilli to 
pyrazinamide is reduced in the presence of BSA, because of its neutralizing effect of the 
pH of the medium and binding of POA; (iii) the age of the cultures: old cultures are 
more susceptible to pyrazinamide than a 4-day log phase culture since actively growing 
bacilli can increase the pH of the media; (iv) efflux of POA: the efflux inhibitor 




pyrazinamide (520). Therefore, all phenotypic pyrazinamide resistant isolates should be 
confirmed by pncA gene mutation analysis and, if possible, pyrazinamidase testing.  
 
Ethambutol  
Ethambutol was synthesized in 1961 (490) and its in vitro and in vivo activity against 
M. tuberculosis was revealed in the same year (207; 208; 445). Ethambutol is only 
active against mycobacteria (215) and, currently, is a key component of the 
antituberculosis therapy.  
Ethambutol inhibits the transfer of mycolic acids to the cell wall but do not inhibit its 
synthesis (433). Ethambutol induces cellular accumulation and subsequent leakage of 
trehalose monomycolate, trehalose dimycolate, and free mycolic acids (216). Later, 
these results were associated with the inhibition of biosynthesis of arabinogalactan 
(434) and the arabinan of lipoarabinomannan (120). The inhibition of arabinan leads to 
the accumulation of decaprenol phosphoarabinase (DPA) (492) which is an arabinosyl 
donor for arabinan biosynthesis, establishing ethambutol as an inhibitor of the 
arabinosyltransferases (236). 
In M. tuberculosis and M. smegmatis were identified three homologous genes (sharing 
65% homology with each other) that encode for arabinosyltransferases: the genes embC, 
embA and embB who are organized in a 10 kb operon, designed as embCAB (441). The 
EmbCAB are integral membrane proteins with 12 transmembrane domains and a C-
terminal globular region of approximately 400 amino acids (441). Structural changes in 
the enzyme, caused by mutations in the recognition site, may prevent the binding of 
ethambutol leading to the development of resistance. The mode of action of ethambutol 
seems to be different on each Emb protein and can be explained by their involvement in 
different pathways. While the EmbC protein is involved in the formation of arabinan in 
lipoarabinomannan, the enzymes EmbA and EmbB participate in the synthesis of 
arabinan in arabinogalactan. According to Telenti et al. (441) the development of 
resistance to ethambutol occurs gradually, involving multiple targets. The mutational 
hotspot occurs between the amino acids 238-436 of the embB gene, known as 
Ethambutol Resistance Determining Region (ERDR), a region highly conserved in M. 




resistant to one or more antibiotics (180, 198, 325; 390) and monoresistance is rare 
(252; 319; 390). Several studies suggest that 69% of ethambutol-resistant M. 
tuberculosis strains carry a mutation in the embB gene, where the mutation in the codon 
306 is the most frequent (180, 198; 325; 336; 348, 370, 412, 413; 414, 417, 441). Five 
distinct structural mutations in codon 306 of embB gene have been described. The most 
common corresponds to the substitutions of the wild type methionine by isoleucine, 
leucine, or valine. The role of the embB306 mutation was established as a cause of low 
and moderate-level (two to seven times the wild type) (370, 371). For strains with the 
substitution M306L or M306V the minimal inhibitory concentrations are generally 
higher than those with the M306I substitutions (348; 412). 
Recent studies describe the occurrence of mutations in embB306 of M. tuberculosis 
isolates phenotypically susceptible to ethambutol (180; 235; 295; 325; 348; 414; 515). 
These studies suggest that mutations in this codon are just a common polymorphism 
that is present in clinical strains of M. tuberculosis that are predisposed to the 
development of resistance to other antituberculosis drugs. Several others mutations have 
been described in the embB gene, as well in embA and embC (198; 337; 348; 414; 441). 
Additionally, the codons embB406 and embB497 could represent additional hotspots for 
mutation (319; 348; 371). These two mutations are associated with high-level resistance 
(≥30 mg/l) to ethambutol comparable to those determined for strains caring the 
embB306 mutations (348; 370, 412). Nonetheless, the embB406 was already found in 
ethambutol susceptible clinical isolates (235; 350; 413). Safi et al. (371) showed that, 
similar to the embB306 alteration, mutations other than embB306 confer only a low to a 
moderate increase in ethambutol minimal inhibitory concentration. 
Recently, it was shown that mutations in embC or very high embC expression confer the 
highest resistance levels (372). The UbiA enzyme synthesizes decaprenylphosphoryl-β-
d-5-phosphoribose (DPPR), which is a precursor of DPA. Mutations in ubiA gene 
(Rv3806c), which encodes the DPPR synthase, UbiA (193) were associated with high-
level resistance and had additive effects with embB mutations on the resistance levels. 
The authors assume that ethambutol resistance is acquired through the acquisition of 
mutations that interact in complex ways to produce a range of minimum inhibitory 
concentrations, from those falling below breakpoint values to the ones representing 




pathways leading to the ethambutol resistant phenotype which make the study on the 
development of resistance to this antibiotic far from being deciphered. 
 
Aminoglycosides 
The great majority of aminoglycosides are bactericidal, possess predictable 
pharmacokinetics, and frequently act in synergy with other antibiotics, properties that 
make them valuable as antimicrobial agents (222). The significant clinical toxicities of 
aminoglycosides are ototoxicity, nephrotoxicity and less frequently neuromuscular 
toxicity (26). In spite of this, these antibiotics are an important component of our 
modern antimicrobial arsenal. Most of aminoglycosides are naturally produced by 
members of the genus Streptomyces and Micromonospora. By convention, those 
originating from the genus Streptomyces are labelled ‘-mycins’, whereas those 
originating from the genus Micromonospora are labelled ‘-micins (512). 
The antimicrobial activity of these drugs results from an interaction with the bacterial 
ribosomes where they bind to the A-site and disrupt protein synthesis.  They also 
decrease the fidelity of mRNA, causing incorporation of incorrect amino acids into the 
growing polypeptide chain (111). The ribosome is composed of two subunits, 30S and 
50S. The primary intracellular target of aminoglycosides is the 30S subunit, although 
some aminoglycosides bind to the 50S subunit of the ribosome. 
Among this class of drugs, the aminoglycosides streptomycin, kanamycin and amikacin 
are those that are used in tuberculosis treatment. Streptomycin is a first-line antibiotic 
whereas kanamycin and amikacin are second-line drugs reserved to the treatment of 
multidrug resistant tuberculosis. However, the extensive clinical use of 
aminoglycosides, mainly as monotherapy, has led to the emergence of resistance. 
Streptomycin was isolated from Streptomyces griseus, in 1944 by Waksman team (382) 
and was the first antibiotic demonstrating activity against M. tuberculosis (375). 
Streptomycin binds to the 30S ribosomal subunit (347). The 30S subunit consists of the 
16S rRNA (encoded by rrs gene) and a set of unique proteins: S1 to S21 (S from small 
subunit). Resistance to streptomycin in M. tuberculosis is usually mediated by 
mutations in rrs and rpsL genes.  The majority of mutations occur in the ribosomal 




occur at position 43 (AAG → ACG) and 88 (AAG →AGG) (152; 347). A second type 
of mutations associated with resistance to streptomycin occurs in the rrs gene, 
especially in region 530 (the most common) and region of codon 915 (347). Generally, 
bacteria have multiple copies of the rrs gene. However, this is not the case of M. 
tuberculosis that only has one copy of this gene. Mutations in rpsL and rrs have been 
described in approximately 65-67% of the streptomycin resistant clinical isolates (347). 
Resistance to streptomycin can be categorized into three types: high-level, intermediate 
and low-level resistance. High-level resistance is found only in isolates with mutations 
in the rpsL gene; intermediate resistance is mostly associated with mutations in the gene 
rrs; and low-level resistance is found in isolates that do not present mutations in rpsL or 
rrs (281). Isolates with low-level resistance corresponds approximately to one-third of 
the clinical isolates with resistance to streptomycin without detectable mutations (152; 
280; 411). These data suggest the existence of other targets or mechanisms associated 
with the resistance to this drug. 
The gidB gene, which encodes for a conserved 7-methylguanosine (m7G) 
methyltransferase specific for 16S rRNA, was identified as being potentially involved in 
low-level resistance to streptomycin (312). The product of this gene is involved in the 
methylation of the 16S rRNA, more specifically at position G527 of E. coli (312). The 
corresponding nucleoside in M. tuberculosis is G518, a residue that is found within the 
530 loop of the 16S rRNA A-site and which interacts directly with streptomycin (309). 
Recently, the study by Wong et al. (493) provided the first microbiological evidence for 
the contribution of this gene to streptomycin resistance by showing that gidB mutations 
confer low-level streptomycin-resistance. Moreover, it was also demonstrated that the 
methylation of G518 affects protein translation and that methylation significantly 
enhances streptomycin binding. In the absence of the methyl modification, due to 
mutations in GidB, which is responsible for G518 methylation, streptomycin binds to 
the ribosome with less affinity, and confers low-level resistance (494). Due to the 
variety of mutations that can occur in gidB and since the impact of specific mutations on 
the resistance level of the isolate remains unclear, phenotypic drug susceptibility testing 





Kanamycin has been used for the treatment of tuberculosis caused by streptomycin 
resistant strains; however, the availability of less toxic alternatives such as amikacin and 
capreomycin (discussed below) has rendered it obsolete. Kanamycin was isolated from 
Streptomyces kanamyceticus and was identified in 1957 (453). Kanamycin comprises 
three components, kanamycin A (major component) and kanamycin B and C (minor 
components). Amikacin is a semi-synthetic derivative of kanamycin A with increased 
potency against M. tuberculosis (85). As referred above, streptomycin resistance is 
mediated by point mutations in rpsL or the rrs genes, however, no cross resistance 
between streptomycin and kanamycin or amikacin has been observed (7). This indicates 
that whereas these drugs bind to the ribosome they bind to a different region. In E. coli, 
ribosomal binding of kanamycin is affected by a mutation in the 1400 region of the rrs 
gene (292). It was also demonstrated that mutations in this region produce resistance to 
several aminoglycosides (124). Alangaden et al. (7) demonstrates that M. tuberculosis 
strains with high-level kanamycin resistance commonly harbour mutations in 1400 
region of rrs gene, particularly the A1401G substitution. The mutations most commonly 
reported to cause resistance to kanamycin and amikacin include the A1401G, C1402T, 
and G1484T substitutions (E. coli numbering; M. tuberculosis positions 1408, 1409 and 
1491, respectively) in the rrs gene (7; 60; 67; 148; 191; 194; 203; 214; 271; 326; 403; 
431). Both the A1401G and G1484T mutations are associated with high-level amikacin 
resistance (MIC ≥80 µg/ml) and cross resistance to kanamycin, whereas low-level 
amikacin resistance is rarely observed (271). Resistance to kanamycin can be classified 
either as high (MIC ≥80 µg/ml) or low (MIC < 80 µg/ml) level (271). The C1402T 
mutation is associated low-level kanamycin resistance. 
Zaunbrecher et al. (511) shown that low-level kanamycin resistance in M. tuberculosis 
is caused by point mutations in the promoter region of the enhanced intracellular 
survival gene, eis. The eis gene encodes an aminoglycoside acetyltransferase that was 
initially thought to be specific for kanamycin. The increase in eis transcript levels and 
the corresponding increase in the levels of the enzyme acetylate and inactivate 
kanamycin (511). Recently Chen et al. (77) demonstrated that Eis has an unprecedented 
ability to acetylate multiple amines of several aminoglycosides, including amikacin but 
not streptomycin. The acetylation mechanism promoted by Eis is supported by a 




related N-acetyltransferase regions. This represents a unique and efficient strategy of 
deactivation of aminoglycosides by multiacetylation. Recently, it was shown that 
mutations in eis promoter are also associated with low-level resistance to amikacin 
(MIC < 4 µg/ml) and high-level cross resistance to kanamycin (328). However, the 
susceptibility levels are dependent on the methodology used. Gikalo et al. (162) 
reported different results for kanamycin susceptibly testing with the absolute 
concentration method (susceptible) or with the proportion method on BACTEC MGIT 
960 (resistant). Due to the disparity between the different methodologies used for drug 
susceptibility testing it is difficult to assess the level of resistance due to eis mutations, 
mainly for low-level resistance. Moreover, the sensitivity of the Genotype MTBDRsl 
assay can be considerably affected by mutations in the eis gene as it cannot detect low-




Capreomycin and the structurally similar compound viomycin, belong to the 
tuberactinomycin class of antibiotics. Viomycin, also known as tuberactinomycin B, 
was isolated in 1951 from Streptomyces puniceus and S. floridae (34; 153). 
Capreomycin was first isolated from Streptomyces capreolus in 1960 by Herr et al. 
(184). The tuberactinomycin antibiotics are essential components used for the treatment 
of multidrug resistant tuberculosis (505). Although viomycin was the first member of 
this family to be discovered, only capreomycin is commonly used clinically as a 
second-line antibiotic against multidrug resistant M. tuberculosis (505). 
The mechanism of action of tuberactinomycins is unique among the ribosome-targeting 
antibiotics as they affect both ribosomal subunits. Tuberactinomycins are cyclic peptide 
antibiotics which target bacterial protein synthesis by binding to the well-conserved 
intersubunit bridge B2a, formed by the interaction between helix 69 (H69) of the 23S 
rRNA and helix 44 (h44) of the 16S rRNA (416). Viomycin interacts with both 
ribosomal subunits (507) and prevents the translocation of the ribosome along the 
mRNA (294). During translocation, a deacylated tRNA moves from the P site to the E 




the next aminoacylated tRNA. Elongation factor G (EF-G) promotes the movement of 
two tRNAs and the mRNA through the ribosome. Viomycin completely inhibits 
translocation but does not interfere with EF-G binding to the ribosome or GTP 
hydrolysis by EF-G (294). 
Capreomycin consists in a mixture of four isoforms, IA, IB, IIA, and IIB (394), all of 
which are active in vitro against mycobacteria (185). The differences in composition 
between isoforms I and II are attributed to the absence of β-lysine in the latter; and B 
differs from A in the exchange of 1 amino acid: it have the serine of the cyclic 
pentapeptide core reduced to alanine. The main difference between the binding of 
viomycin and capreomycin to the 70S ribosome is in the β-lysine side chain of each 
drug (394).  
Mutations in the positions 1401, 1402, and 1484 of 16S rRNA are associated with 
different degrees of resistance to capreomycin and viomycin in M. tuberculosis, while 
simultaneously conferring cross-resistance to the aminoglycosides amikacin and 
kanamycin (148; 203; 271; 403). The rrs mutation A1401G causes low-level resistance 
to capreomycin and high-level resistance to amikacin and kanamycin; the C1402T 
mutation is associated with capreomycin and viomycin resistance and low-level 
kanamycin resistance. The mutation G1484T is responsible for high-level resistance to 
amikacin, kanamycin, capreomycin and viomycin (136; 203; 271; 388; 403; 431; 437). 
In addition, several single nucleotide polymorphisms in tlyA gene have been also 
associated with capreomycin resistance. The tlyA gene encodes a 2’-O-
methyltransferase (rRNA methyltransferase) and the loss of 2’-O-methylation of C1920 
in H69 and that of C1409 in h44 by TlyA is thought to reduce susceptibility to 
capreomycin (201; 272). Thermus thermophiles TlyA modifies only the C1920 in H69 
of 23S rRNA, indicating that sensitivity to capreomycin does not involve the 
methylation of C1409 (296). Moreover, the inactivation of the tlyA gene in T. 
thermophilus does not affect its sensitivity to capreomycin (296), suggesting that 
modification of C1409 is the relevant determinant of increased drug susceptibility due 
to 2’-O-methylation (6). Mutations in tlyA are associated with low-level capreomycin 




The genotypes associated with resistance to the cyclic peptides capreomycin and 
viomycin and the aminoglycosides kanamycin and amikacin are overlapping. For this 
reason, using a combination of a cyclic peptide (capreomycin or viomycin) and an 
aminoglicoside (kanamycin and amikacin) is equivalent to using a single drug with 
respect to the development of resistance. Furthermore, due to indication that the various 
mutations associated with resistance mediate different degree of susceptibility to 
capreomycin, it is indispensable to correlate the phenotypic drug susceptibility testing 
with the genetic basis of capreomycin resistance.  
 
Fluoroquinolones  
Quinolones were discovered in 1962 when Lesher and his colleagues identified 
accidently nalidixic acid as a by-product of the synthesis of the anti-malaria drug 
chloroquine (238). Since their discovery, this class of antibiotics has generated 
considerable clinical and scientific interest. However, the importance of quinolones only 
started in the early 1980s, with the finding that a combination of a fluorine molecule at 
position 6, a piperazine group at position 7, and a carbon associated group at position 8, 
resulted in a wide and potent antimicrobial activity. This combination leads to the 
development of norfloxacin, the first of a new generation of antibiotics (17). Since then, 
the development of new quinolones evolved with third (e.g. ofloxacin and 
ciprofloxacin) and fourth (e.g. levofloxacin, gatifloxacin and moxifloxacin) generations 
of antibiotics, and is regarded today, as an important group of antimicrobial agents, with 
a wide gamut activity (17). The newer fluoroquinolones, such as levofloxacin, 
gatifloxacin and moxifloxacin, have demonstrated high in vivo and in vitro activities 
against multidrug resistant strains and ofloxacin and ciprofloxacin resistant strains (282; 
338; 363; 523). 
Fluoroquinolones are widely used for the treatment of infections caused by non-
mycobacterial agents. In addition, they are also active against nontuberculous 
mycobacteria and, in particular, they display inhibitory activity against M. tuberculosis. 
Presently, fluoroquinolones are essential for the treatment of patients with multidrug 
resistant tuberculosis. The World Health Organization recommends the inclusion of a 




tuberculosis, preferentially, a new-generation fluoroquinolone (505). They are also 
recommended for the treatment of extensively drug resistant tuberculosis even when 
resistance to ofloxacin is present (501). Furthermore, moxifloxacin is recommended for 
the treatment of patients who are intolerant to the first-line antibiotics (48). The 
inclusion of fluoroquinolones in the therapeutic regimen for multi- and extensively drug 
resistant tuberculosis can improve treatment outcome and shorten the duration of the 
treatment (310). Nevertheless, the development of fluoroquinolone resistance is one of 
the causes of treatment failure and death (65). 
The significance and effectiveness of the newer fluoroquinolones in tuberculosis 
treatment is threaten by the extensive use of the older fluoroquinolones, ofloxacin and 
ciprofloxacin, in general medical practice, for the treatment of other bacterial infections 
such as the case of empirical treatment of community-acquired pneumonia. This kind of 
practice contributes for the emergence of resistance since the exposure to 
fluoroquinolone monotherapy in a patient with undiagnosed tuberculosis can result in 
the emergence of fluoroquinolone resistance. Besides this, there is the problem of cross-
resistance between the older and new generation of fluoroquinolones as they share the 
same molecular target, DNA gyrase (241). 
Fluoroquinolones act by inhibiting the type II topoisomerases DNA gyrase and 
topoisomerase IV (134). The molecular mechanism of action of quinolones was 
discovered in 1975 by Crumplin and Smith, which demonstrated that nalidixic acid, 
inhibits a critical enzyme for bacterial multiplication (99). This enzyme was later 
purified by Gellert et al. (160) and designated as DNA gyrase. Topoisomerase IV was 
discovered in 1990 by Kato et al. (209). DNA gyrase and topoisomerase IV possess 
almost 40% amino acid sequence identity (209) and are essential enzymes since both 
are required for cell growth and division and control of DNA topology. Quinolones 
exert their toxicity on the bacterial cell by stabilizing the double-stranded break in DNA 
created by DNA gyrase and inhibiting religation (32). The inhibition of DNA gyrase by 
quinolones will block transcription and DNA replication, which results in cell death 
(491). For this reason, fluoroquinolones are classified as bactericidal antibiotics. Unlike 
other bacterial species, M. tuberculosis lacks topoisomerase IV (89) making DNA 
gyrase the unique target of fluoroquinolones. DNA gyrase is an ATP dependent 




complex (330). GyrA and GyrB are encoded by gyrA and gyrB, respectively (241). 
GyrA, a protein of 97 kDa, is involved in double-strand breakage and reunion reaction, 
and GyrB, 89.9 kDa, is responsible for the ATPase activity of the enzyme (241). The N-
terminal of the subunit A contains the catalytic site of DNA gyrase (64) and also the 
120 bp quinolone resistance determining region (QRDR) comprised between the 
nucleotides 220 and 339 (nt 67 to 106 E. coli numbering system). The QRDR is the 
interaction site between DNA gyrase and quinolones. 
Mutations in the QRDR of gyrA and, to a lesser extent, gyrB genes are 
responsible for fluoroquinolone resistance (230; 392; 435; 473). The most common 
mutations in gyrA occur in position 94 (D94G or D94A), 90 (A90V), 91 (S91P) and 88 
(G88C) (24; 53; 148; 392; 397; 454; 473). Mutations in gyrB are less frequent and some 
nucleotide substitutions have been described in this gene: D472H, R485C, S486F, 
D495N, N533T, N538T, T539P, D500 (A, H, or N), G509A, N510D and E540 (V or D) 
(15; 24; 148; 335; 473). However, the correlation between mutations in gyrB and 
fluoroquinolone resistance needs to be further validated. For example, the mutations 
R485C and S486F were already identified in isolates susceptible to quinolones (316). 
By using gyrase inhibition and mutagenesis assays, it was demonstrated that the 
mutations D500A and N538T, located in the gyrB QRDR, and T539P and E540V, 
located outside the QRDR, are implicated in fluoroquinolone resistance (255; 317). 
Other mutations have been found that are not associated with resistance. The mutation 
gyrA S95T is found in several isolates but is considered to be a natural polymorphism 
and an evolutionary marker (15; 148; 397). 
The level and pattern of resistance to fluoroquinolones varies among the different 
mutations, the different methods employed to their determination and the nature of 
fluoroquinolone tested. The difficulty to perform an accurate evaluation of the levels of 
fluoroquinolone resistance highlights the need for the standardization of 
fluoroquinolone drug susceptibility testing. 
 
 As seen in the main antibiotics used to treat tuberculosis and multidrug resistant 
tuberculosis, the genetic background of the M. tuberculosis strain determines 
significantly its pattern of resistance mainly due to mutations present in the targets of 




M. tuberculosis such as active drug efflux, also play an important role in the overall 
drug resistance levels and contribute significantly to the emergence of drug resistance 
(466, 470). Understanding the mechanisms underlying M. tuberculosis drug resistance 
not only enables the development of more rapid and accurate tools for the guidance of 
antituberculosis therapy but also provides new knowledge for development new 
therapeutic strategies.  
 
Drug efflux, mycobacterial metabolism and new therapeutic targets 
and strategies  
Drug efflux is generally described as an intrinsic or natural characteristic involved in 
drug resistance. In mycobacteria, intrinsic resistance to the majority of compounds is 
usually attributed to reduced permeability of the cell wall, in particular to its complex 
structure and constitution that acts synergistically with the activity of efflux pumps 
present in the membrane (118; 307; 466). Therefore, the intracellular concentration of 
an antibiotic is a balance between influx and efflux of the drug (247). Hydrophobic 
compounds, such as rifampicin and quinolones, can cross the hydrophobic bilayer 
through passive diffusion, whereas hydrophilic compounds, such isoniazid and 
ethambutol, use porin-like channels (306). Porins, or outer membrane proteins (OMPs), 
are water-filled channel-forming proteins that allow the passage of a large variety of 
hydrophilic compounds into the cell without requiring energy consumption (40). In 
response to the presence of toxic compounds, the cell can down-regulate their 
expression or decrease their synthesis (468). Contrary to other bacterial species, porins 
are less abundant in mycobacteria. OmpA of M. tuberculosis and the porin MspA of M. 
smegmatis were shown to be integral OMPs which are accessible at the cell surface 
(386; 415). More recently, two novel putative Omp-like porins (Rv1698 and Rv1973) 
have been identified in M. tuberculosis (408). 
Efflux pumps are now broadly recognized as playing an important role in natural and 
induced drug resistance since they can expel a wide range of structurally dissimilar 
compounds, before they reach their target, being associated with multidrug resistance 
(332). The development of phenotypic drug resistance depends on the constitutive or 




inducers through the regulation of the expression of efflux pumps (468). Efflux pumps 
are cytoplasmic transmembrane proteins involved in the extrusion of toxic compounds 
from within cells into the external environment by using cellular energy, ATP or the 
PMF (483). They are also involved in several physiological processes such as cell-to-
cell communication, bacterial virulence, cellular homeostasis, detoxification of 
intracellular metabolites, and intracellular signal trafficking (261). Efflux pumps are 
found both in Gram-positive and Gram-negative bacteria, however, in the later, the 
resistance mediated by efflux is more complex due to the molecular architecture of the 
cell envelope (227). In this case, drug resistance is attributed to the synergy between 
reduced drug influx mainly due to the reduced permeability of the outer membrane 
(308), and active drug efflux. 
Bacterial efflux systems can be grouped into five superfamilies or families, according to 
their structure, energy source, and phylogenetic relationships: (i) the ATP-binding 
cassette (ABC) superfamily; (ii) the small multidrug resistance (SMR) family; (iii) the 
multidrug and toxic compound extrusion (MATE) family; (iv) the resistance-nodulation 
division (RND) family; and (v) the major facilitator superfamily (MFS) (332). These 
transporters can be classified as primary transporters (ABC), which are energized by the 
hydrolysis of ATP, or secondary transporters (MFS, SMR, RND, and MATE), which 
act based on the electrochemical gradient generated by protons that are transported and 
distributed to the surface of the cell, or PMF (227; 332). These transporters differ in 
size, ranging from about 1000 amino acids for the RND transporters, through 400-450 
amino acids for the MFS and MATE transporters and to 100 amino acids for the SMR 
transporters (274). The role of efflux mechanisms in drug resistance in mycobacteria 
have been demonstrated and extensively reviewed over the last years. Is reviewed in 
detailed in two recent papers (46; 470), thus will be only briefly discussed in this 
section. 
The study of efflux systems in M. tuberculosis is mainly based on the characterization 
of transporter proteins through genetic manipulation and protein expression by using M. 
smegmatis, since is non-pathogenic, fast-growing, and easier to manipulate than M. 
tuberculosis. Using this strategy, several transporters from different classes have been 
characterized as been involved in drug transport in M. tuberculosis, and other 




identified in M. tuberculosis belong to the MFS, SMR and RND families and the fourth 
family (ABC family) uses the hydrolysis of ATP by the ATPase to provide energy for 
active transport. Overall, M. tuberculosis genome encodes for 267 transporters, of 
which, 129 corresponds to ABC transporters, 30 MFS, 14 RND, and 1 SMR (447). The 
most well-characterized efflux pumps described to date in mycobacteria are summarized 




Table I.3. Main putative efflux pumps described in M. tuberculosis.  
 
ABC, ATP-binding cassette; SMR, small multidrug resistance; MFS, major facilitator superfamily; RND, resistance nodulation;  ATP, adenosine triphosphate;  PMF, proton motive force; AMP, ampicillin; 
CAM, chloramphenicol; STR, streptomycin; NVB, novobiocin; TET, tetracycline; VAN, vancomycin; ETB, ethambutol; RIF, rifampicin; INH, isoniazid; FQ, fluoroquinolones; CIP, ciprofloxacin; TPP, 
tetraphenylphosphonium; EtBr, ethidium bromide; ERY, erythromycin; ACR, acriflavine; AGs, aminoglycosides; OFX, ofloxacin; SP, spectinomycin; KAN, kanamycin; BDQ, bedaquiline.    
 
Pump Gene Description Substrates Family Energy source Reference 
Rv0194 Rv0194 Drug transport transmembrane ATP-binding protein AMP; CAM; STR; NVB; TET; VAN ABC ATP 89; 105 
DrrABC Rv2936-Rv2937-Rv2938 Daunorubicin transport ATP-binding proteins TET, STR, ETB, RIF ABC ATP 84; 89; 315 
Rv1218c Rv1218c Probable tetronasin transport ATP-binding protein 
β-lactams; NVB, biarylpiperazines, pyridines, 
bisanilinopyrimidines, pyrroles, pyrazolones 
ABC ATP 28; 89; 126 
BacA bacA (Rv1819c) Drug transport transmembrane ATP-binding protein INH ABC ATP 89; 200 






Antibiotic transport ATP-binding protein FQs ABC ATP 89; 321 
PstB pstB (Rv0933) Phosphate transport ATP-binding protein INH; RIF; ETB; CIP ABC ATP 54; 89; 380 
Mmr mmr (Rv3065) Integral membrane efflux protein  TTP, EtBr, ERY, ACR, Safranin O, Pyronin Y SMR PMF 54; 89; 116 
EfpA efpA (Rv2846c) Integral membrane efflux protein INH, FQ, EtBr, Dyes, ACR MFS PMF 89; 133;  243 
P55 P55 (Rv1410c) 
Aminoglycosides/tetracyclines transport integral 
membrane protein 
INH; RIF; TET; AGs MFS PMF 89; 200; 399 
Rv1258c Rv1258c  Conserved membrane transport protein INH, RIF, ETB, OFX; TET, ERY; SP MFS PMF 5; 89; 200;352; 398;  
Stp stp (Rv2333c) Conserved membrane transport protein TET; SP MFS PMF 89; 351 
Rv1877 Rv1877 Conserved membrane protein TET, KAN, ERY MFS PMF 89; 243 
Rv2459 Rv2459 Conserved integral membrane transport protein INH; ETB  MFS PMF 89; 169 
MmpL5 mmpL5 (Rv0676c) Probable conserved transmembrane transport protein TET; BDQ RND PMF 89; 176; 285  




 iniC (Rv0343) 
Isoniazid- inducible protein IniB 
Isoniazid- inducible protein IniA 








Some of these putative efflux pumps have been associated with the transport of 
fluoroquinolones, isoniazid, rifampicin, ethambutol, β-lactams, doxorubicin, 
aminoglycosides, macrolides, tetracycline, and dyes, among others. Generally, these 
efflux systems are responsible for low-level resistance to antibiotics, contrasting with 
the high-level resistance caused by mutations in the genes that code for the primary 
targets of these antibiotics (117). However, the overexpression of efflux systems can 
result in a decrease of the intracellular levels of antibiotics, allowing the emergence of a 
subpopulation presenting a high-level resistance phenotype. The pressure caused by a 
subinhibitory concentration of antibiotic can result in an increased efflux activity, 
allowing the selection of spontaneous mutants and therefore determining clinically 
significant resistance levels (470). 
Drug resistance mediated by the activity of efflux pumps is hypothesized to be 
dependent on the PMF and the availability of ATP within the cell. The contribution of 
both PMF and ATP dependent efflux systems, on the intrinsic resistance of M. 
smegmatis to isoniazid was first demonstrated in the work by Choudhri et al. (83). In 
that study the accumulation of isoniazid was increased upon addition of the 
protonophore CCCP, suggesting that a PMF dependent efflux system was involved in 
the efflux of isoniazid. Oxidative phosphorylation is the main source of energy 
production in mycobacteria. M. tuberculosis is an obligate aerobe pathogen and 
consequently it depends on oxidative phosphorylation for growth and survival. During 
oxidative phosphorylation, ATP is produced through the activity of the ATPases, which 
is coupled to the PMF (289). The PMF is established through the development of the 
transmembranar proton gradient which occurs due to the movement of electrons through 
the electron transport chain resulting in the establishment of the membrane potential. 
The proton gradient generated through oxidative phosphorylation leads to ATP 
synthesis via the ATP synthase which is responsible for the conversion of the 
electrochemical potential energy generated by the PMF into chemical energy in the 
form of ATP (147). Thus, energy metabolism and ATP production through the PMF, 
which is established by the electron transport chain, significantly contribute to drug 
susceptibility in M. tuberculosis (46). Several drugs whose mechanism of action is 




Below, we describe the mechanism of action of three new drug candidates with 
potential to improve tuberculosis therapy that have reached the phase of clinical testing. 
The discovery of the highly effective antituberculosis drug diarylquinoline highlights 
the importance of energy production pathways for M. tuberculosis. Diarylquinolines 
have been identified in a process of screening various compounds for potential 
antituberculosis activity (18). The lead compound, bedaquiline (also called TMC207, 
R207910, or compound J), an ATP synthase inhibitor, is the first drug to be approved 
for treatment of multidrug resistant tuberculosis in decades. Bedaquiline binds to 
subunit c (AtpE) of mycobacterial ATP synthase enzyme by blocking its action (115; 
223). Bedaquiline possess activity against susceptible and multidrug resistant strains 
(170) both replicating and under hypoxia (224). During hypoxia, diarylquinolines 
inhibit ATP synthesis activity but even at high concentrations had no significant effect 
on membrane potential (224). Recently, was demonstrated that upon bedaquiline 
exposure, the mycobacteria tend to minimize the consumption of cellular ATP and at 
same time enhance the capacity of ATP-generating pathways, which contributes to 
maintaining bacterial viability in spite of antibiotic stress (225). It was also showed that 
mycobacteria grown on lipid-rich media display enhanced bedaquiline mediated killing 
indicating a role of energy source on mycobacterial susceptibility (225). Since 
bedaquiline target differs from that of the currently available antituberculosis drugs it is 
not anticipated the development of cross-resistance (18). This type of compounds 
inhibit ATP synthase not only in bacteria but also in mitochondria (269; 270), however, 
it was shown by Haagsma et al. (173) that bedaquiline may not elicit ATP synthesis-
related toxicity in mammalian cells. Mycobacteria that are resistant to bedaquiline in 
vitro have mutations in the atpE gene, which encodes the subunit c of ATP synthase 
(196; 331). However, resistant strains with no detectable mutations in the complete F0 
ATP synthase operon (atpB, atpE, and atpF genes) and the F1 ATP synthase operon 
(atpH, atpA, atpG, atpD, and atpC genes) were already detected. Recently, clofazimine-
resistant M. tuberculosis mutants isolated in vitro, were found to be also resistant to 
bedaquiline. Mutations in the transcriptional regulator Rv0678, with concomitant 
upregulation of the efflux pump, MmpL5, accounted for this cross-resistance (176). 





Other promising compounds are the nitroimidazopyrans. Nitroimidazofurans, originally 
investigated as radiosensitizers for use in cancer chemotherapy (4), were found to 
possess in vitro activity against M. tuberculosis (22; 301; 475). Nitroimidazopyrans 
have been derived from the bicyclic nitroimidazofurans and are structurally related to 
metronidazole (422). The lead compound PA-824 showed potent bactericidal activity 
against multidrug resistant M. tuberculosis. PA-824 and delamanid (OPC-67683) are 
bicyclic nitroimidazoles (402) in phase II and III of clinical trials, respectively, for the 
treatment of multidrug resistant tuberculosis (58). Both compounds share the same 
mechanism of action. Although delamanid seems to be more active than PA-824 (268), 
PA-824 has been widely used to describe the mechanism of action of this class of 
compounds. PA-824 is active against M. tuberculosis complex (except M. canettii) 
(149) not only against actively replicating but also against non-replicating bacteria. Its 
mechanism of action involves the inhibition of mycolic acids synthesis (422) and 
respiratory poisoning (402). PA-824 is a prodrug that requires activation by the 
deazaflavin (cofactor F420) dependent nitroreductase (Ddn) (256; 268). In turn, F420, 
whose redox cycling requires the glucose-6-phosphate dehydrogenase Fgd1, is 
synthesized by FbiA, FbiB, and FbiC (79; 80). Rv3547, or Ddn, converts PA-824 into 
three primary metabolites; the principal one is des-nitroimidazole (des-nitro) (402). The 
formation of des-nitro metabolite generates reactive nitrogen species, including nitric 
oxide (402). Respiratory poisoning through nitric oxide release seems to be fundamental 
for the anaerobic activity by PA-824 (257; 402). Like cyanide, PA-824 dramatically 
shifted the predominant isoprenoid quinol/quinone ratio (MK9H2/MK9) in a time and 
concentration dependent manner. The effect of PA-824 on the respiratory complex 
under hypoxic non-replicating conditions was also manifested by a rapid drop in 
intracellular ATP levels. By this manner, PA-824 acts by releasing toxic nitric oxide 
within mycobacterial cells and nitric oxide possibly reacts with 
cytochromes/cytochrome oxidase to interfere with the electron flow and ATP 
homeostasis under non-replicating conditions (257). No cross-resistance with current 
antituberculosis drugs has been observed (422). Mutations in any of the mycobacterial 
genes fgd1, fbiA, fbiB, and fbiC lead resistance to PA-824 (79; 80; 256; 422). Mutations 
in the Rv3547 gene, encoding the Ddn, have been described in PA-824 resistant strains 




sequence homology with any other proteins of known function and was shown to be 
nonessential (381). Complementation of the mutants with an intact Rv3547 fully 
restored the ability of the mutants to metabolize PA-824 (256). 
The search for new antituberculosis drugs also prompted studies demonstrating that 
many compounds belonging to other pharmacological groups, such as 
antihypertensives, antipsychotics, and antispasmodic agents also have influence on the 
metabolic energy and on the viability of microorganisms (470). The potential use of 
these drugs in combination with antibiotics can constitute an important alternative as 
adjuvants in the antituberculosis conventional therapeutic regime and possess the 
advantage of being cost effective and time-saving. Data with respect to toxicity and 
pharmacokinetics is already available as they are normally employed in clinical practice 
and are approved by the FDA. Generally, these compounds are dopamine agonists and 
calcium channel blockers, blocking D2 receptors in the dopamine pathways (480). They 
are also called as efflux inhibitors as they can inhibit the efflux of drugs by disruption 
the energy necessary to maintaining the pumps working. 
To date, several compounds have been appointed as potential efflux inhibitors. Among 
these are the ion channel blockers thioridazine and chlorpromazine and its derivative 
flupenthixol; haloperidol, and verapamil (Figure I.8) (470). Ion channel blockers like 
phenothiazines and verapamil have been shown to inhibit the in vitro growth of M. 
tuberculosis strains. Of this group, chlorpromazine was the first antipsychotic drug 
discovered (245). Phenotiazines are divided in three groups: the aminoalkyl compounds, 
like chlorpromazine; piperidine compounds, like thioridazine and; piperazine 
compounds, like fluphenazine (62). This class of drugs are known to inhibit the 
transport of calcium by preventing its binding to calcium dependent enzymes (373). The 
phenotiazines possess a three-ring structure, in which a sulphur atom and a nitrogen 
atom are linked to two benzene rings. In thioxanthenes, the nitrogen was substituted by 
a carbon atom in the central ring (299). Among these compounds, flupentixol is a high-






Figure I.8.  Structures of the most important ion channel blockers reported to have 
inhibitory activity against M. tuberculosis. 
 
Besides the thioxanthenes, the butyrophenones, structurally (piperazine moiety) and 
clinically related with phenothiazines, and whose representative is haloperidol, are also 
used as antipsychotic drugs (41; 62; 88). Thioridazine and chlorpromazine have been 
shown to have active efflux inhibition properties and to inhibit the in vitro growth of M. 
tuberculosis strains alone or in combination with antimycobacterial drugs (14; 250; 
361). Thioridazine demonstrates significant activity against multidrug resistant 
tuberculosis in a murine model (460) and it has been successfully employed to treat 
extensively drug resistant tuberculosis on the basis of compassionate reasons (1). 
Recently, was demonstrated that thioridazine disturbs peptidoglycan synthesis in 
Staphylococcus aureus providing insights on the mechanism underlying the synergism 
between thioridazine and β-lactam antibiotics (445a). Altogether, these data suggests 
that thioridazine may have dual functions. Due to its toxicity, thioridazine was 
discontinued for the treatment of mental disorders in June 2005 (500). Verapamil, a 




contains several alkaloids that belong to two different classes: phenanthrene, that 
includes codeine and morphine, and benzylisoquinoline, that includes papaverine (179). 
Unlike the other alkaloids, papaverine is not an analgesic or narcotic (489). It was 
initially applied to treat angina, hypertension, and arrhythmias but without success (179). 
Instead, it was found useful for the relief of intestinal colic (197). This led, in 1959, to 
the synthesis of a very active synthetic analogue, D365, by Ferdinand Dengel from 
Knoll AG (Ludwigshafen/Germany). Latter it was called verapamil. Its pharmacological 
properties as calcium antagonist were first described by Fleckenstein in 1963. In 1972, 
Schamroth, Krikler, and Garrett were the firsts to link the arrhythmia terminating action 
of verapamil with the concept of calcium channel blockade (179). Nowadays, verapamil 
is extensively used for the treatment of various disorders such as angina, hypertension 
and cardiac arrhythmia (16; 277). Verapamil is also an inhibitor of P-glycoprotein in 
mammalian cells (143). Verapamil has been shown to be the most potent mycobacterial 
inhibitor, being able to enhance the inhibitory activity of isoniazid (250; 361) and 
rifampicin (248) in M. tuberculosis clinical strains. Recently, Gupta et al. (170) 
demonstrate that efflux inhibition by verapamil can potentiate the activity of 
bedaquiline. It has also been shown that the addition of verapamil accelerates the 
bactericidal and sterilising activities of tuberculosis therapy in the mouse model (171). 
The concept of enhancing the utility of the current antituberculosis drugs by employing 
ion channel blockers is quite appealing. However, their mechanism of action is not 
completely elucidated. Nowadays, evidence is emerging that their inhibitory functions 
possibly involve a role in cellular calcium homeostasis. In eukaryotic cells, L-type 
calcium channels need cell depolarization for activation (509). Cell trauma leads to 
intracellular calcium overload resulting in membrane depolarization (480). Once 
membrane depolarization occurs, calcium enters and initiates several damage 
mechanisms such as mitochondrial dysfunction which leads to a failure of aerobic 
energy metabolism (respiration dependent on calcium transport) (480). The role of ion 
channel blockers is to restore the homeostasis at membrane level inhibiting the influx of 
calcium and retention of dopamine. The activity of ion channel blockers is attributed to 
their effect on the mitochondrial electron transport chain. In eukaryotic cells, the 
neuroleptics haloperidol and chlorpromazine inhibit the mitochondrial NADH: 




electron transport chain on the mode of action of neuroleptic compounds in M. 
tuberculosis comes from the studies performed with the phenotiazines. Phenothiazines 
are known to inhibit one of the key enzymes of the mycobacterial respiratory chain, the 
type II NADH: menaquinone oxidoreductase (NDH-2) (476; 484) also called as 
alternative NADH dehydrogenase (212). M. tuberculosis possesses two NADH 
dehydrogenases: the NDH-1, encoded by the nuo operon, which is non-essential in M. 
tuberculosis (353) and, the non-proton-translocating NDH-2, encoded by the ndh gene, 
which is essential for M. tuberculosis survival (284). NDH-1 is an equivalent of 
mitochondrial complex I, while NDH-2 is a single subunit enzyme with NADH/quinol 
oxidoreductase activity (508). In M. tuberculosis, energy generation is mainly 
performed by NDH-2 (353) whereas NDH-1 is mostly implicated on anti-apoptotic 
activity of host cells and, not on its original function of generation of energy (461). Rao 
et al. (353) established a link between NDH-2 and PMF through the demonstration that 
the inhibition of NDH-2 by thioridazine dissipates the membrane potential. Thioridazine 
and chlorpromazine act as partial uncouplers of oxidative phosphorylation in 
mitochondria (293) and was recently demonstrated that besides their inhibitory effect on 
NDH-2 they also act as uncouplers of oxidative phosphorylation in S. aureus (383). The 
increase on intracellular calcium levels is one of the major consequences of the 
inhibition of the respiratory chain. Reactive oxygen species (ROS) is responsible for the 
increase of calcium and this calcium increase is linked to the dissipation of membrane 
potential (279). The collapse of PMF has detrimental effects on the bacterial cell such as 
increased production of ROS, inhibition of ATP synthesis, and disruption of calcium 
homeostasis leading to cell death. 
The search for novel compounds to be used in combination with antibiotics to treat drug 
resistant tuberculosis infections has become a major goal of drug discovery programs. 
The compounds presented here act on the mycobacterial electron transport chain. 
Besides, some of them also target M. tuberculosis efflux pumps through the disruption 
of energy necessary for their function. The inhibition of these functions will result in the 
intracellular accumulation of antibiotics and prevention of drug resistance. Furthermore, 
enhanced killing of the macrophage using ion channel blockers has also been 
demonstrated and proceeds through a mechanism that promotes the acidification of the 




above mentioned compounds have been shown to be effective efflux inhibitors with 
activity against a large range of bacteria. These compounds are ideal candidates that can 
be tested in combination with conventional antibiotics not only because they promote 
the retention of the co-administered antibiotics but also because these compounds 
enhance the killing activity of the macrophages. The observed killing enhancement has 
been postulated to be due to the inhibition of calcium and potassium transport. These 
ions are necessary to activate hydrolases required for the subsequent killing of 
intracellular bacteria. Furthermore, Adams et al. (3a) shown that the selective pressure 
exerted by the macrophage on internalized M. tuberculosis can induce the bacteria 
efflux pumps and thus drug-tolerance. The addition of the calcium channel blocker, 
verapamil or its metabolites reverses the tolerance to isoniazid and rifampicin (3a; 3b). 
These data highlight the importance and benefits of combined therapeutic regimens 
(261a). The delivery of antituberculosis drugs in conjunction with inhibitors of transport 
of calcium and potassium may provide a novel and effective therapeutic approach that 
obviates the serious side effects resulting from the current chemotherapeutic 
applications and provides a new approach for the therapy of multidrug resistant 
infections. 
 
 In conclusion, these compounds seems to be promising antituberculosis drug 
candidates for the treatment of drug resistant tuberculosis infections. Understanding the 
dynamic underlying the bacterial antibiotic-induced systems could provide a route for 
new chemotherapeutic approaches. By this manner, in the particular case of M. 
tuberculosis, the inhibition of its antibiotic intrinsic resistance could render this 
organism susceptible to many of the currently accessible antibiotics, allowing the 
recovery of compounds that are already out of the clinical usage rather development 
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Objectives of the thesis 
M. tuberculosis strains with multi- or extensively drug resistance are a major threat for 
human health, worldwide. In order to efficiently treat infections caused by multidrug 
resistant strains its necessary to know the molecular basis of its resistance, understand 
how acquired drug resistance develops in a patient under treatment and how it can be 
controlled and/or prevented. The major objective of this work was to understand the 
basis of the development of resistance in M. tuberculosis, in order to design strategies to 
circumvent/or prevent its development. This study is divided into three main chapters 
which focus on the major aspects of M. tuberculosis drug resistance: (i) the description 
of the molecular genetic basis of drug resistance in M. tuberculosis clinical strains; (ii) 
the study on the contribution of efflux to the emergence of drug resistance in M. 
tuberculosis, and (iii) the description of the mechanism of action of putative efflux 
inhibitors that can be used as adjuvants on tuberculosis therapy.   
 
Particular emphasis was given to:  
(i) Characterization of the genetic profile for first- and second-line 
antituberculosis drugs of multidrug resistance M. tuberculosis strains 
circulating in the Lisbon metropolitan area (Portugal). 
(ii) Determination the antibiotic susceptibility pattern to first- and second-line 
antituberculosis drugs, as well its levels of resistance.    
(iii) Epidemiological characterization of the isolates by using MIRU-VNTR 
typing.  
(iv) Analysis of the expression level of genes that code for efflux pumps by qRT-
PCR.  
(v) Identification of the efflux pumps involved in the development of drug 
resistance. 
(vi) Evaluation of efflux activity by real-time fluorometry.  
(vii) Susceptibility testing for the antituberculosis drugs in the presence/absence 
of selected efflux inhibitors.  




(ix) Investigation on the mechanism of action of the efflux inhibitors namely on 
their activity either directly on the pump or by depletion of the energy 
sources.  
(x) Study the antimycobacterial activity of the efflux inhibitors ex vivo by using 
the macrophage model. 
 
The enlighten of the dynamics of acquired drug resistance in M. tuberculosis, exploring 
the biological basis of multi- and extensively drug resistant tuberculosis, in order to 
identify new and alternative combinational therapeutic strategies to prevent and/or treat 
tuberculosis (in particular drug-resistant forms) is the ultimate objective of this thesis 






































































Preface to Chapter II 
 
Multidrug resistant tuberculosis is still increasing worldwide. The emergence of 
multidrug resistant and extensively drug resistant tuberculosis demands accurate and 
reproducible drug susceptibility testing and the efforts to contain the disease depends on 
its rapid detection and implementation of effective treatment together with public health 
interventions. The existence of drug resistant tuberculosis reflects the failure the 
strategies of implementation of effective tuberculosis control programs and the 
inefficacy of the health care system to contain the dissemination of the disease. Failure 
in the antibiotic provision and supply, inadequate prescription, non-adherence to the 
treatment, inadequate training of health care providers and the association HIV-
tuberculosis are some of the contributing factors to the development of drug resistance. 
The management of multidrug resistant tuberculosis is hindered by the inexistence of 
standard procedures for detection of drug resistant M. tuberculosis strains and second 
line drug susceptibility testing. 
To develop guidelines for the efficient clinical and laboratory diagnosis of all forms of 
tuberculosis and to optimize the appropriate treatment of drug resistant tuberculosis it is 
essential to perform accurate drug susceptibility testing and to understand the genetic 
basis of M. tuberculosis drug resistance. With the advances in the molecular biology 
field, rapid detection of drug resistance has been shown to be an important tool to 
improve the efficacy of treatment and reduce the spread of these strains. 
Although the present official multidrug resistance rates in Portugal are low (0.56% of 
all new cases detected in 2012 in Portugal), the proportion of extensively drug resistant 
cases among these is high. In this chapter (Part A and B), we aimed to characterize gene 
mutations conferring resistance to the first and second line antituberculosis drugs and 
evaluate its correlation with the phenotypic levels of resistance in M. tuberculosis 
isolates collected from multidrug resistant patients from Lisbon. Based on the gene 
mutations patterns, its geographic specificity and its correlation with phenotypic levels 
drug resistance, we hope to contribute with increased knowledge on how the 
methodologies here used can be applied for the detection of drug resistant M. 





Chapter IIA. Exploring the molecular genetic basis of drug-resistant 
Mycobacterium tuberculosis strains in Lisbon, Portugal: correlation 
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The spread of multi- and extensively drug resistant Mycobacterium tuberculosis poses a 
serious threat to the control of tuberculosis. Accurate drug susceptibility testing is 
essential to reduce the dissemination of the disease. The purpose of this study was to 
determine the resistance patterns of M. tuberculosis strains circulating in Lisbon and its 
correlation with mutations associated with that resistance. Seventeen multidrug resistant 
strains isolated from patients residing in this area were characterized by first- and 
second-line drug quantitative susceptibility testing with the aid of BACTEC MGIT 960 
system equipped with the TB eXIST software. Genotypic characterization focused on 
the analysis of the genes involved in drug resistance with the aid of the line-probe 
assays Genotype MTBDRplus and MTBDRsl and/or DNA sequencing. The results 
show a clear correlation between the presence of a mutation in the target gene and the 
resistance phenotype. The only exception is related with PAS resistance for which we 
could not find an explanation so far. The description of the resistance profiles of drug 
resistant M. tuberculosis strains adds new knowledge to the design of more effective 
tools for the diagnosis of tuberculosis. Together, quantitative drug susceptibility testing 
and the detection of mutations associated with resistance will allow the early 
administration of appropriate therapy since strains with low-level resistance may still 





Mycobacterium tuberculosis remains one of the most important human pathogens. 
Despite the innumerous efforts for its control, tuberculosis is one of the leading causes 
of death worldwide. According to the World Health Organization, in 2012, an estimated 
8.6 million people developed tuberculosis and 1.3 million died from the disease (60). A 
further concern is the emergence and spread of multidrug resistant strains of M. 
tuberculosis. In 2012, there were an estimated 450 000 new cases of multidrug resistant 
tuberculosis worldwide, that resulted in 170 000 deaths. The average proportion of 
multidrug resistant tuberculosis cases with extensively drug resistance was 9.6% (60). 
The accurate and rapid detection of multi- and extensively drug resistant tuberculosis is 
imperative for the prompt application of appropriate treatment and isolation measures, 
and to prevent the transmission of the disease. For these reasons, the delay in the 
identification of resistant strains threatens the efforts to control the disease. Multidrug 
resistance is defined as resistance to both isoniazid and rifampicin, and extensively drug 
resistance is defined as resistance to isoniazid and rifampicin with additional resistance 
to any fluoroquinolone and at least one of the three second-line injectable drugs: 
amikacin, capreomycin, or kanamycin. The management of multidrug resistant 
tuberculosis is expensive, prolonged, and less effective when compared with the 
treatment for drug susceptible strains. The treatment for extensively drug resistant 
tuberculosis is even more difficult, and the prognosis is significantly worse (60).  
 According to the Portuguese National Health Authorities, in 2012 it was 
estimated an incidence of 21.6 new cases of tuberculosis per 100 000 inhabitants and an 
average of 0.56% cases of multidrug resistant tuberculosis, of which 20% corresponded 
to extensively drug resistant tuberculosis. 65% of the multidrug resistant cases where 
living in the metropolitan area of Lisbon (8). This indicates that although tuberculosis 
incidence is decreasing from 2011 to 2012 (23 to 21.6/ 100 000 respectively), multidrug 
resistant rates are increasing. Therefore, the national situation requires attention. In 
order to contain the spread of these strains it is necessary the development of guidelines 
for diagnosis and optimization of the treatment of drug resistant tuberculosis with the 
implementation of accurate drug susceptibility testing for first and second line drugs 




 It is known that the frequency and specificity of the resistance-associated 
mutations differ among different geographical areas. A precise understanding of the 
genetic diversity of M. tuberculosis complex strains is required in order to interpret the 
results of molecular methods for drug susceptibility testing (21). M. tuberculosis drug 
resistance is associated with mutations that occur in specific regions of genes whose 
products are targeted by the antibiotics. Isoniazid resistance is mainly associated with 
mutations in the catalase peroxidase (katG) gene and/or regulatory region of the inhA 
gene (56). Resistance to rifampicin is linked to mutations in the 81 bp rifampicin 
resistance determining region (RRDR) of the rpoB gene, which encodes the β subunit of 
RNA polymerase (53). Resistance to fluoroquinolones is associated with mutations in 
gyrA gene, which encodes the DNA gyrase (4), resistance to aminoglycosides (amikacin 
and kanamycin) and capreomycin is associated with mutations in rrs gene that encodes 
the 16S rRNA (1; 26), resistance to streptomycin is associated with mutations in rrs 
and/or rpsL (27), ethambutol resistance is associated with mutations in the embB gene, 
where the mutation in the codon 306 is the most frequent (2). pncA mutations are 
associated with pyrazinamide resistance (46), and ethA mutations with ethionamide 
resistance, along with mutations in inhA promoter (28). Despite the characterization of 
the above genes, some cases of drug resistance among clinical M. tuberculosis strains 
presented with wild-type sequences at the above genes, which indicates the need for 
further studies. It was described that gidB mutations are associated with streptomycin 
resistance (30; 34) and mutations in eis promoter region with amikacin and kanamycin 
resistance (33; 62).  
 In this work, we aimed to describe the prevalence and pattern of gene mutations 
associated with resistance to the first- and second-line drugs, as well as its levels of 
resistance, in a collection of multi- and extensively drug resistant strains isolated from 
patients from the Lisbon metropolitan area. By exploring the genetic basis of M. 
tuberculosis drug resistance we hope to contribute to the selection of effective methods 






3. Material and methods 
M. tuberculosis strains. Seventeen multidrug resistant strains were included in the 
study. The isolates were obtained from different patients with active tuberculosis from 
hospitals of the Lisbon region and correspond to all multidrug resistant strains received 
in our laboratory during 2009-2011 for identification and first-line susceptibility testing. 
The selection criterion for this study was only multidrug resistant strains. The strains 
were grown in Lowenstein-Jensen solid media and MGIT tubes for the BACTEC MGIT 
960 liquid culture system (MGIT690; Becton and Dickinson Diagnostic Systems, 
Sparks, MD, USA). Cultures were identified with M. tuberculosis complex probes of 
the AccuProbe system (GenProbe Inc., San Diego, CA, USA) according to the 
recommendations of the manufacturer. The M. tuberculosis H37Rv ATCC27294T and 
two clinical strains susceptible to all drugs in study were used as controls. 
 
Antibiotics. Isoniazid, rifampicin, ofloxacin, amikacin, capreomycin, rifabutin, 
ethionamide, and paraamino-salicylic acid (PAS) were obtained from Sigma-Aldrich 
(St. Louis, MO, USA); moxifloxacin was obtained from Merck (Whitehouse Station, 
USA); and linezolid was obtained from Pfizer (New York, USA). All drugs were 
prepared in sterile deionized water except rifampicin and ethionamide which was 
prepared in dimethyl sulfoxide (DMSO); rifabutin in 10% methanol, ofloxacin, 10% 
sodium hydroxide, and PAS, 1% ethanol. The lyophilized drugs (BACTECTM MGITTM 
960 SIRE and PZA kits; SIRE: streptomycin, isoniazid, rifampicin and ethambutol; 
PZA: pyrazinamide) used in standard susceptibility testing were purchased from Becton 
Dickinson and the stock solutions prepared as per manufacturer’s instructions.  
 
Susceptibility testing. Drug susceptibility testing for standard first-line drugs was 
performed with the MGIT960 system, according to the manufacturer’s instructions. 
Drug susceptibility testing for the second-line drugs rifabutin, amikacin, capreomycin, 
ofloxacin, moxifloxacin, ethionamide, PAS, and linezolid was conducted using the 
MGIT960 system and the Epicenter V5.80A software equipped with the TB eXIST 
module (Becton Dickinson) as previously described (47). MGIT tubes were inoculated 
with 0.8 ml of SIRE supplement (Becton Dickinson), 0.1 ml of antibiotic at the desired 
concentration and 0.5 ml of the strain suspension. For the preparation of the drug-free 




a sterile saline solution and 0.5 ml inoculated into the MGIT tube. For first- and second-
line drug susceptibility testing, strains were considered resistant when growth at 
critical/screening concentration was obtained. Quantitative drug susceptibility testing of 
the drugs was conducted using the MGIT960 system and the Epicenter V5.80A/TB 
eXIST module as described above. The interpretation of the results was performed as 
per Springer et al. (47). Briefly, at the time of growth of the proportional control 
(Growth Units [GU] =400), the comparison between this tube and the tubes containing 
the drugs(s) was performed. If the GU of the tubes containing the drug were >100, they 
were considered to be resistant to that concentration. If the GU value were <100 they 
were considered susceptible. The concentrations used for first- and second-line drug 
susceptibility testing and for quantitative drug susceptibility testing are described in 
Table IIA.1.  
 
Detection of mutations associated with resistance. Genomic DNA was extracted using 
the QIAamp DNA Mini kit (QIAGEN, GmbH, Hilden, Germany) according to the 
manufacturer’s instructions and used for PCR amplification for line probe assays and/or 
DNA sequencing.  
(i) Line probe assays. The most common mutations in rpoB and katG genes and inhA 
regulatory region were investigated using Genotype MTBDRplus (Hain Lifescience 
GmbH, Nehren, Germany) according to the manufacturer’s instructions. The search for 
the most frequent mutations in rrs, gyrA and embB was performed with Genotype 
MTBDRsl (Hain) according to the manufacturer’s instructions.  
(ii) DNA sequencing. Genomic analysis of the regions of interest of rpoB, inhA, katG, 
ethA, pncA, rpsL, rrs, tlyA, gidB, gyrA, gyrB, eis, embB, and thyA genes (Table IIA.2) 
was performed by PCR amplification using the primers described in Table IIA.3 
followed by DNA sequencing. The PCR reactions were performed with the following 
amplification profile: initial denaturation at 94ºC for 5 minutes, followed by 
denaturation at 94ºC for 1 minute, primer dependent annealing temperature for 1 minute 
and extension at 72ºC for 1 minute during 40 cycles. The final extension occurred at 
72ºC for 10 minutes.  
 
Strain typing. Mycobacterial interspersed repetitive unit – variable number of tandem 




24 loci, as described by Supply et al. (51). The genotype of these strains was analyzed 
using the MIRU-VNTRplus web application (3; 59). 
4. Results and discussion 
The purpose of this study was to determine the drug resistance patterns of M. 
tuberculosis multidrug resistant strains (n=17) circulating in Lisbon and its correlation 
with mutations associated with resistance. The results obtained are presented in Table 
IIA.4. 
 Resistance to rifampicin is mainly due to point mutations in the rpoB gene 
encoding the β subunit of the RNA polymerase (53). In this study, 17/17 strains were 
resistant to rifampicin. Sixteen out of 17 strains were resistant to >20 µg/ml and all have 
the mutation S531L in rpoB gene. The remaining strain was resistant at 4 µg/ml and 
susceptible at 20 µg/ml of rifampicin. This strain possesses the mutation D516V in 
rpoB. For rifabutin, 7/17 strains were resistant to >2 µg/ml, 9 strains resistant at 0.4 
µg/ml and susceptible at 2 µg/ml, all of them presenting the mutation S531L in rpoB. 
The remaining strain was resistant at 1 µg/ml and susceptible at 0.4 µg/ml and 
corresponds to the one that has the mutation D516V in rpoB. Cross-resistance between 
rifampicin and rifabutin was observed for all strains. The results shown that the 
mutation S531L is associated with high-level resistance to both rifampicin and rifabutin; 
and that the mutation D516V is associated with intermediate level of resistance to 
rifampicin and low-level resistance to rifabutin. The mutation S531L was the most 
common found which is in agreement with other reported studies (5; 7; 19; 57). This 
mutation was shown to be associated with rifampicin high-level resistance and cross-
resistance with rifabutin, as already described (17). Moreover, in this work, the 
importance of the detection of rifampicin mutations as a surrogate marker for multidrug 
resistance in the metropolitan area of Lisbon has been once again demonstrated since all 
strains were also resistant to isoniazid (57). 
 In contrast, mutations associated with isoniazid resistance have been associated 
with several targets genes such as katG, inhA, kasA and ahpC genes (18; 38). However, 
the majority of isoniazid resistant isolates carry a mutation at either katG gene or in the 
promoter region of the inhA gene (14). The proportion of each mutation varies 




be restricted to mutations in inhA and katG gene. Seventeen out of 17 strains display 
high-level resistance to isoniazid. Among these, 3 strains were resistant at 10 µg/ml and 
14 were resistant at 1 µg/ml and susceptible at 3 µg/ml of isoniazid. Sixteen out of 17 
strains possesses the mutation C-15T in inhA promoter region coupled with the 
mutations S94A (nine strains) or I194T (seven strains) on the structural region of the 
gene. One strain has the mutation S315T in katG, the most commonly found among 
isoniazid resistant isolates (5; 54). 
 Mutations within the ethA and inhA structural genes are associated with high-
levels of ethionamide resistance (28). In the present study, 17/17 strains presented high-
level resistance to ethionamide (R > 25 µg/ml). The high-level resistance to 
ethionamide was associated with the presence of mutations in inhA gene in 16/17 
strains, and for one strain the high-level resistance was caused by a mutation in ethA 
gene. Since mutations in inhA not only cause isoniazid resistance, but they also confer 
cross-resistance to ethionamide, the inclusion of ethionamide in the second-line 
therapeutic regimen for these strains will be useless. 
  Resistance to ethambutol is mainly associated with a mutation at codon 306 in 
embB (2). In the present study, 11/17 strains presented resistance to ethambutol. Five 
out of 11 strains were resistant at 12.5 µg/ml and susceptible at 50 µg/ml, all carrying 
the mutation M306V in embB gene. Six out of 11 strains were resistant at 5 µg/ml and 
susceptible at 12.5 µg/ml. Of these, two strains presented the mutation M306V whereas 
no mutation was found for the remaining four strains. Was identified one strain 
susceptible at critical concentration (5 µg/ml) with the mutation M306V in embB. Some 
studies also describe the occurrence of mutations in embB306 of M. tuberculosis 
isolates phenotypically susceptible to ethambutol (13; 31; 49). The identification of 
mutations in drug susceptible strains can indicate that the breakpoint for ethambutol 
resistance should be revised. Additional studies are needed in order to find the value at 
which the phenotypic resistance correlates with genotypic resistance. One strain was 
found to be resistant at critical concentration of ethambutol without a mutation in the 
ethambutol resistance determining region (ERDR). This indicates the presence of a 
mutation in other regions of embB or in other genes such as embC and embA (35; 49). 




detected in the ERDR. These results indicated that embB306 mutation is associated with 
low- and moderate-level of resistance to ethambutol as previously shown (42; 43). 
 Resistance to pyrazinamide is mainly associated with mutations in pncA gene 
(45). In this work, resistance at critical concentration (100 µg/ml) was detected in 13/17 
strains all of them with associated mutations in pncA gene. The mutation V125G was 
found in 7/10 strains. From the remaining strains, one presents the mutation A-11G in 
the promoter region, three with a mutation in the initiation codon, M1T, one with an 
insertion of a cytosine at position 247, and one with a stop codon at position 123 (codon 
41). Four strains were susceptible to pyrazinamide. These results indicated that 
resistance to pyrazinamide among our strains is associated with mutations in pncA gene. 
In parallel, pyrazinamidase activity was determined for the 13 strains tested resistant at 
critical concentration and no activity was detected in these strains which confirms the 
results above. Pyrazinamide susceptibility testing is complicated by the fact that 
pyrazinamide is only active in an acidic media. In this study, two strains were initially 
tested as resistant to pyrazinamide. PZAse activity was positive and no mutations were 
found in these strains. The repetition of the pyrazinamide susceptibility testing for the 
discordant isolates gave susceptibility results to the two strains. Similar results were 
reported in the study by Chedore et al. (6). Pyrazinamide susceptibility testing is affect 
by i) the inoculum size; ii) the presence of bovine serum albumin on OADC supplement 
and iii) the age of the cultures (64). All these factors can increase the pH of the media 
originating false resistance. Therefore, it is recommended that all phenotypic 
pyrazinamide resistant isolates should be confirmed by pncA gene mutation analysis 
and, if possible, by pyrazinamidase testing. 
  Mutations associated with streptomycin resistance in M. tuberculosis have been 
described in the genes encoding the 16S rRNA (rrs) and ribosomal protein S12 (rpsL) 
(11; 29; 38). Seventeen out of 17 strains were resistant to streptomycin at critical 
concentration. Ten out of 17 strains were resistant at >20 µg/ml, all with the mutation 
K43R in rpsL gene. Six out of 17 strains were resistance at 4 µg/ml and susceptible at 
20 µg/ml and the remaining strain was resistant at 1 µg/ml and susceptible at 4 µg/ml. 
These seven strains harboured a mutation in the gidB gene (A80P). No mutations were 




and are in agreement with other studies (27). The mutations in gidB were shown to 
confer only low-level resistance to streptomycin as previously demonstrated (34).    
 Resistance to amikacin and capreomycin has been associated with mutations in 
the 1400 region of the rrs gene (26). The mutations most commonly reported as a cause 
of resistance include the A1401G, C1402T, and G1484T substitutions (1; 26; 32). From 
the 17 strains evaluated, 12 were resistant to amikacin and capreomycin. Regarding 
amikacin, 6/12 strains presented low-level resistance, i.e., they are resistant at critical 
concentration (1 µg/ml) and susceptible at 4 µg/ml. These strains do not have any 
mutation in the region studied of the rrs gene. The only mutation found in rrs 
corresponds to a common polymorphism that is not associated with resistance (insertion 
of a thymine at position 1078) (Table IIA.4). In these six strains was found a mutation 
in eis promoter region (G-10A). This mutation was established to be associated with 
amikacin low-level resistance in the study by Perdigão et al. (33). The remaining 6/12 
strains were resistant at >20 µg/ml which corresponds to amikacin high-level resistance 
and correlates well with the mutation detected in rrs, A1401G as described (26). In 
relation to capreomycin, 6/12 strains with the mutation A1401G in rrs, three presented 
high-level resistance (R >25 µg/ml); and the remaining three presented low-level 
resistance to capreomycin (resistant at 5 µg/ml and susceptible at 25 µg/ml). All six 
strains presented also high-level resistance to amikacin indicating that this substitution 
confers cross-resistance between amikacin (high-level) and capreomycin (low/high-
level). In the remaining six strains resistant to capreomycin for which we do not detect a 
mutation in rrs was found an insertion of a GT base pair at position 755/756 of tlyA 
gene. Three out of six strains presented high-level resistance to capreomycin and the 
remaining three display low-level resistance. The six strains with mutation on tlyA 
exhibit low-level resistance to amikacin. For strain MTB12 with the mutation A1401G, 
the wild-type sequence was simultaneously detected by the Genotype MTBDRsl. This 
indicates that both wild-type and resistant population are in sufficient number to be 
detected by the assay. Of notice is that during the susceptibility testing for amikacin and 
capreomycin the resistant population was selected. This laboratory result anticipates 
what happens in vivo during amikacin/capreomycin therapy. Heteroresistance can result 




different strain in a patient under therapy and was already described for rifampicin, 
isoniazid, ethambutol and amikacin (16; 41; 63).   
 Mutations in the quinolone resistance determining region of gyrA gene (QRDR) 
of gyrA and, to a lesser extent, gyrB genes are responsible for fluoroquinolones 
resistance (51; 57). The most common mutations in gyrA occur in position 94 (D94G or 
D94A), 90 (A90V), 91 (S91P) and 88 (G88C) (4; 58). In this study, resistance to 
ofloxacin and moxifloxacin was detected in 10/17 strains. These strains were resistant at 
2 µg/ml and susceptible at 10 µg/ml of ofloxacin, and resistant at 0.25 µg/ml and 
susceptible at 5 µg/ml of moxifloxacin, indicating low-level cross-resistance for the two 
antibiotics. All the fluoroquinolone resistant strains harbored a mutation in the QRDR 
of gyrA gene, S91P (seven strains) and D94A (three strains). No mutations were found 
in the QRDR of gyrB. From the 17 multidrug resistant strains, nine were found to be 
extensively drug resistant. This represents 52.9% of the sample.  
 PAS target the folate pathway (39) and mutations in thyA gene, which encodes a 
thymidylate synthase, have been implicated in clinical PAS resistance (12; 25; 39; 65). 
In the present work, high-level resistance to PAS (R >64 µg/ml) was detected in four 
strains. We analyzed the thyA gene to search for mutations and found the mutation 
T202A in the four strains. Feuerriegel et al. (10) showed that the T202A polymorphism 
in thyA is not a valid marker for PAS resistance rather a phylogenetic marker for the 
Latino-American-Mediterranean (LAM) lineage. To evaluate the role of this mutation 
on PAS resistance we sequence thyA gene for the remaining strains. The T202A was 
also found in 12 strains susceptible to PAS; hence, the involvement of this mutation in 
PAS resistance is questionable and remains to be clarified. Strain MTB12 possesses a 
wild type sequence and corresponds to the only Beijing strain among the collection. The 
remaining 16 strains belong to LAM lineage (see below). 
 Resistance to linezolid is rarely found among M. tuberculosis clinical isolates 
(15; 40) and when it happens, the resistance is associated with mutations in the rrl gene 
(20; 37; 61) or to non-ribosomal mechanisms (44). In this study, no resistant strains 
were detected which is in accordance to the previously described. Mutation rate for 
linezolid is low, 10-8-10-9 (15). This can explain the reduced prevalence of resistant 
mutants due to the defects caused by the drug in the growth rate as already described for 




 MIRU-VNTR typing of the 17 strains shows that 16/17 strains belong to the 
LAM genotype and that can be divided in two clusters: cluster Lisboa3 and cluster Q1 
(Figure IIA.1). The remaining strain corresponds to a Beijing strain. Both Lisboa3 and 
Q1 clusters can be distinguished by its mutational pattern regarding the mutations 
associated with resistance: cluster Lisboa3 comprised the nine strains with the inhA 
S94A, rpsL K43R, tlyA GT 755/766, eis G-10A, and gyrA S91P; the seven strains 
clustered in Q1 possess the following mutational pattern: inhA I194T, embB M306V, 
pncA V125G, gidB A80P, rrs A1401G, and gyrA D94A (Figure IIA.1).  
 This study is limited by the size of the sample evaluated. It will be necessary to 
study more strains including mono- and poly resistant M. tuberculosis strains to support 
this data.  
 
5. Conclusions 
To reduce the development and the spread of drug resistance among M. tuberculosis 
strains several control approaches have been developed such as (i) the timely 
implementation of an effective tuberculosis treatment that desperately needs to be 
guided by information coming from the performance of accurate drug susceptibility 
tests for first- and second-line drugs, and (ii) the simultaneous development and 
implementation of molecular tools for the detection of M. tuberculosis and mutations 
associated with drug resistance. Here, we shown that i) there is a clear correlation 
between the development of gene mutations in the drug targets and the resistance 
phenotype of a strain; ii) the chromosomal alterations associated with resistance are 
greatly conserved; and ii) the mutations can be associated with a specific genotype. 
Additionally, we were able to establish an association between the mutations and the 
levels of resistance for the antituberculosis drugs. Concerning the molecular detection of 
resistance, the Genotype MTBDRplus proved to be reliable method for predicting 
multidrug resistance. However, mutational analyses for inhA should be complemented 
with DNA sequencing. Concerning the detection of strains with extensively drug 
resistance, our study demonstrates that the Genotype MTBDRsl can only cover half of 
the M. tuberculosis strains. Strains with mutations in genes that are associated with low-




and tlyA for capreomycin). Besides these systems, the recently lunched AID TB 
resistance assay (GenID, Autoimmun Diagnostika, GmbH, Strassberg, Germany) can be 
used for the detection of mutations associated with streptomycin resistance; however, 
low-level streptomycin resistance due to mutations in gidB will not be detected. The 
targets for the remaining antibiotics have to be screened by DNA sequencing.  
 It is known that the mutational pattern of a strain varies according to 
geographical regions and our results are in accordance with it. The variability of drug 
mutations according to the genotype of a strain constitutes a major drawback for the 
application of molecular assays of the detection of drug resistance in a routine basis. 
Despite their advances, molecular methods do not identify all phenotypically resistant 
strains, as we have put in evidence in this work. This fact highlights the limitations of 
the molecular testing and the need for their complementation with accurate drug 
susceptibility testing. The implementation of these methods on a routine basis should be 
done carefully and the best results are those obtained when these methods are combined 
with the drug susceptibility testing. In Figure IIA.2, a working algorithm is presented 
showing how drug susceptibility testing can be complemented with the molecular 
detection of mutations associated with drug resistance.   
 In conclusion, the description of the resistance profiles of drug resistant M. 
tuberculosis strains circulating in Lisbon adds new knowledge for the design of more 
effective tools for the diagnosis of tuberculosis and for the treatment of patients infected 
with drug resistant strains. False resistance cases are a major cause for the incorrect 
diagnosis of drug resistant M. tuberculosis and may lead to unnecessary reduction of the 
drugs available for the therapeutic regimen. Together, drug susceptibility testing with 
the simultaneous detection of mutations associated with resistance will allow the early 
administration of appropriate therapy and strains with low-level resistance may still 








Figure IIA.1. Cladrogram based on 24 loci MIRU-VNTR of the 17 multidrug resistant M. tuberculosis isolates from Lisbon, Portugal. The 
boxes highlights clusters Q1 and Lisboa3. Inside of each box are depicted the mutational pattern for each cluster regarding the mutations associated with 
resistance. From left to right are shown lineage, strain number and MIRU-VNTR profile. The linkage distance scale is indicated at the bottom. LAM: 
Latino-American-Mediterranean; MTB: M. tuberculosis.   
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Figure IIA.2. Working algorithm for the application of drug susceptibility testing for first 








Table IIA.1. Concentrations used for first line, second line, and quantitative drug 
susceptibility testing.  
Antibiotics 
 
Critical/screening concentration (µg/ml) 
 Concentration 
for quantitative testing (µg/ml) 
Isoniazid  0.1  0.4, 1.0, 3.0, 10.0 
Rifampicin  1.0  10.0 
Ethambutol  5.0  12.5, 50 
Pyrazinamide  100.0  - 
Streptomycin  1.0  4.0, 20.0 
Rifabutin  0.1  0.4, 2.0 
Amikacin  1.0  4.0, 20.0 
Capreomycin  2.5  5.0, 25.0 
Ofloxacin  1.0  2.0, 10.0 
Moxifloxacin  0.25  0.5, 2.5, 7.5 
Ethionamide  5.0  10.0, 25.0 
PAS  4.0  16.0, 64.0 
Linezolid  1.0  4.0, 16.0 
 
 
Table IIA.2.  Algorithm used for the molecular analysis. 
Antibiotic  Target gene  Additional testing 
Rifampicin   rpoB RRDR  rpoB 
Isoniazid   inhA prom, katG 315  inhA structural region 
Ethionamide   inhA, ethA   
Ethambutol   embB 306   
Pyrazinamide   pncA  pyrazinamidase activity 
Streptomycin   rpsL (43, 88); rrs 530 region  gidB 
Amikacin   rrs 1401 and 1490 region  eis  
Capreomycin   rrs1401 and 1490 region  tlyA 
Fluoroquinolones   gyrA QRDR  gyrB 
PAS   thyA   
Linezolid   rrl   
















Primer sequence  (5’-3’) 
 Annealing 
(0C) 
 Length (bp)  Ref. 
rpoB 








 rpoB-2  GCG GTA CGG CGT TTC GAT GAA C   
inhA 








 inhA-2  ATC CCC CGG TTT CCT CCG GT   




 inhA-4  AGC GCC TTG GCC ATC GAA GCA   





 inhA-5R  TTC CGG TCC GCC GAA CGA CAG   
katG 








 P4_Rv  TTG TCC AAG CTG GCG TTG TC   
 P5_Fw  CGA CAA CGC CAG CTT GGA C   
518 
 P5_Rv  CGG TTC CGG TGC CAT ACG   
 P6_Fw  AGC TCG TAT GGC ACC GGA AC   
619 
 P6_Rv  TGA CCT CCC ACC CGA CTT GT   
 P7_Fw  ACA AGT CGG GTG GGA GGT C   
574 
 P7_Rv  CTG CCG GTC CAC TTC ACC TT   
 P8_Fw  GGG ACC TAC CAG GGC AAG GA   
629 
 P8_Rv  CCG GGA GTC AGC AAG TCA CC   
rrs 






 rrs_990R  CTAGACGCGTCCTGTGCATGT   
 




 This study 
 rrs1539  GGG GCG TTT TCG TGG TGC TCC    1  
tlyA 






 tlyAas  GGT CTC GGT GGC TTC GTC    
eis 






 eisR1   GTA GAT GCC GCC CTC GCT AG    
gidB 






 gidB_Rv  CTG GCC CGA CCT TAC GAG    
pncA 






 pncA_promP2  TCG GCC AGG TAG TCG CTG AT    






 pncA_Rv  CAA CAG TTC ATC CCG GTT CG    
gyrA 






 gyrA_Rv  GGC CGT CGT AGT TAG GGA TG    
ethA 






 ethA5  ACT ACA ACC CCT GGG ACC    





 ethA9  CCT CGA GTA CGT CAA GAG CAC    





 ethA10  CGT TGA CGG CCT CGA CAT TAC    
embB 






 embB-R2  GGT CTG GCA GGC GCA TCC    
gyrB 






 gyrB_Rv  GTG GAA ATA TGT TGG CCG TC    
rpsL 






 rpsL_Rv  GTT CAC CAA CTG GGT GAC    
thyA 






 Rv2764b_Rv  CTT GAG CCC AGA TCA GCC C    






Table IIA.4. Quantitative drug susceptibility testing using the MGIT960 system and the Epicenter TB eXIST software and molecular 












pncA PZAse activity 
0.1 0.4 1.0 3.0 10.0 2.5 5.0 25.0 1.0 4.0 20.0 0.1 0.4 2.0 5.0 12.5 50.0 100.0 
MTB1 R R R S S C-15T S94A wt R  R R wt R R R R R S S531L S S S wt S wt positive 
MTB2 R R R S S C-15T S94A wt R R R wt R R R R R R S531L S nd nd wt S wt positive 
MTB3 R R R  S  S  C-15T S94A wt R  R R  wt R R R R R S S531L S nd nd wt S  wt positive  
MTB4  R R R S S C-15T S94A wt R R R wt R R S R S S D516V S nd nd wt R ins of C at position 247 negative 
MTB5  R  R  R  S S  C-15T I194T wt R  R  R  wt R R R R R R S531L R R S M306V R  V125G negative  
MTB6 R  R  R  S S  C-15T I194T  wt R  R R  wt R R R R R R S531L R R S M306V R  V125G negative 
MTB7  R  R  R  S S C-15T I194T  wt R R  R  wt R R R R R S S531L S nd nd M306V R  V125G negative  
MTB8 R  R R  S  S  C-15T S94A  wt R  R  R  wt R R R R R S S531L S nd nd wt R  M1T  negative 
MTB9 R  R R  R  R  C-15T S94A wt R R R  wt R R R R R R S531L R S S wt R  A-11G negative 
MTB10 R R R S S C-15T I194T wt R R R wt R R R R R R S531L R S S M306V R V125G negative 
MTB11 R  R R  S  S  C-15T S94A wt R  R  R  wt R R R R R S S531L R S S wt R M1T  negative 
MTB12 R  R R  R  R  wt wt S315T R R R S266R R R R R R R S531L R R S M306V R TAC41→STOP negative 
MTB13 R  R  R  S S  C-15T I194T  wt R R R wt R R R R R R S531L R R S M306V R V125G negative 
MTB14 R  R  R  S S  C-15T S94A wt R R R wt R R R R R S S531L R S S wt R M1T negative 
MTB15 R  R R  R  R  C-15T S94A wt R R R wt R R R R R S S531L R S S wt S wt positive 
MTB16 R  R  R  S S  C-15T I194T  wt R R R wt R R R R R S S531L R S S M306V R V125G negative 
MTB17 R  R  R  S S  C-15T I194T  wt R R R wt R R R R R S S531L R R S M306V R V125G negative 
MTB18 S S S S S wt wt wt S S S wt S S S S S S wt S S S wt S wt positive 
MTB19 S S S S S wt wt wt S S S wt S S S S S S wt S S S wt S wt positive 
H37Rv S S S S S wt wt wt S S S wt S S S S S S wt S S S wt S wt positive 






Table IIA.4. Quantitative drug susceptibility testing using the MGIT960 system and the Epicenter TB eXIST software and molecular 
characterization of resistance associated mutations (cont.). 
Strain 










1.0 4.0 20.0 1.0 4.0 20.0 2.5 5.0 25.0 4.0 16.0 64.0 1.0 2.0 10.0 0.25 0.5 2.5 7.5 1.0 4.0 16.0 
MTB1 R R R nd nd K43R S S S S nd nd wt wt  nd S nd nd T202A R R S R R S S S91P S nd nd 
MTB2 R R R wt nd K43R S nd nd S S S wt wt  nd S nd nd T202A S nd nd S nd nd nd wt S nd nd 
MTB3 R R R nd nd K43R R S S R R  S  ins T at pos 1078 ins GT at pos 755/756 G-10A R R R T202A R R S R R S S S91P S nd nd 
MTB4  R R R wt nd K43R S nd nd S nd nd wt wt  wt S nd nd T202A S nd nd S nd nd nd wt S nd nd 
MTB5  R R S wt A80P wt R R R R  R  S  A1401G wt wt S nd nd T202A R R S R R S S D94A S nd nd 
MTB6 R R S wt A80P wt R R R R  R  S  A1401G wt wt S nd nd T202A R R S R R S S D94A S nd nd 
MTB7  R R S wt A80P wt S nd nd S S  S  wt wt  wt S nd nd T202A S nd nd S nd nd nd wt S nd nd 
MTB8 R R R wt wt K43R R S S R  R  S  ins T at pos 1078 ins GT at pos 755/756 G-10A S nd nd T202A R R S R R S S S91P S nd nd 
MTB9 R R R wt wt K43R R S S R R  S  ins T at pos 1078 ins GT at pos 755/756 G-10A R R R T202A R R S R R S S S91P S nd nd 
MTB10 R S S wt A80P wt S nd nd S S S wt wt  nd S nd nd T202A S nd nd S nd nd nd wt S nd nd 
MTB11 R R R nd nd K43R R S S R R R ins T at pos 1078 ins GT at pos 755/756 G-10A S nd nd T202A R R S R R S S S91P S nd nd 
MTB12 R R R nd nd K43R R R R R R  S  wt/A1401G nd nd S nd nd wt S nd nd S nd nd nd wt S nd nd 
MTB13 R R S wt A80P wt R R R R R R A1401G wt wt S nd nd T202A S nd nd S nd nd nd wt S nd wt 
MTB14 R R R nd nd K43R R S S R R R ins T at pos 1078 ins GT at pos 755/756 G-10A R R R T202A R R S R R S S S91P S nd nd 
MTB15 R R R wt wt K43R R S S R R R ins T at pos 1078 ins GT at pos 755/756 G-10A R R R T202A R R S R R S S S91P S nd nd 
MTB16 R R S wt A80P wt R R R R R R A1401G wt wt S nd nd T202A S nd nd S nd nd nd wt S nd wt 
MTB17 R R S wt A80P wt R R R R R R A1401G nd nd S nd nd T202A R R S R R S S D94A S nd nd 
MTB18 S S S wt nd wt S S S S S S wt wt wt S S S wt S S S S S S S wt S S S 
MTB19 S S S wt nd wt S S S S S S wt wt wt S S S wt S S S S S S S wt S S S 
H37Rv S S S wt nd wt S S S S S S wt wt wt S S S wt S S S S S S S wt S S S 
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1. Synopsis  
 
Objectives: The purpose of this study was to determine the levels of isoniazid and 
ethionamide resistance and to identify associated mutations in endemic multidrug 
resistant (MDR) strains of M. tuberculosis from the Lisbon metropolitan area, Portugal.  
Methods: Seventeen clinical MDR tuberculosis (TB) strains were characterized by 
standard and semi-quantitative drug susceptibility testing to assess the level of isoniazid 
and ethionamide resistance. The genes katG, inhA, ethA and ndh were screened for 
mutations. All strains were genotyped by 24 loci mycobacterial interspersed repetitive 
unit-variable number of tandem repeats (MIRU-VNTR) analysis. 
Results: All strains showed high-level resistance to both isoniazid (>1 mg/L) and 
ethionamide (>25 mg/L). MIRU-VNTR typing revealed the presence of two main 
clusters, Lisboa3 and Q1, in 16/17 strains, all of which showed the C-15T mutation in 
the promoter region of the inhA gene. The 16 strains belong to the Latino-American-
Mediterranean (LAM) genotype and the other strain belongs to the Beijing genotype. 
Sequencing of the inhA open reading frame revealed that the 16 strains also had 
mutations in the structural region of the gene, leading to the S94A substitution in 9 
strains and the I194T substitution in 7 strains. 
Conclusions: The results reveal that the presence of a mutation in the inhA regulatory 
region together with a mutation in the inhA coding region can lead to the development 
of high level isoniazid resistance and cross resistance to ethionamide among the MDR-
TB strains circulating in Lisbon. This mutational pattern also hints to a possible 
involvement of strain-specific factors that could be a feature of the Portuguese MDR-








Isoniazid is one of the most effective drugs for the treatment of tuberculosis (TB). 
Ethionamide is a second-line drug used in the treatment of multidrug-resistant (MDR) 
TB. Both compounds are pro-drugs that need activation by different enzymes but share 
common pathways, which can lead to cross-resistance. The majority of the mutations 
responsible for high-level isoniazid resistance in Mycobacterium tuberculosis are found 
in the katG gene.1 The second most commonly found mutations are observed in the 
promoter of inhA.1 These mutations increase InhA expression and confer low-level 
resistance to isoniazid (0.1<MIC<1.0 mg/L).2 Mutations in the inhA promoter also 
confer resistance to ethionamide, whose activity against M. tuberculosis depends on the 
activation by EthA.3 In addition to inhA promoter mutations, decreased susceptibility to 
isoniazid and ethionamide is associated with mutations in the structural region of inhA 
that decrease the affinity to the drug-NAD adduct.2  
In Portugal, the incidence rate of TB is high and the prevalence of MDR-TB and 
extensively drug resistant (XDR) TB in the Lisbon region is a cause of major concern.4 
More than 90% of these strains show high-level isoniazid resistance associated with the 
C-15T inhA promoter mutation. This genotype was also related with the high prevalence 
of ethionamide resistance.5 To address the apparent incomprehensiveness between the 
level of isoniazid and ethionamide resistance in these strains and their mutation profile, 
we analysed the level of resistance towards isoniazid and ethionamide and identified 
associated mutations in the MDR-TB strains isolated during 2009-2011 at the 
Mycobacteriology Laboratory of the Instituto de Higiene e Medicina Tropical of the 
Universidade Nova de Lisboa.  
 
3. Material and methods 
 
Strains. Seventeen clinical strains of M. tuberculosis were included in the study (see 
Table 1). The isolates were obtained from different patients with active TB from 
hospitals of the Lisbon region and correspond to all MDR-TB strains received in our 
laboratory during 2009-2011 for identification and first-line susceptibility testing. The 




using the AccuProbe MTBC test (GenProbe Inc., SanDiego, CA, USA) according to the 
manufacturer’s instructions. The M. tuberculosis reference strain H37Rv ATCC27294T 
was included as the control. 
 
Susceptibility testing. First-line susceptibility testing was carried out with the 
BACTECTM MGITTM 960 (Becton Dickinson Diagnostic Systems, Sparks, MD, USA) 
for streptomycin, isoniazid, rifampicin, ethambutol and pyrazinamide, according to the 
manufacturer’s instructions. Semi-quantitative drug susceptibility testing of isoniazid 
and ethionamide was conducted using the MGIT 960 system and the Epicenter V5.80A 
software equipped with the TB eXIST module (Becton Dickinson), as previously 
described.6,7  
 
Detection of mutations associated with resistance. Genomic DNA was extracted using 
the QIAamp DNA Mini kit (QIAGEN, GmbH, Hilden, Germany) according to the 
manufacturer’s instructions. The most common mutations in the structural katG gene 
and in the inhA regulatory region were investigated using Genotype MTBDRplus (Hain 
Lifescience GmbH, Germany) according to the manufacturer’s instructions. Nucleic 
acid analysis of the complete inhA, katG and ethA genes and an internal fragment of the 
ndh gene (nt 560 to 931) (for a list of the primers and conditions see Table IIB-S1, 
available as Supplementary data) was performed by DNA sequencing. 
 
Strain typing. Mycobacterial interspersed repetitive unit – variable number of tandem 
repeats (MIRU-VNTR) genotyping was performed by multiplex PCR amplification of 
24 loci, as described by Supply et al.8 The genotype of these strains was analyzed using 




The quantitative isoniazid resistance levels were determined for the seventeen MDR-TB 
isolates and the results are summarized in Table IIB-1. All isolates display isoniazid 
resistance levels >1 mg/L. According to the Genotype MTBDRplus assay, 16 of the 17 
strains contain a mutation the inhA promoter region (C-15T); one strain (MTB12) has a 




group of strains (MTB2, 4, 5, 9, 10, and 13-17), but no mutation was found. The C-15T 
mutation is described to confer cross-resistance to ethionamide. All isolates show high-
level ethionamide resistance (>25 mg/L) (Table IIB-1). Sequencing of the inhA open 
reading frame (ORF) revealed that all strains in addition to the C-15T mutation in the 
inhA promoter harbour point mutations in the inhA structural gene (Table IIB-1). Nine 
of these isolates carried the S94A mutation. In the remaining seven isolates, we detected 
the I194T mutation. The single isolate with a mutation in katG, in addition carries a 
mutation previously described in ethA, S266R.11 No mutation was found in the region of 
the ndh gene analyzed.  
Analysis of the 17 strains by MIRU-VNTR typing revealed that 16/17 strains 
represent two clusters, cluster Lisboa3 and cluster Q1 (Figure IIB.1). These 16 strains 
can be assigned to the Latino-American-Mediterranean (LAM) genotype and the 
remaining 1 to the Beijing genotype. Cluster Lisboa3 comprised the nine strains with 
the C-15T/S94A mutations and the seven strains with the C-15T/I194T substitutions 
were clustered in Q1 (Figure IIB.1). 
 
5. Discussion 
In the present study, we determined the levels of resistance to isoniazid and ethionamide 
for all MDR-TB strains isolated from 2009 to 2011 in our laboratory and we searched 
for mutations in target genes associated with resistance to isoniazid and ethionamide. 
We found that 16 strains have cumulative mutations in inhA gene: the C-15T mutation 
in the regulatory region coupled with mutations in the structural region of the gene, 
leading to the S94A and I194T substitutions. The presence of the mutation C-15T has 
been reported to confer low-level resistance to isoniazid and cross-resistance to 
ethionamide.1 The mutations S94A2 and I194T12,13 have also been reported to cause 
isoniazid resistance and both were associated with low-level resistance to isoniazid.11,13 
However, there are few reports on the combinations C-15T/S94A3,11 and C-
15T/I194T.12 The double mutation C-15T/S94A has been reported to confer low-level 
resistance11, while the C-15T/I194T combination was identified in one isolate with 
high-level resistance to isoniazid.12 All 16 strains with a double mutation studied in our 




compare the level of resistance of these strains carrying double mutations with the 
resistance level of strains carrying only the C-15T mutation, we searched for additional 
isoniazid-resistant strains in our laboratory isolated during the same period. This C-15T 
mutation alone was found among non-MDR strains and was correlated with low-level 
resistance to isoniazid (data not shown).    
MIRU-VNTR typing of the strains showed the presence of two main clusters, 
Lisboa3 and Q1, indicating that the dissemination of these strains is clonal. However, 
the mutational profile related to drug resistance indicates that the acquisition of drug 
resistance-associated mutations is non-clonal (data not shown), except for isoniazid and 
rifampicin. Thus, resistance to isoniazid has been transmitted clonally, as all strains 
share the same C-15T mutation and the S94A/I194T mutations were acquired 
subsequent to the C-15T mutation. Sixteen out of 17 strains were found to belong to the 
LAM genotype, previously shown to be the main genotype circulating in Portugal.5,14 
Fenner et al,15 recently proposed that the genetic background of a strain may influence 
the level of resistance to isoniazid conveyed by particular drug resistance-conferring 
mutations. Our results suggest that these two mutations, when combined with the C-15T 
mutation, can act synergistically to confer high-level resistance in this particular group 
of strains. All non-MDR strains evaluated during the period of this study, with low-level 
resistance to isoniazid, belong to the LAM genotype with only one belonging to 
Lisboa3 (data not shown). The single strain with a KatG S315T alteration is positioned 
in a completely separated branch and comprises the only Beijing strain found. From this 
we conclude that strain MTB12 is a foreign strain imported into the Lisbon area, not 
being part of the endemic circulating MDR clones. Comparison of the 12 loci MIRU 
with the SITVITWEB showed that MTB12 possess the MIRU international type 
MIT83, which corresponds to a modern Beijing type.   
Given the high-level ethionamide resistance observed in our isolates, the 
inclusion of ethionamide in second-line treatment regimens will have no benefit and 
other therapeutic combinations must be considered.16 Our data point to the need of rapid 
diagnostic methods for the detection of these strains and strong laboratory support to 
provide timely and accurate drug resistance information to guide the implementation of 




strains investigated account for ≈45% of all the MDR-TB strains isolated in Lisbon 
during this period.17-19  
In conclusion, we report that the presence of a mutation in the inhA regulatory 
region together with a mutation in the inhA coding region is associated with high-level 
resistance to both isoniazid and ethionamide among the MDR-TB strains circulating in 
Lisbon. Furthermore, we demonstrate that MDR-TB cases in Lisbon continue to be 
caused by a closely related family of strains, identified several years ago as being 
associated with MDR/XDR-TB.20 This mutational pattern also suggests the involvement 
of strain-specific factors that could be a feature of the Portuguese MDR-TB strains with 








Figure IIB.1. Cladogram based on 24 loci MIRU-VNTR of the 17 MDR M. tuberculosis isolates from Lisbon, Portugal. The grey box highlights 
clusters Q1 and Lisboa3 (both belonging to the LAM genotype). From left to right are shown lineage, strain number and MIRU-VNTR profile. The 
linkage distance scale is indicated at the bottom. LAM, Latino-American-Mediterranean; MTB, M. tuberculosis.   
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7. Tables  
 
Table IIB.1. Quantitative drug susceptibility profile of isoniazid and ethionamide and associated mutations in the 17 M. tuberculosis isolates. 
Strain 
 
Standard DST profile 
 INH qDST  (mg/L) ETH qDST (mg/L)  Gene mutations 
  0.1 0.4 1 3 10 5 10 25  inhAprom inhA ORF katG ethA ndh 
H37Rv  INHS, RIFS, STRS, ETBS, PZAS  S S S S S S S S  none none none none none 
MTB1  INHR, RIFR, STRR, ETBS, PZAR  R R R S S R R R  C-15T S94A none none none 
MTB2  INHR, RIFR, STRR, ETBS, PZAS  R R R S S R R R  C-15T S94A none none none 
MTB3  INHR, RIFR, STRR, ETBS, PZAS  R R R S S R R R  C-15T S94A none none none 
MTB4  INHR, RIFR, STRR, ETBS, PZAR  R R R S S R R R  C-15T S94A none none none 
MTB5  INHR, RIFR, STRR, ETBR, PZAR  R R R S S R R R  C-15T I194T none none none 
MTB6  INHR, RIFR, STRR, ETBR, PZAR  R R R S S R R R  C-15T I194T none none none 
MTB7  INHR, RIFR, STRR, ETBS, PZAR  R R R S S R R R  C-15T I194T none none none 
MTB8  INHR, RIFR, STRR, ETBS, PZAR  R R R S S R R R  C-15T S94A none none none 
MTB9  INHR, RIFR, STRR, ETBR, PZAR  R R R R R R R R  C-15T S94A none none none 
MTB10  INHR, RIFR, STRR, ETBR, PZAR  R R R S S R R R  C-15T I194T none none none 
MTB11  INHR, RIFR, STRR, ETBR, PZAR  R R R S S R R R  C-15T S94A none none none 
MTB12  INHR, RIFR, STRR, ETBR, PZAR  R R R R R R R R  none none S315T S266R none 
MTB13  INHR, RIFR, STRR, ETBR, PZAR  R R R I S R R R  C-15T I194T none none none 
MTB14  INHR, RIFR, STRR, ETBR, PZAR  R R R S S R R R  C-15T S94A none none none 
MTB15  INHR, RIFR, STRR, ETBR, PZAS  R R R S S R R R  C-15T S94A none none none 
MTB16  INHR, RIFR, STRR, ETBR, PZAR  R R R S S R R R  C-15T I194T none none none 
MTB17  INHR, RIFR, STRR, ETBR, PZAR  R R R S S R R R  C-15T I194T none none none 
MTB, M. tuberculosis; DST, drug susceptibility testing; qDST, quantitative drug susceptibility testing; prom, promoter; INH, isoniazid; ETH, ethionamide; 
RIF, rifampicin; STR, streptomycin; ETB, ethambutol; PZA, pyrazinamide; R, resistant; I, intermediate; S, susceptible. 
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8. Supplementary Material and methods 
Table IIB.S1. Primers used in this study. 






inhA inhA-3 AGG TCG CCG GGG TGG TCA GC 
64 517 1 
 inhA-4 AGC GCC TTG GCC ATC GAA GCA 
 inhA-3F CCA CAT CTC GGC GTA TTC G 
60 501 2 
 inhA-5R TTC CGG TCC GCC GAA CGA CAG 
ethA ethA1 ATC ATC GTC GTC TGA CTA TGG 
55 667 1 
 ethA5 ACT ACA ACC CCT GGG ACC 
 ethA4 CCT CGA CCT TCC CGT GA 
64 692 1 
 ethA9 CCT CGA GTA CGT CAA GAG CAC 
 ethA8 GGT GGA ACC GGA TAT GCC TG 
68 342 1 
 ethA10 CGT TGA CGG CCT CGA CAT TAC 
ndh ndh3S GAC AGA TCG CCG AGC TGG C 
60 372 3 
 ndh3AS TGG ACA GGT CGG GCA GCA C 
katG P4_Fw CGG ACC ATA ACG GCT TCC TG 
62 563 This study 
 P4_Rv TTG TCC AAG CTG GCG TTG TC 
 P5_Fw CGA CAA CGC CAG CTT GGA C 
62 518 This study 
 P5_Rv CGG TTC CGG TGC CAT ACG 
 P6_Fw AGC TCG TAT GGC ACC GGA AC 
62 619 This study 
 P6_Rv TGA CCT CCC ACC CGA CTT GT 
 P7_Fw ACA AGT CGG GTG GGA GGT C 
62 574 This study 
 P7_Rv CTG CCG GTC CAC TTC ACC TT 
 P8_Fw GGG ACC TAC CAG GGC AAG GA 
62 627 This study 
 P8_Rv CCG GGA GTC AGC AAG TCA CC 
Fw/F: forward; Rv/R: reverse; S: sense; AS: antisense. 
 
The reaction mixtures were prepared for a total reaction volume of 50 µl consisting of 
1x Taq buffer (Fermentas, Ontario, Canada), 1.75 mM MgCl2 (1.5 mM for inhA/katG), 
200 mM of each dNTP, 6 pmol of each primer (20 pmol for inhA; 10 pmol for katG), 
1.5U Taq DNA Polymerase (Fermentas), and 5 µl of chromosomal DNA. The PCR 
reactions were performed with the following amplification profile: initial denaturation at 
94ºC for 5 minutes, followed by denaturation at 94ºC for 1 minute, primer dependent 
annealing temperature for 1 minute and extension at 72ºC for 1 minute during 40 cycles. 
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Preface to Chapter III 
 
From the results obtained in Chapter II we can conclude that i) there is a clear 
correlation between the occurrence of gene mutations in the drug targets and the 
resistance phenotype of a strain and, ii) the chromosomal alterations associated with 
resistance are greatly conserved. There is, however, little information available on the 
mechanism behind the development of such resistance and how it emerges in a patient 
under therapy.  
Acquired drug resistance during tuberculosis treatment occurs mainly due to poor 
compliance resulting in sub-optimal therapeutic conditions that select drug resistant 
variants. Mutational resistance is responsible for treatment failure and for the emergence 
of resistance. Preliminary work performed by our group has demonstrated that the 
exposure of M. tuberculosis strains to isoniazid induces the activity of efflux pumps that 
make the bacteria more resistant to this antibiotic. However, the biological basis of 
these events remains to be fully characterized. It is now generally accepted that the 
overall M. tuberculosis resistance to any antituberculosis drug is not merely a 
consequence of the occurrence of gene mutations in the drug target but a balance 
between the acquisition of mutations and the efflux of antibiotics. Intrinsic drug 
resistance in mycobacteria is mainly attributed to the reduced permeability of the cell 
wall that acts synergistically with the activity of efflux pumps present in that wall and 
the increased expression of genes that code for those efflux pumps. This combined 
mechanism may constitute the first step for the development of drug resistance in M. 
tuberculosis. 
In this chapter, we focus on the understanding of the chain of events leading to the 
development of resistance in M. tuberculosis, with particular emphasis on the 
differential activity of genes that code for the main M. tuberculosis efflux pumps prior 
to, during and, after the establishment of the resistance phenotype and their interaction 
with the genetically based resistance. The underlying concept of this study is that 
increased activity of efflux pumps allows a sustainable resistant population to be 
maintained in the patient under therapy, from which genetically resistant mutants will 
emerge with increased frequency. This experimentally produced adaptive phenotypic 





treatment with those antibiotics is sub-optimal. Testing efflux pumps inhibitors on these 
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1. Abstract  
Multidrug resistant (MDR) tuberculosis is caused by Mycobacterium tuberculosis 
resistant to isoniazid and rifampicin, the two most effective drugs used in tuberculosis 
therapy. Here, we investigated the mechanism by which resistance towards isoniazid 
develops and how overexpression of efflux pumps favors accumulation of mutations in 
isoniazid targets, thus establishing a MDR phenotype. The study was based on the in 
vitro induction of an isoniazid resistant phenotype by prolonged serial exposure of M. 
tuberculosis strains to the critical concentration of isoniazid employed for determination 
of drug susceptibility testing in clinical isolates. Results show that susceptible and 
rifampicin monoresistant strains exposed to this concentration become resistant to 
isoniazid after three weeks; and that resistance observed for the majority of these strains 
could be reduced by means of efflux pumps inhibitors. RT-qPCR assessment of efflux 
pump genes expression showed overexpression of all tested genes. Enhanced real-time 
efflux of ethidium bromide, a common efflux pump substrate, was also observed, 
showing a clear relation between overexpression of the genes and increased efflux pump 
function. Further exposure to isoniazid resulted in the selection and stabilization of 
spontaneous mutations and deletions in the katG gene, alongside with sustained 
increased efflux activity. Together, results demonstrate the relevance of efflux pumps as 
one of the factors of isoniazid resistance in M. tuberculosis. These results support the 
hypothesis that activity of efflux pumps allows the maintenance of an isoniazid resistant 
population in a sub-optimally treated patient from which isoniazid genetically resistant 
mutants emerge. Therefore, the use of inhibitors of efflux should be considered in the 




Tuberculosis (TB) remains a serious public health threat around the world, and  
according to the World Health Organization, nearly two billion people are infected with 
Mycobacterium tuberculosis, with about 8.8 million of new TB cases and 1.3 million 




tuberculosis simultaneously resistant to isoniazid and rifampicin, the two most effective 
anti-bacillary drugs used in TB therapy, represents a challenge to the control of the 
disease since 650,000 of the TB cases in 2010 are estimated to be MDR-TB cases [1]. 
Chromosomal gene mutation has been considered the single cause for antibiotic 
resistance in M. tuberculosis, with multidrug resistance arising as a consequence of 
sequential accumulation of spontaneous mutations in target genes [2]. Resistance to 
rifampicin is almost always due to point mutations in the rpoB gene encoding the β 
subunit of the RNA polymerase [3]. Furthermore, monoresistance to rifampicin is rare 
and almost all M. tuberculosis strains resistant to rifampicin are also resistant to 
isoniazid [2,4,5]. Isoniazid is a prodrug that requires activation by the catalase-
peroxidase enzyme (KatG) [6] and its molecular target is InhA, a NADH-dependent 
enoyl acyl carrier protein reductase involved in the synthesis of mycolic acids [7]. The 
main mechanism of resistance to isoniazid is the occurrence of mutations in its 
activator, KatG [6,8], whereas mutations in the inhA gene represent the second most 
common mechanism. Together, mutations in these two genes are responsible for 
approximately 75% of the cases of M. tuberculosis resistance to isoniazid in the clinical 
setting [9]. Resistance to isoniazid has also been associated with mutations in several 
other genes (e.g. ndh, kasA and oxyR–ahpC intergenic region) [10], but its direct 
association with resistance is still unclear.  
Isoniazid is highly effective against M. tuberculosis (bactericidal at low concentrations), 
the reason why it remains a key component in multiple drug treatment regimens. 
However, resistant isolates are rapidly generated during monotherapy or inappropriate 
treatment, and many clinical isolates with no identified mutation have been described 
[9,11]. As with other bacterial species, these resistant phenotypes also receive 
significant contributions from membrane transport proteins that prevent the compound 
from reaching the cellular target [12,13]. The analysis of genome sequences has shown 
that mycobacteria have multiple putative efflux pumps [14] and to date, several pumps 
have been identified in various species of mycobacteria in association with low level 
resistance to various compounds, including isoniazid [15-20].  
In general, increased activity of efflux systems is responsible for conferring low-level 
resistance to antibiotics, contrasting with the high-level resistance caused by mutations 




efflux systems results in the reduction of intracellular levels of the antibiotic, which 
may enable the survival of a bacterial subpopulation under constant stress promoted by 
a sub-lethal level of antibiotic. During this period, mutants with alterations in the genes 
that favour resistance can be selected, therefore insuring the establishment of an 
antibiotic resistant population that is clinically significant [22-24]. It is this sub-
population of bacteria that may then accumulate mutations with prolonged exposure to a 
constant concentration of antibiotic [25,26]. 
 
Here, we investigated the mechanisms underlying the development of multidrug 
resistance in M. tuberculosis via the constant exposure of several isoniazid susceptible 
M. tuberculosis strains to the critical concentration of isoniazid, 0.1 µg/ml; followed by 
the evaluation of the effect of efflux inhibitors on the isoniazid minimum inhibitory 
concentration for the original and isoniazid exposed resistant strains. Analysis of gene 
expression of six efflux pumps related to isoniazid resistance in M. tuberculosis 
[12,15,19] and its correlation with the cell´s ability to efflux ethidium bromide (a 
common efflux substrate), provides strong evidence that when challenged with 
isoniazid, M. tuberculosis reacts by a prompt efflux-mediated response. We further 
demonstrate that this isoniazid induced resistance can be reverted by efflux inhibitors, 




Exposure to isoniazid 
Two M. tuberculosis strains susceptible to the first-line antibiotics (including the 
H37Rv reference strain) and two clinical strains monoresistant to rifampicin were 
constantly exposed to the critical concentration of isoniazid, 0.1 µg/ml, during an 
extended period of time – see Figure III.1. Two independent exposure processes were 
carried out for each strain (exposure process A and B in Figure III.1) to assess the 
stochastic behaviour of the biological events involved. 
The effect of 0.1 µg/ml isoniazid exposure on the minimum inhibitory concentration of 




initial value of 0.05-0.1 µg/ml to as high as 256 µg/ ml (Table III.1). Exposure to 
isoniazid had no effect on the MIC of rifampicin against all strains (data not shown). 
Additionally, susceptibility testing for the five 1st line antibiotics (streptomycin, 
isoniazid, rifampicin, ethambutol and pyrazinamide) applied to all strains at the 
beginning of the experiments and after the last passage in isoniazid indicated that 
development of resistance was restricted to isoniazid only (data not shown). We also 
observed that the time required for growth detection decreased with the number of 
passages (Table III.1).  
Typing by MIRU-VNTR analysis 
To confirm the isogenic nature of the exposed and initial parental strains, all strains 
were subjected to molecular typing by MIRU-VNTR analysis, which confirmed the 
identity of each culture during the antibiotic exposure processes (Tables III.2 and III.3). 
Detection of mutations associated with isoniazid resistance  
Cultures corresponding to selected passages of isoniazid exposure were preliminarily 
monitored for mutations in katG and mabA-inhA operon by the Genotype MTBDRplus 
system. These strains were later analyzed by DNA sequencing of specific fragments of 
these same genes – see Table III.2 and III.3.  
For strain H37Rv, two different results were obtained for the two independent isoniazid 
exposure processes. In one of the duplicates, total deletion of katG gene was observed at 
passage #3 (H37RvINH(a)3, GenBank accession number JQ406585). The precise extent 
and location of this deletion was defined by sequencing and chromosomal primer 
walking to be located between positions 5’-2150314 and 5’-2159943 of the M. 
tuberculosis H37Rv genome [14]. This deletion, 8084 bp in length, resulted in the 
complete loss of genes Rv1903, Rv1904, aao, Rv1906c, Rv1907c, katG, furA, Rv1910c, 
lppc and disruption of  fadB5 (Figure III.2).  
Conversely, no alterations were detected on katG or any of the other gene targets tested 
during strain H37Rv second isoniazid exposure process (cf. Tables III.2 and III.3). 
Interestingly, both isoniazid-exposed cultures evidenced the same levels of resistance at 
equivalent passages of the exposure process (Table III.1). For the three clinical strains 




for the appearance of a STOP codon in position 1314 of the katG gene (codon 438) for 
strain 359/03. This alteration occurred at passage #2 (359/03INH(a)2, accession number 
JQ316462) of the first exposure process (Table III.2), whereas no alteration was 
detected in the second exposure process of this same strain (Table III.3). Again, no 
differences were observed between the isoniazid resistance levels of the two isoniazid-
exposed 359/03 cultures (Table III.1).  
Effect of EIs on the susceptibility to isoniazid  
To test for the involvement of efflux on the increased resistance to isoniazid noticed 
through the exposure process, we determined the INH MIC in the first passage where 
this increased resistance was first noticed and in last passage (#26) of the exposure 
process, in the absence and presence of compounds known to act as efflux inhibitors 
(EIs). The compounds selected were thioridazine, chlorpromazine and verapamil, for 
which inhibitory activity against mycobacterial efflux pumps was already demonstrated 
[16,27, 28]. The effects of these EIs on the INH MICs are summarized in Table III.4. 
The INH MIC was reduced by thioridazine, chlorpromazine and verapamil to levels 
equal or below the critical concentration used for the standard susceptibility testing of 
this antibiotic in the majority of cases. We then assayed the efflux activity of these 
cultures by a semi-automated fluorometric method [27,29], which uses the broad-range 
efflux substrate EtBr, in the presence and absence of an EI. 
Real-time detection of efflux activity  
The assays were performed for all isoniazid non-exposed strains (#0) and at passages #1 
and #26 of the two exposure processes (A and B).  
The EtBr accumulation assays, used to determine the highest concentration of EtBr that 
cells can handle without detectable accumulation (see Material and Methods), showed 
that the clinical strains are able to handle higher EtBr concentrations than H37Rv (0.25-
0.5 and 0.125 µg/ml of EtBr, respectively – see values at bold type in legends of Figure 
III.3A). This means that the concentration at which EtBr influx and efflux reach steady 
state equilibrium is higher for the clinical strains than for H37Rv, i.e. that the former 
have higher efflux capacity than that of the reference strain [29]. With exposure to 
isoniazid, this efflux capacity increase, as shown by the flatness of the accumulation 




continuation of exposure to isoniazid, this efflux activity decreases, as shown by the 
lower EtBr concentrations needed to reach observable accumulation for cultures at 
passage #26 (cf. Fig III.3C with III.3B), however not to the original levels shown by the 
non-exposed cultures (cf. Fig III.3C with III.3A). Interestingly, this decrease of efflux 
activity with the prolonged exposure to isoniazid is observable for the clinical strains 
but not for H37Rv. For the sake of space, only the results for exposure process A are 
shown in Figure III.3, but the same behavior was obtained for the exposure process B, 
for all the strains. 
These assays were then performed using the EtBr concentrations for which influx-efflux 
are at equilibrium, but now in the presence of verapamil (efflux inhibitor) at sub-
inhibitory concentrations (see dotted curves in Figure III.3). Results clearly show that 
inhibition of efflux occurs, leading to an increased EtBr accumulation within cells. 
Again, this effect is more pronounced at the first step of isoniazid exposure (passage 
#1), except for H37Rv, which reinforces the hypothesis that this is the step in which the 
increase of efflux activity is more significant. Similar results were obtained for 
thioridazine and chlorpromazine, however with lower inhibitory effect (data not shown).  
Finally, we evaluated the expression levels of genes coding for the main M. tuberculosis 
efflux pumps for cultures at the different isoniazid exposure steps.  
 
Expression analysis of genes coding for efflux pumps in response to isoniazid 
The analysis of the relative expression of efflux pump genes previously identified as 
transporters of isoniazid was performed for all strains at passages #1 and #26. As 
detailed in Material and Methods, the expression levels of these genes were determined 
in the presence of isoniazid and compared to those obtained for the non-exposed culture 
(#0) [30].  
Table III.5 shows that the four strains reacted to the presence of isoniazid by 
overexpressing the majority of the efflux pump genes tested in a way that is not 
consistent among the two isoniazid exposures processes to which each strain was 
submitted. Additionally, and perhaps the most striking observation resulting from 
expression data, was the absence of a clearly defined pattern of gene expression in 
response to isoniazid exposure. Nevertheless, a general and strong increase in the 
expression was observed for the majority of the genes tested, mmpL7, p55, efpA, mmr, 





In this work, we addressed three questions related to the molecular mechanisms 
involved in M. tuberculosis resistance to isoniazid: i. What are the effects of continuous 
exposure of M. tuberculosis strains to the critical concentration of isoniazid? ii. What 
are the biological events involved, in particular, which is the role played by efflux 
pumps in the emergence of resistance? and, iii. Does the final outcome vary when 
independent exposures are performed for the same strain?  
For this purpose, we studied a panel of four M. tuberculosis strains, two fully 
susceptible and two monoresistant to rifampicin, through their independent exposure to 
a constant concentration of 0.1 µg/ml of isoniazid. During this process, strains became 
phenotypically resistant with an increase in their INH MIC exceeding 64 µg/ ml, which 
is considered high-level resistance. The susceptibility towards the other 1st line anti-
tuberculosis drugs was not affected by this process, indicating the development of an 
isoniazid specific resistance mechanism. 
In terms of the biological events occurring during exposure to isoniazid (question ii), we 
observed that for two strains, alterations occurred at the katG gene, corresponding to a 
full deletion in the case of H37Rv and the introduction of a stop codon for strain 359/03. 
Both alteration occurred early in the exposure process and were maintained for the 
remaining of the assays. These alterations in katG correlated with the loss of catalase 
activity (data not shown). The mutation found in clinical isolate 359/03 is rarely 
described in literature; however it fits into the known strategy of KatG functional 
weakening by introduction of mutations during isoniazid exposure [10,31]. Others have 
also reported the in vitro deletion of total or part of the katG gene in strains exposed to 
isoniazid [31,32], and total/partial deletion of the katG gene of isoniazid-resistant 
clinical isolates has also been previously reported [8,33]. Interestingly, no genetic 
changes were detected in the second isoniazid-exposure procedure, run in parallel for 
these same strains, indicating that evolution of the same strain in the same conditions 
can bring about, in a non-deterministic course, cells that significantly differ both 




Our results clearly show that, in addition to the occurrence of spontaneous mutations, 
efflux systems play a role in the development of isoniazid resistance. This occurs quite 
early during exposure to isoniazid and allows cells to survive in the presence of this 
antibiotic until a mutation conferring high level and stable resistance emerges. Recently, 
Srivastava et al., suggested a model for the development of drug resistance in the M. 
tuberculosis reference strain H37Rv, enabling the rapid emergence of high level 
resistance to both ethambutol and isoniazid [34]. In this model, it is proposed that 
induction of an efflux pump which transports two or more drugs is the first step to the 
emergence of resistance. Our results provide the experimental data that confirm the 
model proposed by these authors and demonstrate that this mechanism is extendable to 
clinical isolates.  
Moreover, our work provides, for the first time, data captured on a real-time basis for 
increased efflux activity as the first-line response of M. tuberculosis to the critical 
concentration of isoniazid. This efflux-mediated response was detected for both 
susceptible and rifampicin monoresistant, reference or clinical strains and provide the 
cells with a rapid, nonspecific response to a highly noxious agent. As the isoniazid 
exposure process continues, two different patterns were observed: the susceptible 
reference strain H37Rv increased its efflux activity, even after deletion of the entire 
katG gene, whereas the clinical strains showed a decreased efflux activity in the last 
passage of isoniazid exposure. During the entire process, the clinical strains showed a 
capacity to handle higher EtBr concentrations than H37Rv, an additional evidence of 
their higher efflux capacity. Overall, the clinical strains appear to be more prompt to 
respond, via an efflux-mediated pathway, to noxious agents, such as EtBr or isoniazid, 
whereas H37Rv shows a less prompt, but more stable/prolonged use of efflux as a 
detoxifying response to these drugs. These results suggest that clinical M. tuberculosis 
strains are primed to efflux noxious compounds, as already observed in other bacteria 
[35]. The presence of such efflux system(s) and their role in resistance to these drugs 
was additionally confirmed by the use of efflux inhibitors in both real-time efflux assays 
and MIC determinations. While in the first assays, these compounds were able to reduce 
efflux of EtBr, their use in INH MIC determination showed the involvement of efflux 
on the high level resistance to this antibiotic. For some strains, the reduction on INH 




This clearly shows that in these cases, high level isoniazid resistance is mainly efflux-
driven. From the several inhibitors tested, chlorpromazine and verapamil were the two 
most effective for inhibiting isoniazid efflux in M. tuberculosis, as previously 
demonstrated for M. tuberculosis complex [36].  
It is worth noticing that EIs show a more significant effect on the MICs for cultures at 
first passage compared to their effect on the MICs of the last passage (#26). For strain 
401/06, submitted to exposure process A, despite the fact that no evident genetic 
alteration was detected, the high INH MIC obtained after isoniazid exposure could not 
be reduced by any of the EIs tested (Table III.4). This result suggests that, for this 
culture, the isoniazid high level resistance detectable at first passage is already 
mutation-driven. Interestingly strain 267/05, without detectable mutations is the one 
with the highest level of expression of genes for efflux further supporting that 
overexpression of efflux-pumps can sustain isoniazid resistance to levels as high as 
those achieved by the canonical mutations. 
To identify the efflux system(s) involved in this first-line response to isoniazid, we 
selected a set of genes coding for efflux pumps reported to be involved in the transport 
of noxious substances, including isoniazid [12,15,37]. The detection by RT-qPCR of 
highly increased expression of these genes following isoniazid exposure, further 
evidences that an efflux-mediated response provides an early stress response that creates 
opportunity for other resistance mechanisms to arise.  
Although we detected a general and marked increase of efflux pumps genes, most of 
which being significantly overexpressed, we also noted the absence of a clearly defined 
pattern of specific gene expression in response to isoniazid exposure. Efflux pumps 
seem to be promiscuous in their activity as we cannot associate extrusion of isoniazid to 
a specific gene. Similar results were obtained by others regarding the extrusion of 
rifampicin [38]. As described in Materials and Methods, the RT-qPCR data were 
analyzed considering a cut-off value of fourfold as corresponding to significant 
overexpression [39]. This can be considered a stringent cut-off and somehow limit our 
analysis [40], since the levels of gene expression obtained, in comparison to the non-
exposed condition, lied in the majority of the cases, above two/three fold. Nevertheless, 




efflux pump genes overexpression in response to isoniazid presence was observed along 
the exposure processes, for all strains. The genes for which a more consistent isoniazid-
mediated response was observed, were the genes involved in the transport and synthesis 
of mycolic acids, mmpL7 and efpA respectively [41,42], and p55, considered to be 
involved in isoniazid transport [17,20,38,43,44]. Again, our study complements other 
earlier findings [15,34,36], who suggested the involvement of these genes in the 
resistance to isoniazid, by providing experimental data showing that susceptible 
reference strain and clinical strains use these pumps as an immediate response to the 
presence of isoniazid concentrations that are considered to be inhibitory.  
Finally, concerning the third question raised in this work - does the final outcome vary 
when independent exposures are performed for the same strain, we have found that each 
strain may differ at the final outcome of the process of its exposure to the isoniazid 
critical concentration, in terms of the resistance mechanism it may adopt (mutations in 
different target genes, etc), although no differences were observed at the resistance 
level, which was always well above 64 µg/ml of isoniazid. Nevertheless, they all 
respond in a similar way at the first steps of this process and that is through isoniazid 
efflux, which may constitute an early stress response of bacteria against environmental 
noxious agents such as appears to be the case for isoniazid. After this first, efflux-
mediated response, evolution may take different non-deterministic paths conducting to 
high level resistance. Collectively, these observations support the experimental strategy 
followed in this work that highlighted alternative pathways by which the same M. 
tuberculosis strain responds to 0.1 µg/ml isoniazid, all resulting in the same high 
resistance level.  
In conclusion, constant exposure of M. tuberculosis to the commonly used critical 
concentration of isoniazid causes susceptible strains to become highly resistant to this 
key anti-tuberculosis drug. The same procedure applied to strains initially monoresistant 
to rifampin results in the development of multidrug resistance as defined by the WHO, 
i.e, resistance to isoniazid and rifampicin. To our knowledge, this is the first 
presentation of an in vitro process that mimics the development of multidrug resistant 
M. tuberculosis strains, which correlates with the anticipated development of MDR-TB 




for effective therapy. Therefore, the results obtained in this work emphasize the need for 
revising isoniazid critical concentration and reinforce the importance of multiple drug 
therapy in all anti-tuberculosis regimens [45,46]. Furthermore, efflux inhibitors like the 
ones tested in this work represent relevant alternatives in the search for new effective 
compounds and new therapeutic strategies for preventing the emergence of and possibly 
in the treatment of MDR-TB. 
 
5. Materials and Methods 
M. tuberculosis strains 
The strains studied included two M. tuberculosis strains susceptible to the first-line 
antibiotics, the reference strain H37Rv ATCC27294T and a clinical isolate 401/06, plus; 
two clinical isolates 359/03 and 267/05, both monoresistant to rifampicin, harboring the 
most common rpoB mutation in clinical isolates, S531L, all from the culture collection 
of Grupo de Micobactérias, Unidade de Microbiologia Médica, Instituto de Higiene e 
Medicina Tropical (IHMT, UNL). 
Cultures, susceptibility testing, minimum inhibitory concentration (MIC) determination 
and antibiotic exposure process was conducted using the  BACTECTM MGITTM 960 
system (BACTEC 960) and the Epicenter V5.53A software equipped with the TB 
eXIST module (Becton Dickinson Diagnostic Systems, Sparks, MD, USA).  
 
Antimicrobial agents 
The lyophilized drugs (BACTECTM MGITTM 960 SIRE and PZA kits; SIRE: 
streptomycin, isoniazid, rifampicin and ethambutol; PZA: pyrazinamide) used in the 
standard susceptibility testing and in the exposure process to isoniazid and rifampicin 
were purchased from Becton Dickinson and the stock solutions prepared as per the 
manufacturer’s instructions. Isoniazid for MIC determination and efflux inhibitors 
verapamil, thioridazine and chlorpromazine, as well as the efflux substrate ethidium 
bromide (EtBr), were purchased from Sigma-Aldrich (St. Louis, MO, USA). All drugs 







Exposure process to the critical concentration of isoniazid 
Each strain was exposed to isoniazid (0.1 μg/ml) in duplicate (Figure III.1 – Schematic 
example for isoniazid exposure of strain H37Rv ATCC27294T). This concentration is 
defined as the lowest concentration necessary to inhibit 99% of the wild-type strains of 
M. tuberculosis that were never in contact with this antibiotic, and is the critical 
concentration used for the BACTECTM MGITTM 960 SIRE AST procedure [47,48]. 
Briefly, the exposure process for strains susceptible to isoniazid began with the 
preparation of MGIT tubes containing SIRE supplement (Becton Dickinson) and 0.1 
μg/ml of isoniazid. These tubes were then inoculated with 0.5 ml of the initial culture 
and subsequently incubated at 37ºC in the BACTEC 960 system until full growth was 
evident. For each strain, this process was done in duplicate – see Figure III.1 for 
example.  
For convenience, the various passages of the strains are identified as follows: strain 
number, antibiotic, exposure process (A or B) and the number of the passage. For 
example, H37RvINH (a)26 refers to strain H37Rv exposed to isoniazid, exposure process 
A, passage 26 – see Figure III.1 for example. 
 
MIC determination and antibiotic susceptibility testing  
(i) MIC determination: The MICs of the antibiotics and efflux inhibitors (EIs) were 
performed in accordance to the procedures issued by the manufacturer of the BACTEC 
960 system revised by Springer et al. [48,49] for the parental strains at the initial 
process and periodically for each of the progeny cultures (Figure III.1). The 
concentrations used were as follows: isoniazid: 0.025 to 256 µg/ml; verapamil: 30 to 
512 μg/ml; thioridazine and chlorpromazine: 7.5 to 60 μg/ml; EtBr: 0.25 to 4 μg/ml. At 
the time of testing, two-fold serial dilutions were prepared to achieve the desired 
concentrations. Each drug-containing tube was inoculated with 0.8 ml of SIRE 
supplement, 0.1 ml of each drug in the appropriated concentration and 0.5 ml of the 
culture. For the preparation of the drug-free growth control tube (proportional control), 
the culture was diluted 1:100 with a sterile saline solution and 0.5 ml transferred into a 
new MGIT tube. Additionally, a second drug-free growth control, inoculated with 0.5 
ml of the undiluted suspension of the strain, was prepared and served as absolute control 




monitored with the TB eXIST module. The interpretation of the results was performed 
as proposed by Springer et al. [49].  
(ii) Isoniazid MIC determination in the presence of EIs: The MICs of isoniazid (INH 
MIC) in combination with the EIs were performed in the first passage where the 
increased resistance was first noticed and in the last passage (#26) of the serial exposure 
process to isoniazid – Figure III.1. The EIs were used at a concentration corresponding 
to ½ of the respective MIC. This concentration was selected since it has no effect on the 
growth of the strains following the protocol described above.  
(iii) Susceptibility testing in the presence and absence of EIs: For standard 
susceptibility testing against isoniazid, rifampicin, pyrazinamide, streptomycin and 
ethambutol, the readings were automatically interpreted by the BACTEC 960 system 
and reported as either susceptible or resistant. The preparation of the drug containing 
tubes and controls was done as described above. For the susceptibility testing for 
isoniazid in the presence of the EIs, the tubes containing 0.1 µg/ml of isoniazid were 
inoculated with the EI at ½ of the MIC. 
 
Genotypic characterization of the strains 
(i) DNA extraction: Genomic DNA was extracted using the QIAamp DNA mini kit 
(QIAGEN, GmbH, Hilden, Germany) according to the manufacturer’s instructions.  
(ii) Screening of mutations: The most common mutations in rpoB, katG and the mabA-
inhA operon were screened during the exposure process, using the system Genotype 
MTBDRplus (Hain Lifescience GmbH, Nehren, Germany) according to the 
manufacturer’s instructions.  
(iii) DNA sequencing: The analysis of internal fragments of the genes associated with 
isoniazid resistance, katG and the mabA-inhA operon, was performed according to 
Perdigão et al. [50].  
(iv) MIRU-VNTR analysis: MIRU-VNTR genotyping was performed for each strain 
and at defined passages of the exposure process by multiplex PCR amplification of 24 
MIRU–VNTR loci, as described by Supply et al. [51].  
 
Quantification of expression of genes coding for efflux pumps by RT-qPCR 
(i) RNA extraction: Total RNA was isolated from the cells using the RNeasy mini kit 




100-200 GU (about 106-108 cells/ml), 1 ml aliquot was removed and centrifuged at 13 
000 rpm during 10 minutes. Then, 500 µl supernatant was removed and 1 ml of 
RNAprotect Bacteria reagent (QIAGEN) added. An enzymatic lysis step was carried 
out with lysozyme at 3 µg/ml (Sigma) for 10 minutes, followed by lysis in an ultrasonic 
bath at 35 kHz (Gen-Probe, California, USA) during 15 minutes. The RNA was then 
purified using the RNeasy kit (QIAGEN) and treated with RNase-free DNase I 
(QIAGEN) during 2 hours and 15 minutes by on-column digestion at room temperature 
to reduce the presence of contaminating DNA. All RNA samples were aliquoted and 
frozen at -20ºC until required.  (ii) RT-qPCR assay: The relative expression level of 
the genes that code for the main membrane efflux transporters in M. tuberculosis 
(mmpL7, p55, efpA, mmr, Rv1258c and Rv2459) were analyzed by RT-qPCR in the first 
passage where the increased resistance was first noticed and in last passage (#26) of the 
exposure process to isoniazid – Figure III.1. The normalization of the data was done 
using the M. tuberculosis 16S rDNA for each experiment. The forward and reversed 
primers employed are described in Table III.6. The RT-qPCR procedure was performed 
in a Rotor-GeneTM 3000 thermocycler and followed the protocol recommended for use 
with the QuantiTect SYBR Green RT-PCR Kit (QIAGEN). The determination of the 
relative mRNA expression level was performed using the comparative quantification 
cycle (Cq) method [40]. The relative expression of the six efflux pump genes analyzed 
was assessed by comparison of the relative quantity of the respective mRNA in the 
presence of isoniazid to the non-exposed culture, following the same technical approach 
previously published [30]. Each culture was assayed in triplicate using total RNA 
obtained from three independent cultures. A level of relative expression equal to 1 
indicates that the expression level was identical to the unexposed strain. Genes showing 
expression levels equal or above four, when compared with the unexposed strain, were 
considered to be overexpressed [39].  
 
Semi-automated fluorometric method  
This method allows the real-time fluorometric detection of the accumulation and 
extrusion of EtBr, using the Rotor-Gene 3000TM thermocycler (Corbett Research, 
Sidney, Australia) [29,52]. The assays were performed based on the protocol previously 




microorganism, mainly the slow generation time and the minimization of cell clumps. 
Increased biosafety measures were taken to prevent the production and dispersal of 
aerosols with infective particles since we were dealing with a Level 3 pathogen. The 
semi-automated fluorometric method was applied to the initial strains and to the 
isoniazid exposed strains, at the first passage where the increased resistance was first 
noticed and in the last passage (#26) of the adaptation process to isoniazid 
independently of the genetic background of each adapted culture. The strains were 
grown in 100 ml of Middlebrook 7H9 medium (DIFCO, Madrid, Spain) in Erlenmeyer 
flasks containing 10% OADC enrichment (Becton Dickinson) and 0.05% Tween 80. All 
cultures were incubated at 37ºC, without stirring, until they reached an approximate 
optical density at 600 nm (OD600) of 0.8 (mid-log phase). After the cultures reached the 
desired OD600, 25 ml cultures were centrifuged at 2700 g during 3 minutes at 25ºC. 
After this, the supernatant were discarded, the pellet washed, resuspended in PBS and 
centrifuged as before. This procedure was performed twice. For accumulation assays, 
the washed cells were re-suspended in PBS and the OD600 adjusted to 0.8. In order to 
determine the lowest concentration of EtBr that causes accumulation, 50 µl of the 
bacterial suspension was added to 0.2 ml PCR tubes containing different concentrations 
of EtBr that ranged from 0.0625 to 5 µg/ml and glucose at a final concentration of 0.4%. 
The final OD600 of the bacterial suspension in the assay was 0.4. The assays were 
conducted at 37ºC in a Rotor-Gene 3000TM, and the fluorescence of EtBr was measured 
(530/585 nm) at the end of each cycle of 60 seconds, for 60 minutes. After determining 
the higher concentration of EtBr that do not causes accumulation, the effect of the EIs 
verapamil, thioridazine and chlorpromazine on the accumulation of EtBr was evaluated. 
These assays were performed like described above with each EI at ½ of the MIC, EtBr 
at the higher concentration that do not cause accumulation (determined for each strain 










6. Figures  
 
Figure III.1. Schematic representation of exposure of strain H37Rv to 0.1 μg/ml INH using 
the BACTECTM MGITTM 960 and characterization assays performed at selected points. 
For each strain, exposure to INH was done in duplicate, in two independent assays - processes 
A and B. INH(a): exposure process A; INH(b): exposure process B; INH: isoniazid; EI: efflux 
inhibitor. Vertical arrows represent transfer to new MGIT tubes containing 0.1 µg/ml INH. Seq: 
nucleotide sequence determination for specific fragments of the genes involved in the resistance 
to INH; AST: susceptibility testing to all first line antibiotics. MICINH: minimum inhibitory 
concentration determination of isoniazid. Note: This same procedure, here depicted as an 
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Figure III.2. Map of the region deleted in the M. tuberculosis H37Rv reference strain as a 
result of the exposure to isoniazid. The region analyzed spans from positions 5’-2150314 to 
5’-2159943 of the M. tuberculosis H37Rv genome sequence [14], adapted from Tuberculist, 
2010, http://tuberculist.epfl.ch/. The area delimited corresponds to the fragment deleted in strain 
H37RvINH(a)3. 
  





















Figure III.3. Accumulation of EtBr by the M. tuberculosis strains tested.  The figure shows 
the accumulation of EtBr by the strains from adaptation process A as an example. The values at 
bold type correspond to the higher concentration of EtBr that cells can handle without detectable 
accumulation. The dotted line corresponds to the assay run using the EtBr concentrations for 
which influx-efflux are at equilibrium, in the presence of the EI verapamil, at sub-inhibitory 
concentrations. Panel (A): Parental strains (passage #0); Panel (B) strains after first passage 
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7. Tables  
 
Table III.1. The effect of serial passages in a constant concentration of isoniazid (0.1 
μg/ml) on the INH MIC and the number of days required for detection of growth.  
 INH MIC (μg/ml) (days required for detection of growth) 
 #0 #1 #2 #3 #5 #13 #26 
Fully susceptible strains 
H37Rv INH (a) 0.05 (-) 128 (19) 128 (5) 128 (4) 128 (4) 128 (4) 128 (4) 
H37Rv INH (b) 0.05 (-) 128 (14) 128 (8) 128 (5) 128 (3) 128 (3) 128 (3) 
401/06 INH (a) 0.1 (-) 256 (20) 256 (6) 256 (4) 256 (4) 256 (4) 256 (3) 
401/06 INH (b) 0.1 (-) 64 (32) 256 (14) 256 (18) 256 (7) 256 (4) 256 (3) 
Rifampicin monoresistant strains 
267/05 INH (a) 0.1 (-) 128 (15) 128 (7) 128 (4) 128 (6) 128 (3) 128 (3) 
267/05 INH (b) 0.1 (-) 128 (17) 128 (5) 128 (4) 128 (7) 128 (4) 128 (3) 
359/03 INH (a) 0.05 (-) 256 (18) 256 (13) 256 (6) 256 (4) 256 (4) 256 (3) 
359/03 INH (b) 0.05 (-) 128 (17) 256 (16) 256 (3) 256 (3) 256 (8) 256 (3) 





Table III.2. Genotypic characterization of the strains and derived cultures exposed to isoniazid (adaptation process A). 
 
Legend: INH: isoniazid; RIF: rifampicin; wt: wild type; Δ: deletion of katG gene; S: serine; L: leucine. MIRU-VNTR profile A: 2,4,2,2,3,4,2,3,2,3,2,4,2,2,6,1,6,3,1,3,1,7,2,2;  
profile B: 2,4,4,2,3,4,3,3,2,4,2,4,2,2,6,1,5,3,1,3,1,5,2,2; profile C: 2,1,4,2,1,3,2,3,2,2,2,5,1,2,6,1,6,3,3,3,2,4,2,2. 
 Genotype MTBDRplus DNA Sequencing  
Strain/Passage rpoB mabA-inhA katG mabA-inhA katG MIRU-VNTR profile 
H37Rv Wt wt wt wt Wt H37Rv 
H37Rv INH (a)1 Wt wt wt wt wt H37Rv 
H37Rv INH (a)2 Wt wt wt wt wt  
H37Rv INH (a)3 Wt wt Δ katG wt Δ katG  
H37Rv INH (a)5 Wt wt Δ katG wt Δ katG H37Rv 
H37Rv INH (a)13 Wt wt Δ katG wt Δ katG  
H37Rv INH (a)26 Wt wt Δ katG wt Δ katG H37Rv 
401/06 Wt wt wt wt wt A 
401/06 INH (a)5 Wt wt wt wt wt A 
401/06 INH (a)13 Wt wt wt wt wt  
401/06 INH (a)26 Wt wt wt wt wt A 
267/05 S531L wt wt wt wt B 
267/05 INH (a)5 S531L wt wt wt wt B 
267/05 INH (a)13 S531L wt wt wt wt  
267/05 INH (a)26 S531L wt wt wt wt B 
359/03 S531L wt wt wt wt C 
359/03 INH (a)1 S531L wt wt wt wt C 
359/03 INH (a)2 S531L wt wt wt TGG438→STOP  
359/03 INH (a)5 S531L wt wt wt TGG438→STOP C 
359/03 INH (a)13 S531L wt wt wt TGG438→STOP  




Table III.3. Genotypic characterization of the strains and derived cultures adapted to isoniazid (adaptation process B). 
 Genotype MTBDRplus DNA Sequencing  
Strain/Passage rpoB mabA-inhA katG mabA-inhA katG MIRU-VNTR profile 
H37Rv INH (b)5 Wt wt wt wt wt H37Rv 
H37Rv INH (b)13 Wt wt wt wt wt  
H37Rv INH (b)26 Wt wt wt wt wt H37Rv 
401/06 INH (b)5 Wt wt wt wt wt A 
401/06 INH (b)13 Wt wt wt wt wt  
401/06 INH (b)26 Wt wt wt wt wt A 
267/05 INH (b)5 S531L wt wt wt wt B 
267/05 INH (b)13 S531L wt wt wt wt  
267/05 INH (b)26 S531L wt wt wt wt B 
359/03 INH (b)5 S531L wt wt wt wt C 
359/03 INH (b)13 S531L wt wt wt wt  
359/03 INH (b)26 S531L wt wt wt wt C 
Legend: INH: isoniazid; RIF: rifampicin; wt: wild type; S: serine; L: leucine. MIRU-VNTR profile A: 2,4,2,2,3,4,2,3,2,3,2,4,2,2,6,1,6,3,1,3,1,7,2,2;  









Table III.4. MIC determination and susceptibility testing for the strains exposed to isoniazid in the presence and absence of efflux inhibitors. 
 INH MIC (µg/ml)  (Susceptibility testing for INH) 
 #0 #1 #26 
Strain +TZ +CPZ + VP no EI +TZ +CPZ + VP no EI +TZ +CPZ + VP 
H37Rv INH (a) 0.05 (S) 0.05 (S) 0.05 (S) 128 (R) 128 (R) 0.05 (S) 0.06 (S) 128 (R) 128 (R) 128 (R) 128 (R) 
H37Rv INH (b) 0.05 (S) 0.05 (S) 0.05 (S) 128 (R) 128 (R) 0.1 (S) 0.1 (S) 128 (R) 128 (R) 0.1 (S) 0.1 (S) 
401/06 INH (a) 0.1 (S) 0.1 (S) 0.1 (S) 256 (R) 256 (R) 128 (R) 256 (R) 256 (R) 256 (R) 128 (R) 256 (R) 
401/06 INH (b) 0.1 (S) 0.1 (S) 0.1 (S) 64 (R) 0.1(S) 0.1 (S) 0.1 (S) 256 (R) 256 (R) 64 (R) 256 (R) 
267/05 INH (a) 0.1 (S) 0.1 (S) 0.1 (S) 128 (R) 0.1 (S) 0.1 (S) 128 (R) 128 (R) 0.1 (S) 0.1 (S) 128 (R) 
267/05 INH (b) 0.1 (S) 0.1 (S) 0.1 (S) 128 (R) 0.1 (S) 0.1 (S) 128 (R) 128 (R) 0.1 (S) 0.1 (S) 128 (R) 
359/03 INH (a) 0.05 (S) 0.05 (S) 0.05 (S) 256 (R) 128 (R) 0.1 (S) 0.03 (S) 256 (R) 128 (R) 0.1 (S) 0.03 (S) 
359/03 INH (b) 0.05 (S) 0.05 (S) 0.05 (S) 128 (R) 0.1 (S) 0.1 (S) 0.1 (S) 256 (R) 128 (R) 0.1 (S) 0.1 (S) 
Legend: INH: isoniazid; INH (a): exposure process A; INH (b): exposure process B. S: susceptible; R: resistant. Values in bold correspond to full reversion of the INH resistance 
phenotype. EIs were used at ½ of their MIC. MICs for the EIs (passage 1): thioridazine (TZ): H37Rv and 359/03: 15 µg/ml, 401/06 and 267/05: 30 µg/ml; chlorpromazine (CPZ): 30 
µg/ml for all strains; verapamil (VP): 256 µg/ml for all strains. MICs for the EIs (passage 26): TZ: H37Rv and 359/03: 15 µg/ml, 401/06(a)26: 15 µg/ml; 401/06(b)26: 30 µg/ml; 267/05: 




Table III.5. Average quantification of the relative expression level, by RT-qPCR, of the 
genes that code for efflux pumps in M. tuberculosis in the two independent isoniazid 
exposure processes.  
 Relative expression level ± SD 
 mmpl7 Rv1258c p55 efpA mmr Rv2459 
Fully susceptible strains 
H37Rv INH(a)1 8.00 ± 2.38 16.00 ± 1.16 13.00 ± 2.23 9.85 ± 1.41 16.65 ± 2.44 25.99 ± 2.56 
H37Rv INH(a)26 0.44 ± 0.12 1.99 ± 0.66 0.82 ± 0.15 0.34 ± 0.28 0.44 ± 0.16 0.50 ± 0.02 
H37Rv INH(b)1 10.56 ± 3.48 15.26 ± 0.46 6.96 ± 1.36 8.00 ± 2.98 9.95 ± 2.03 22.63 ± 1.56 
H37Rv INH(b)26 4.57 ± 0.25 2.53 ± 0.03 2.70 ± 0.43 4.41 ± 0.21 1.54 ± 0.29 2.31 ± 0.13 
401/06 INH(a)1 34.30 ± 1.24 22.63 ± 0.47 18.38 ± 1.94 16.00 ± 1.32 24.25 ± 2.34 9.19 ± 0.11 
401/06 INH(a)26 17.15 ± 0.23 14.93 ± 2.30 9.85 ± 0.99 6.96 ± 1.57 9.19 ± 1.76 27.86 ± 1.3 
401/06 INH(b)1 1.53 ± 0.29 1.77 ± 0.75 3.47 ± 1.16 6.50 ± 1.30 1.47 ± 0.07 0.20 ± 0.05 
401/06 INH(b)26 4.16 ± 0.66 7.80 ± 4.96 11.31 ± 1.11 8.57 ± 2.66 2.29 ± 0.77 2.64 ± 0.39 
Rifampicin monoresistant strains 
267/05 INH(a)1 6.06 ± 0.53 4.29 ± 0.24 5.28 ± 0.48 9.85 ± 0.17 3.73 ± 0.13 6.50 ± 1.03 
267/05 INH(a)26 115.56 ± 59.44 53.85 ± 2.64 110.80 ± 66.17 341.05 ± 66.43 59.06 ± 53.66 32.00 ± 1.98 
267/05 INH(b)1 5.01 ± 1.10 2.00 ± 0.21 3.10 ± 0.43 3.90 ± 0.28 2.62 ± 0.54 1.69 ± 0.36 
267/05 INH(b)26 17.15 ± 1.24 3.04 ± 0.29 12.13 ± 0.67 22.63 ± 3.09 3.89 ± 0.57 0.64 ± 0.09 
359/03 INH(a)1 4.00 ± 0.03 1.62 ± 0.54 2.08 ± 1.06 1.87 ± 0.00 2.03 ± 0.86 0.76 ± 0.09 
359/03 INH(a)26 13.96 ± 1.36 9.01 ± 2.17 8.53 ± 2.86 10.66 ± 2.07 11.46 ± 4.9 32.00  ± 2.01 
359/03 INH(b)1 9.85 ± 2.35 5.66 ± 1.24 4.00 ± 0.06 5.11 ± 2.62 6.06 ± 0.54 0.25  ± 0.03 
359/03 INH(b)26 25.99 ± 1.33 29.86 ± 3.29 29.86 ± 2.56 2.30 ± 0.83 10.56 ± 1.36 2.30  ± 0.12 
Legend: (a)1: exposition process A, first passage; (b)1: exposition process B, first passage; (a)26: exposition process 
A, passage twenty six; (b)26: exposition process B, passage twenty six. The relative expression of the efflux pump 
genes was assessed by comparison of the relative quantity of the respective mRNA in the presence of isoniazid to the 
non-exposed strain. Each culture was assayed in triplicate using total RNA obtained from three independent cultures. 
A level of relative expression equal to 1 indicates that the expression level was identical to the strain that was being 
compared. Genes showing expression levels equal or above four, when compared to the non-exposed strain, were 








Table III.6. Sequences of the primers used in the RT-qPCR assays.  




mmpL7_Fw TAC CCA AGC TGG AAA CAA 214 [36]  
mmpL7_Rv CCG TCA GAA TAG AGG AAC CAG 214 [36] 
p55_Fw AGT GGG AAA TAA GCC AGT AA 198 [36] 
p55_Rv TGG TTG ATG TCG AGC TGT 198 [36] 
efpA_Fw ATG GTA ATG CCT GAC ATC C 131 [36] 
efpA_Rv CTA CGG GAA ACC AAC AAA G 131 [36] 
mmr_Fw AAC CAG CCT GCT CAA AAG 221 [36] 
mmr_Rv CAA CCA CCT TCA TCA CAG A 221 [36] 
Rv1258c_Fw AGT TAT AGA TCG GCT GGA TG 268 [36] 
Rv1258c_Rv GTG CTG TTC CCG AAA TAC 268 [36] 
Rv2459_Fw CAT CTT CAT GGT GTT CGT G 232 This study 
Rv2459_Rv CGG TAG CAC ACA GAC AAT AG 232 This study 
16S_Fw CAA GGC TAA AAC TCA AAG GA 197 [36] 
16S_Rv GGA CTT AAC CCA ACA TCT CA 197 [36] 
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Preface to Chapter IV 
 
In the previous chapter, we have presented a model on how multidrug resistance 
develops in tuberculosis patients, the role of efflux pumps on the development of 
isoniazid resistance once exposed to the critical concentration of this antituberculosis 
drug and how these events determine the basis of acquired multidrug resistance. The 
demonstration of the involvement of efflux pumps on the development of drug 
resistance make these proteins interesting targets for the discovery of novel 
antituberculosis drugs and, being the efflux an important contributor to mycobacterial 
drug resistance, as we have previously demonstrated, the identification and 
characterization of mycobacterial efflux inhibitors is an approach that can be 
advantageous for the development of new effective anti-tuberculosis therapies. 
The use of compounds that have the ability to inhibit mycobacterial efflux pumps 
promoting the retention of co-administered antibiotics that are subject to efflux will 
obviously improve the efficacy and will extend the clinical utility of the existing 
antibiotics. To date, several compounds have been appointed as putative efflux 
inhibitors in vitro. Previously, we have shown that isoniazid phenotypic resistance can 
be reduced by the use of verapamil, thioridazine and chlorpromazine. Furthermore, 
these compounds were also shown to enhance the killing of intracellular mycobacteria. 
They are used in clinical practice as antipsychotics and/or antihypertensive; however, 
despite several efforts employed on their characterization, the mechanism of action of 
these compounds remains largely unknown. 
In this chapter we aim to contribute to the clarification of the mechanism of action of 
these putative efflux inhibitors, against drug resistant M. tuberculosis. For that purpose, 
we have designed and applied several experimental procedures to investigate the 
antimycobacterial properties of a panel of compounds, both in vitro and in human 
monocyte-derived macrophages. We hypothesized that their inhibitory activity involves 
the disruption cell energy, which will trigger a cascade of events that culminates with 
the death of the bacteria. The concept behind this study highlights the value of these 




tuberculosis therapeutics, and reveals the basis for the identification of novel agents to 
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1. Abstract  
Here we investigate the antimycobacterial properties of the ion channel blockers 
verapamil, thioridazine, chlorpromazine, flupenthixol and haloperidol, in vitro and in 
infected human monocyte-derived macrophages. All compounds exhibited synergistic 
inhibitory activities when combined with the main first-line antituberculosis drugs, 
isoniazid and rifampicin, and were able to inhibit active efflux, demonstrating their role 
as efflux inhibitors. Gene expression analysis showed that efflux genes were 
overexpressed in response to antibiotic exposure, in vitro and ex vivo, indicating that M. 
tuberculosis drug resistance within macrophages is also mediated by the expression of 
efflux pumps that can be inhibited by these inhibitors. These compounds displayed a 
rapid and high killing activity for M. tuberculosis that can be correlated with a decrease 
in intracellular ATP levels. The compounds lead to a decrease in the intracellular 
mycobacterial load that resulted from their ability to induce phagosome acidification 
that results in the expression of lysosomal hydrolases. Altogether, we demonstrate that 
these inhibitors display a dual antimycobacterial inhibitory effect as they target both the 
bacteria and the host cell. On the bacteria side we hypothesized that these compounds 
inhibit the mycobacterial respiratory chain which leads to the dissipation of membrane 
potential, depletion of ATP, reactive oxygen species generation and cell death. 
Disruption of the proton motive force (PMF), due to inhibition of the respiratory chain, 
results in the inhibition of PMF-dependent efflux systems in M. tuberculosis, therefore 
promoting the retention of antibiotics subject to active efflux. Concerning the host cell, 
the phagosomal acidification stimulated by these compounds synergize with several 
components of the host immune response, restricting M. tuberculosis intracellular 
growth. In conclusion, we provide direct, experimental evidence that these ion channel 
blockers act as antimicrobial agents and enhancers of macrophage killing activity. This 
work further highlights the value of these compounds as adjuvants of drug resistant 
tuberculosis chemotherapy. 
 
2. Author summary  
Mycobacterium tuberculosis, the causative agent of tuberculosis, claims millions of 




pathogen within phagocytic cells and its propensity to develop resistance to the existing 
antituberculosis drugs, its treatment requires new approaches. The main objectives of 
ongoing antituberculosis drug discovery programs are the identification of compounds 
that have a new mode of action with potential to shorten the duration of chemotherapy. 
Here we show the potential use of some clinically approved drugs, with 
antimycobacterial and immunomodulatory properties, as adjuvants for the conventional 
antituberculosis therapeutic regimen. The ion channel blockers verapamil, thioridazine, 
chlorpromazine, flupenthixol and haloperidol, demonstrated to be potent inhibitory 
agents against M. tuberculosis both in vitro and ex vivo. We propose that their inhibitory 
activity involves the disruption of cell energy which triggers a cascade of events on the 
bacteria and on the host that, combined, culminates with bacterial death, providing a 
new insight into the mechanism of the pathogen–host interaction in tuberculosis. The 
discovery of such antituberculosis properties in drugs already in clinical practice, will 
contribute to identify new compounds for drug development and therapeutic 
interventions, shortening the bench to bedside timeline of drug discovery. 
 
3. Introduction 
Mycobacterium tuberculosis is a difficult pathogen, mostly due to its impenetrable cell 
wall coupled with a long generation time, a plastic metabolism and a remarkable ability 
to establish persistent and opportunistic infections. Consequently, the therapeutic 
regimen for tuberculosis requires a prolonged antibiotic treatment through, at least, six 
months in order to attain a favourable clinical outcome (37). Nevertheless, antibiotic 
resistance arises frequently. Although infections with drug-susceptible M. tuberculosis 
strains can be effectively treated with the current regimen of first-line antituberculosis 
drugs, the increase of antibiotic resistant M. tuberculosis strains represents an ongoing 
threat to the control of the disease. According to the World Health Organization, in 
2012, there were an estimated 450 000 new cases of multidrug resistant tuberculosis 
(MDRTB, simultaneous resistance to isoniazid and rifampicin) worldwide. The average 
proportion of MDRTB cases with extensively drug resistance (XDRTB, MDR plus 
resistance to fluoroquinolones, aminoglycosides and cyclic peptides) was 9.6% (67). 
Regrettably, these numbers indicate that, despite all efforts, antibiotic resistance in 




Resistance to antituberculosis drugs is assumed to be a consequence of the development 
of spontaneous mutations in defined genes or its promoter regions and the resulting 
resistance levels can be influenced by the type of alteration in the target gene (8). 
However, in a proportion of strains, the resistance to a certain drug cannot be solely 
explained by classical gene mutations, which suggests the presence of additional 
mechanisms of resistance (31; 32). In mycobacteria, the physiological resistance is 
generally attributed to the low permeability of the cell wall, which may limit the entry 
of antibiotics. Besides this reduced permeability, efflux systems also promote the 
development of resistance by the extrusion of molecules entering the cell prior to their 
access to the intended target (30). 
The contribution of efflux mechanisms to antibiotic resistance in M. tuberculosis has 
been highlighted in a number of studies over the last years. In these studies, several 
putative efflux pumps of different classes have been described and various have been 
shown to be involved in the transport of different compounds (61). Besides, it has been 
demonstrated that the overexpression of efflux pumps contributes to resistance allowing 
the bacteria to survive for a longer period of time in the presence of sub-inhibitory 
concentrations of antibiotics, until mutations emerge (32). Concomitantly, it was 
demonstrated that the resistance level to a given antibiotic can be significantly reduced 
by an efflux inhibitor despite the presence of a mutation, highlighting the contribution 
of active efflux to the overall resistance level of a drug resistant strain of M. 
tuberculosis (31; 32).  
The addition of an efflux inhibitor to tuberculosis chemotherapy can enhance 
antimycobacterial killing, prevent the emergence of drug resistance (2; 32; 49) and 
reduce the duration of tuberculosis treatment (2; 24). To date, several compounds have 
been appointed as potential efflux inhibitors. These compounds are ion channel blockers 
and comprised the phenotiazines thioridazine and chlorpromazine and its derivative 
flupenthixol, a high-potency thioxanthene; haloperidol, a butyrophenone structurally 
and clinically related with phenothiazines, and verapamil, a phenylalkylamine (61). 
These compounds are approved by the Food and Drug Administration (FDA) to be used 
in the treatment of several mental disorders or hypertension, with well characterized 




Ion channel blockers like thioridazine and verapamil have been shown to have active 
efflux inhibition properties and to inhibit the in vitro growth of M. tuberculosis strains 
alone or in combination with antimycobacterial drugs (5; 6; 11; 32). Thioridazine 
demonstrated significant activity against MDRTB in a murine model (57) and it has 
been successfully employed to treat XDRTB patients on the basis of compassionate 
reasons (1). Verapamil has been shown to be the most potent mycobacterial inhibitor to 
date, being able to enhance the inhibitory activity of isoniazid (32; 49) and rifampicin 
(31) in M. tuberculosis clinical strains. Recently, Gupta et al. (23) demonstrated that 
efflux inhibition by verapamil can potentiate the activity of bedaquiline, a 
diarylquinoline recently approved for the treatment of MDRTB (66). It has also been 
shown that the addition of verapamil accelerates the bactericidal and sterilising 
activities of tuberculosis therapy in the mouse model (24). Beyond their 
antimycobacterial activity, these compounds also present immunomodulatory abilities 
on M. tuberculosis-infected macrophages. Previously, we had shown that inhibitors of 
calcium and potassium channels can enhance the killing of M. tuberculosis by 
macrophages (35; 41). Afterwards, it was demonstrated that the inhibition of 
macrophage calcium channels increases intracellular concentrations of calcium which, 
consequently, activates an immune response against intracellular M. tuberculosis (22). 
Further evidence in favour of the usefulness of the ion channel blockers is reported in 
the elegant studies by Adams et al. (2; 3), wherein the selective pressure exerted by the 
macrophage on internalized M. tuberculosis can induce the bacteria efflux pumps and 
thereby drug-tolerance. Additionally, the authors also show that this macrophage drug-
induced tolerance can be reduced by verapamil or derived metabolites (2; 3). 
Having established the significance of the use of ion channel blockers as 
adjuvants in tuberculosis chemotherapy, it is important to understand their 
antimycobacterial properties both in vitro and in the macrophage model. In this study, 
we demonstrate that these compounds are efflux inhibitors with direct antimycobacterial 
activity towards M. tuberculosis. We show that they can enhance the inhibitory 
activities of the antibiotics against M. tuberculosis in vitro and enhance the killing 
activity of the macrophage against intracellular M. tuberculosis. Furthermore, we 
demonstrate that these compounds are able to induce phagosome acidification, whose 




of the internalized mycobacteria. Our findings contribute to a better understanding of 
the mode of action of these ion channel blockers and provide insights to identify the 
mediators of their antimycobacterial and immunomodulatory activity. 
 
4. Results 
Ion channel blockers enhance the inhibitory activity of antibiotics against M. 
tuberculosis.  
To determine whether the selected ion channel blockers known to act as efflux 
inhibitors show synergistic activity when combined with the antituberculosis drugs 
against the drug susceptible and resistant panel of M. tuberculosis strains used in this 
study, the susceptibility of isoniazid, rifampicin, amikacin and ofloxacin was 
investigated in the presence and absence of subinhibitory concentrations of verapamil, 
thioridazine, chlorpromazine, flupenthixol and haloperidol. The in vitro interaction of 
two agents in combination can be interpreted as synergistic, indifferent, or antagonistic 
depending on whether the activity of the combination is superior, comparable to, or 
smaller than the activities of the individual drugs, respectively. The efficiency of the 
drug combination was determined through the calculation of the fractional inhibitory 
concentrations (FIC) (29). The characterization of the nine M. tuberculosis strains is 
presented in Table IV.1. The minimum inhibitory concentrations (MICs) and FICs 
obtained with the combinations of the inhibitors and the antibiotics against the M. 
tuberculosis strains are listed in Table IV.2. As can be observed, the combination of 
isoniazid with the five compounds consistently demonstrated synergy, with FIC values 
ranging from 0.15 to 0.5, for the five clinical multi- and extensively drug resistant 
strains. For these, the MIC values of isoniazid were reduced from 2- to 20-fold 
depending on the strain and the inhibitor tested. No effect of the compounds was 
observed on the MIC of the isoniazid-monoresistant strains H37RvΔkatG and 294/09 
(single inhA promoter C-15T mutation), demonstrating indifference. However, the 
combination between the phenotiazines with isoniazid demonstrated synergistic effect 
against the isoniazid-monoresistant strain 269/03 (single katG S315T mutation), being 
able to reduce 6-fold the MIC of isoniazid (FIC of 0.3). Contrary to the study by 




three phenotiazines in study. For rifampicin, significant synergistic activity was 
observed mainly with verapamil and chlorpromazine. The combination of verapamil 
and rifampicin reduced the MIC values of rifampicin 16-fold in four strains and 4-fold 
in one strain, all carrying the rpoB S531L mutation. The FIC for this combination was 
0.06 and 0.25, respectively. Chlorpromazine reduced the MIC of rifampicin 16-fold in 
three strains and 4-fold in one strain, showing a FIC of 0.06 and 0.05, respectively. For 
strain 286/09, the MIC of rifampicin was reduced 20-fold by chlorpromazine and 
flupenthixol, and 4-fold by verapamil, thioridazine and haloperidol, originating a FIC of 
0.05 and 0.25, respectively. For strains 149/09 and 29/12 rifampicin MIC values were 
reduced 8-fold. Only in one isolate (69/11), an heteroresistant strain for amikacin with 
simultaneous presence of drug susceptible and drug resistant genotype carrying the rrs 
A1401G mutation, was observed significant synergy when the combination of the 
compounds and amikacin was evaluated. For this strain, the MIC values were reduced 
40-fold, to which corresponds a FIC of 0.03 for all the five inhibitors tested. For the 
remaining three amikacin-resistant strains carrying the rrs A1401G mutation, none of 
the inhibitors, except chlorpromazine, demonstrated any synergy. Chlorpromazine was 
found to have a FIC value of 0.13 for strains 149/09 and 29/12. The combination of the 
compounds with ofloxacin, for the three ofloxacin-resistant strains, was interpreted has 
being indifferent, with FIC of 1 for all the compounds tested. Collectively, these results 
support the hypothesis that using synergistic combinations of inhibitors with 
antituberculosis drugs can significantly enhance the activities of first and second line 
antituberculosis drugs. However, can this synergistic enhancement bring back the 
clinical and therapeutic effect of the antibiotics that became non-effective due to the 
presence of mutations associated with resistance? To address this question, we 
performed quantitative drug susceptibility testing for the four antibiotics in the presence 
of the inhibitors to assess the levels of resistance and correlate them with the mutations 
associated with clinical resistance. 
 
 
Ion channel blockers reduce the resistance level of first and second line 
antituberculosis drugs. 
To assess the clinical effect of these compounds in combination with antituberculosis 




presence of mutations associated with resistance, the levels of resistance to isoniazid, 
rifampicin, amikacin, and ofloxacin were evaluated with the MGIT960 system and the 
Epicenter V5.80A software equipped with the TB eXIST module. The results are 
presented in Table IV.3. The addition of the compounds promotes a significant 
reduction of the resistance levels for all antibiotics except for ofloxacin.  
In Figure IV.1 is shown the growth curves for strain 29/12, with and without verapamil, 
in the presence of isoniazid, as an example. This strain, which was initially resistant at 1 
µg/ml of isoniazid, upon addition of ½ MIC of verapamil had its high-level of resistance 
decreased to low-level resistance (<1 µg/ml) (see full vs. dotted pink line in Figure 
IV.1). The resistance levels to isoniazid were reduced from high-level to low-level in 
4/8 of the resistant strains, with verapamil, flupenthixol and chlorpromazine and 2/8 
with thioridazine. The strain is considered resistant when the number of drug-resistant 
bacteria present in the drug-containing tube at critical concentration is greater than 1%, 
when compared with the drug-free growth control and correlates well with an effective 
clinical outcome (see Materials and Methods for critical concentrations) (10). None of 
the strains had reversal of resistance since the resistance levels did not drop below the 
isoniazid critical concentration of 0.1 µg/ml (Table IV.3). Correlating the resistance 
levels to the antibiotics with the presence of mutations associated with resistance: four 
strains for which the resistance level was reduced in the presence of the inhibitors 
harbored double mutations in inhA gene, 2 with C-15T/S94A and 2 with C-15T/I194A 
substitutions. The four remaining strains, where residual or no change of the resistance 
level was noticed in presence of the inhibitors, possessed single mutations: the C-15T 
mutation in inhA promoter in one strain, two strains with the S315T mutation in katG, 
and one with a complete deletion of katG. Strain H37RvΔkatG was included in the 
study as a negative control, as it harbors a complete deletion of the katG gene and 
demonstrates no efflux activity (32). Regarding the strains with the katG S315T 
mutation, only a slight enhancement of the antimicrobial effect of isoniazid was 
observed for both strains in the presence of the phenothiazines thioridazine, 
chlorpromazine and flupenthixol (Table IV.3). However, this potentiation was not 
enough to reach low-level isoniazid resistance. Regarding the strain 294/09 with the C-
15T mutation in the promoter region of inhA gene, this strain display low-level 




isoniazid resistance cannot be overcome by the inhibitors tested. Concerning rifampicin, 
all strains presented high-level resistance due to the presence of the mutation S531L in 
rpoB. The resistance level was remarkably reduced from high- to low-level in presence 
of verapamil (5/5), chlorpromazine (4/5), and thioridazine, flupenthixol and haloperidol 
(1/5) (Tables IV.2 and IV.3). Four strains presented resistance to amikacin and for all 
was demonstrated the presence of a mutation in a gene associated with amikacin 
resistance. Three strains presented mutations in rrs1400 region and one strain has a 
mutation in eis promoter region. The high-level resistance conferred by mutations in rrs 
could not be reduced in the presence of the inhibitors in 2/3 strains. Nevertheless, 
resistance to amikacin was reversed in strain 69/11. The amikacin resistance profile 
changed from high-level resistance to susceptible in presence of the five compounds. In 
this case, rrs hybridization pattern given by Genotype MTBDRsl assay indicated 
heteroresistance, i.e. the coexistence of a population of bacilli susceptible and resistant 
to amikacin. This is especially important since heteroresistance plays a role in 
development of resistance in M. tuberculosis (25). Our data demonstrates that these 
inhibitors are capable to prevent the development of resistance to antituberculosis drugs. 
The amikacin low-level resistance due to the mutation in eis promoter region could not 
be reduced. For ofloxacin, low-level resistance was detected in three strains and 
correlated with mutations in gyrA gene. With this panel of strains, ofloxacin resistance 
could not be reduced by any of the inhibitors tested. 
With this methodology, we have been able to demonstrate that the addition of 
ion channel blockers enhances the therapeutic effect of the main antituberculosis drugs, 
isoniazid and rifampicin, in multi- and extensively drug resistant strains, despite the 
presence of a mutation conferring resistance. However, their effect on isoniazid 
resistance seems to be limited to strains with mutations in inhA gene. The fact that 
strains changed their resistance profile from high- to low-level upon the addition of the 
inhibitors brings clinical implications. The serum concentrations of isoniazid and 
rifampicin attained in vivo, 7 and 10 µg/ml respectively, are much higher than the 
respective MICs for the majority of strains (29). In the presence of a high-level 
resistance strain (see Material and Methods section for breakpoints), these drugs are 
predicted to be useless. However, in the presence of a low-level resistance strain it is 




synergistic combination of these inhibitors with conventional therapy, seen in vitro, is 
expected to be beneficial in reducing the resistance level of the strain.  
 
The ion channel blockers display rapid and high killing activity. 
One of the prerequisites for the development of new antituberculosis drugs includes the 
need for compounds that have bactericidal activity. This is important to prevent the 
development of drug resistance and act rapidly to reduce the duration of the treatment 
(19). To characterize the bactericidal activity of the ion channel blockers and evaluate if 
they can enhance the bactericidal efficacy of the antituberculosis drugs, we measured 
their antimycobacterial killing activity against the strains H37Rv (drug-susceptible) and 
149/09 (drug-resistant) through time-kill studies. The time-kill kinetics of the 
compounds and antibiotics on M. tuberculosis H37Rv is shown in Figure IV.2. All the 
compounds exhibit time-dependent bactericidal activity. After seven days, flupenthixol, 
chlorpromazine, thioridazine, haloperidol, and verapamil were able to eliminate all M. 
tuberculosis cells. Flupenthixol reduced the cell number to zero at day one, 
chlorpromazine and thioridazine at day two, and verapamil and haloperidol at day 
seven. Moreover, at the end of 100 days all cultures remain negative. Isoniazid, 
rifampicin, amikacin, and ofloxacin were not able to reduce the viable number of M. 
tuberculosis cells to zero by the end of the seven days. On the seventh day of 
incubation, a 3log10 CFU/ml decrease by rifampicin, amikacin, and ofloxacin was 
observed. For isoniazid was notice a 2log10 reduction in the same time frame.  
The most effective ion channel blocker previously tested, verapamil, was 
selected for the evaluation of the synergistic effect with the antibiotics through time-kill 
studies. The data presented in Figure IV.2B corresponds to the measurement of time-kill 
kinetics for verapamil with isoniazid, rifampicin, amikacin and ofloxacin for H37Rv. It 
can be observed that the activity of the antibiotics was strongly potentiated. By the end 
of day seven no bacteria remained viable for the five combinations tested. The 
combination of verapamil plus amikacin reduced the CFU/ml to zero at day two; 
verapamil and rifampicin at day three; verapamil and ofloxacin also at day three; and 
verapamil and isoniazid at day seven. Similar results were obtained for the multidrug 
resistant strain (data not shown). These results demonstrate that flupenthixol, 
chlorpromazine, thioridazine, haloperidol, and verapamil have direct bactericidal 




effect against both drug susceptible and multidrug resistant M. tuberculosis, therefore 
fulfilling both criteria mentioned above. 
 
ATP depletion occurs in response to the treatment with the ion channel blockers. 
To determine whether the treatment with the ion channel blockers could have an effect 
on bacterial intracellular ATP levels, we monitored the intracellular ATP levels over 
seven days. ATP levels and killing activity was recorded after day one, two, three and 
seven of exposure to the compounds. The ATP levels in cultures of M. tuberculosis 
H37Rv, exposed to 5X the MIC for each compound, are shown in Figure IV.3A and 
viability, in Figure IV.3B. A rapid drop in intracellular ATP levels of M. tuberculosis 
H37Rv was notice after one day of exposure with all compounds, which progressively 
falls during the seven days of exposure. This decrease in the ATP levels was correlated 
with an increased killing activity. Isoniazid and rifampicin do not have a significant 
effect on the ATP levels. These results confirm that ATP depletion occurs in 
consequence of exposure to the compounds and indicates that the metabolic state of the 
cells is directly affected by them with anticipated effects on the bacterial energy 
available for active efflux.      
 
Inhibition of ethidium bromide efflux demonstrates the role of the ion channel 
blockers as efflux inhibitors.  
The ability of verapamil, thioridazine, chlorpromazine, flupenthixol and haloperidol to 
inhibit the efflux activity of the M. tuberculosis strains used in this study was carried 
out using an semi-automated ethidium bromide fluorometric method (60) with a 
modified protocol for M. tuberculosis (32). When data for the clinical strains were 
compared with those for the H37Rv strain, different levels of accumulation were 
observed for all isolates. The results showed that the clinical strains are able to handle 
higher ethidium bromide concentrations than H37Rv. This means that the clinical 
strains have higher efflux capacity than that of the reference strain as previously 
described (32). These assays were then performed in the presence of the same 
compounds at sub-inhibitory concentrations. In Figure IV.4A is shown the ethidium 
bromide accumulation assay for strain 29/12, in the presence of the inhibitors, as an 
example. The inhibitory indexes of activity of each compound against the M. 




corresponds to a measure of how efficient is the inhibitory effect of the compounds on 
efflux by comparison of the final fluorescence of the cells exposed to ethidium bromide 
plus the compound against cells exposed only to ethidium bromide (taken as 0). The 
accumulation of ethidium bromide increased in the presence of all inhibitors. Verapamil 
promoted the highest increase in accumulation in all strains, except H37RvΔkatG and 
269/03 (6/8), followed by the phenotiazines. Among this class of compounds, 
flupenthixol demonstrated the highest inhibitory effect (3/8), followed by thioridazine 
and chlorpromazine, which demonstrated similar activity against 2/8 of the multidrug 
resistant strains. Haloperidol was the compound that demonstrated the lowest effect on 
the accumulation of ethidium bromide. The multidrug resistant strains showed 
significantly higher levels of ethidium bromide accumulation in presence of the 
inhibitors, whereas the clinical isoniazid monoresistant strains accumulated significantly 
lower levels of ethidium bromide when compared with those from the multidrug 
resistant strains. For the katG deleted strain, only a minor effect was observed with 
verapamil.  
To directly assess efflux, we selected verapamil to measure the inhibition of ethidium 
bromide efflux on these strains (Figure IV.4B). The results showed that the ethidium 
bromide efflux is greatly inhibited in the presence of verapamil. Therefore, from the 
analysis of Figure IV.4B we correlate these results with the effect on the ethidium 
bromide accumulation observed in Figure IV.4A and conclude that the inhibition of 
efflux pumps retain ethidium bromide inside the cells. All together, the MICs results 
followed the same pattern as in the ethidium bromide accumulation promoted by the 
inhibitors, correlating the resistance levels of these strains with their ability to efflux 
noxious compounds.  
 
Overexpression of efflux pumps in response to the antibiotic pressure leads to 
increased tolerance towards antibiotics. 
In a previous work we have been able to correlate the increased ethidium bromide efflux 
in M. tuberculosis with efflux-mediated increased isoniazid resistance as the result of 
the activity of several overexpressed efflux pumps working in combination (32). Here, 
we assess the contribution of the M. tuberculosis membrane transporters for the 




multidrug resistant M. tuberculosis strains. For that, these strains were exposed to sub-
inhibitory concentrations of isoniazid or rifampicin and the expression levels of genes 
that code for 10 efflux pumps and the global regulator whiB7 were evaluated by RT-
qPCR. Table IV.5 and IV.6 show the results obtained for the quantification of gene 
expression of the bacteria exposed to isoniazid and rifampicin, respectively. The relative 
expression of the efflux-pump genes was determined by comparison of the relative 
quantity of the respective mRNA in the presence of the antibiotic to the non-exposed 
condition. As can be observed, the majority of the efflux genes are overexpressed in 
response to isoniazid and rifampicin exposure. Although we cannot observe a specific 
pattern of expression, the genes mmr, mmpl7, p55, Rv1217c and efpA showed a 
significantly increase in their expression levels in the presence of isoniazid. Regarding 
the exposure to rifampicin, we can observe an increase in the expression of the majority 
of the genes albeit at lower absolute levels than those obtained for the isoniazid exposed 
strains. Of all pumps studied, P55 a member of the major facilitator superfamily efflux-
pump, described in 2001 by Silva et al. (11), was found to be consistently expressed in 
all strains, presenting a 1.54 to 9.88-fold increase in the presence of rifampicin. 
 This systematic increase in efflux pumps gene expression after isoniazid and 
rifampicin exposure, correlated with increased efflux and antibiotic resistance, can 
occur due to two possible mechanisms. First, increase in gene expression due to a 
mutation in a regulatory or promoter region of the efflux pump gene leading to 
constitutive gene expression. Secondly, this increase can be due to the induction 
promoted by the compounds that are substrates of the efflux pumps. To clarify which 
inductive mechanism is promoting this overexpression, we searched for mutations on 
the transporters studied. Despite missense and silent mutations in the coding regions of 
these genes, no other mutations were found on putative promoter or regulatory regions 
in these strains (Table IV.S1). This indicates that the overexpression detected in these 
strains is induced by the antibiotic substrates and is not constitutive. Afterwards, we 
sought to see if the expression of some of these pumps can be induced upon 
macrophage residence. As proof of evidence, we selected one multidrug resistant strain, 
M. tuberculosis 82/09, to study the expression of five efflux genes, mmr, mmpl7, 
Rv1258c, p55 and efpA, and determined their expression level upon exposure to 




also expressed inside the macrophages upon exposure to isoniazid (Figure IV.5) 
demonstrating that M. tuberculosis drug resistance in macrophages is mediated by the 
expression of pumps that help the bacteria to reduce the intracellular concentration of 
the antibiotic. Our results are in agreement with other previously reported data (2; 3). 
Collectively, these results reinforce the concept that induction of efflux pumps is one of 
the mechanisms involved in drug resistance in M. tuberculosis. Similar to our previous 
work, we conclude that efflux pumps are promiscuous in their activity, as we could not 
associate extrusion of isoniazid or rifampicin to a specific pump (32). Moreover, the 
results indicate that the compounds are not acting on a specific pump but on multiple 
pumps, and induction of efflux pumps seems to be a general stress response to the 
presence of noxious compounds, instead of a specific response of a specific pump. The 
differences observed in the gene expression profiles in each clinical strain most 
probably reflect their history of different antibiotic pressures in the clinical settings. The 
data obtained with the fluorometric method for the non-exposed strains and RT-qPCR 
for exposed strains indicates that these strains may be already primed to react in 
presence of toxic compounds.  
 
The ion channel blockers enhance the killing activity of macrophages against 
intracellular M. tuberculosis. 
Since M. tuberculosis infects mainly macrophages, the compounds to be applied as 
antimicrobials or enhancers of antimycobacterial agents should demonstrate activity 
against intracellular M. tuberculosis. For this purpose, we examined the intracellular 
activity of verapamil, flupenthixol, thioridazine, chlorpromazine, and haloperidol, and 
their ability to potentiate isoniazid activity, on human monocyte-derived macrophages. 
Isoniazid was chosen due to be one of the most effective antituberculosis agents known 
to date (37). We used one susceptible strain, H37Rv, and four isoniazid resistant strains 
with commonly described isoniazid-associated resistance mutations in katG and inhA. 
The enhancement of intracellular killing activity promoted by the compounds and their 
combined effect with isoniazid and the kinetics during 3 days post infection is presented 
in Figure IV.6. We found that all the compounds impaired growth of intracellular M. 
tuberculosis for both wild-type and resistant strains. When tested for the enhancement 
of the killing activity by the macrophage, thioridazine demonstrates to be the most 




whereas the remaining compounds demonstrated rates of killing of 12% to 64% with 
verapamil, 37% to 60% with chlorpromazine, 27% to 43% with flupenthixol, and 11% 
to 37% with haloperidol. The co-administration of isoniazid with any of the compounds 
studied in this work has led to a strong enhancement of the killing activity against the 
H37Rv strain. Conversely, no additional killing was observed in the isoniazid-resistant 
strains when isoniazid was used in combination with the compounds, as expected. This 
result is in agreement with the fact that all strains, except H37Rv, harbored a mutation 
that confers isoniazid resistance. Collectively, these results allow us to show that 
verapamil, flupenthixol, thioridazine, chlorpromazine, and haloperidol strengthen the 
killing activity of human macrophages against M. tuberculosis. 
 
The ion channel blockers promote intracellular acidification. 
Restriction of mycobacterial growth requires acidification of phagosomes (64). Since 
the inhibitors enhance the antimycobacterial activity of human macrophages, we 
hypothesized that these compounds can induce phagosome acidification. To test this 
hypothesis, human monocyte-derived macrophages infected with M. bovis BCG-GFP 
were treated with the compounds and stained with LysoSensor, an acidotropic probe 
that emits fluorescence when pH reaches 4.2. Figure VI.7 depicts representative images 
of vesicles positive and negative with LysoSensor. As can be observed, LysoSensor 
staining is weak in non-treated human monocyte-derived macrophages. In the presence 
of the ion channel blockers the fluorescence intensity increases indicating a decreased 
pH. We also observed colocalization of M. bovis and LysoSensor inside the vesicles 
which demonstrates that the compounds mediate acidification of M. bovis BCG-
containing vesicles. The quantification of vesicle acidification in human monocyte-
derived macrophages was measured by the accumulation of Lysotracker Red, a 
lysosomotropic probe, using flow cytometry. First, we analysed the increase in the 
fluorescence of Lysotracker RED positive cells. The results show that all the 
compounds increase significantly the percentage of cells stained positive for 
Lysotracker RED (Figure VI.8). Next, we measured the increase on the overall number 
of Lysotracker RED stained vesicles per cell (average fluorescence intensity). We 
observed that all the compounds increase the overall number of stained cells (Figure 
IV.S1). In both cases, verapamil, thioridazine and haloperidol induced the strongest 




acidification. However, it is unlikely that pH alone is responsible for the death of 
intracellular bacilli. It is described that M. tuberculosis is able to survive in the acidic 
environment of the phagolysosome of activated macrophages and its survival or 
elimination depends on the ability of the macrophage to activate its pH depended 
lysosomal hydrolases (58). Following this rational, we assessed the impact of pH on the 
survival of M. tuberculosis in vitro and we observed that M. tuberculosis can cope in an 
acidic environment (Figure IV.S2). However, M. tuberculosis becomes sensitive to low 
pH in combination with other antimicrobial factors such as low pH activated lysosomal 
hydrolases, so we measured the activity of cathepsin B, a lysosomal cysteine protease, 
which enters in the phagosome early in their maturation (54). Increased activity of 
cathepsin B was detected in cultures treated with the compounds (Figure IV.9). When 
compared with the untreated control cultures, cathepsin B activity was induced by 21% 
by verapamil, 42% by thioridazine, 33% by chlorpromazine and flupenthixol, and 32% 
by haloperidol, in average, regardless the macrophage is infected or not infected. These 
observations indicate that the inhibitors prompted the acidification of the phagosomes 
containing M. tuberculosis and enhance the expression of cathepsin B promoting the 
hydrolytic features of the phagosome. These results show that phagosome acidification 
is important for the function of degradative hydrolases as well as other phagosomal 
functions, as previously suggested (58). Furthermore, it is known that phagosomal 
acidification is established by the V-ATPases (55) and that the accumulation of V-
ATPases is associated with an enhancement of the expression of the aspartic protease 
cathepsin D (54). We are currently evaluating the expression of cathepsin D and V-
ATPases and determining if the compounds-mediated acidification could be inhibited 
by a V-ATPase inhibitor and, if this inhibition can lead to enhanced mycobacterial 
replication inside the macrophages.  
 
Multidrug resistant M. tuberculosis strains demonstrate enhanced fitness. 
We have noticed that the activity of the compounds was influenced by the genotype and 
fitness of the strains. In this sense, we characterized the genotype of these strains and 
evaluated the growth patterns in vitro and ex vivo as indicators of fitness. Five strains 
were found to belong to LAM genotype: two belonging to cluster Q1, two from cluster 
Lisboa3, and one non-clustered strain; one Beijing strain, and one strain with a non-




database and the corresponding MIRU12-VNTR pattern was designated as VNTR 
international type VIT21. Next, we determined the growth rates for all strains grown in 
liquid media. First, we examined the time necessary for the strains to adapt to a new 
environment in liquid culture starting with a well-defined inoculum. All grew slightly 
faster when compared with the control strain, H37Rv (Figure IV.S3A), except strains 
286/09 and 69/11. Second, we evaluated the growth rate, i.e., the time necessary to 
reach 400 GU (the acceleration phase). All strains demonstrated similar growth rates, 
except strains belonging to cluster Q1 (149/09 and 29/12) and the isoniazid resistant 
strain 294/09. We observed that strains belonging to cluster Q1 take more time to reach 
the same growth units than strains from cluster Lisboa3 and Beijing, and less than 
H37Rv (Figure IV.S3B). Strain 294/09 showed a dramatically slower replication rate 
when compared with the other strains with the same mutation. Whilst 294/09 is resistant 
just to isoniazid, the other strains are multidrug resistant. Collectively, the results show 
that multidrug resistant strains included in this study have a similar ability to adapt to a 
new environment but differ in their growth rates in vitro. Next, we evaluate the ability 
of some of these strains to grow inside macrophages as a surrogate of intracellular 
fitness. For that, human monocyte-derived macrophages were infected with multidrug 
resistant strains belonging to cluster Lisboa3 and Q1, the isoniazid monoresistant strains 
294/09, 269/03, and the H37Rv katG deletion mutant. As a control, we used the H37Rv 
reference strain. We found that the M. tuberculosis multidrug resistant strains have 
enhanced fitness when compared with susceptible or monoresistant strains. As can be 
observed in Figure IV.10, both strains grew more quickly in macrophages than all other 
strains. At the end of five days, the number of viable bacteria was significantly higher 
than the one reached by the susceptible strain H37Rv. Moreover, H37Rv was able to 
replicate much faster than the isoniazid monoresistant strains. Regarding H37RvΔkatG, 
this strain is highly resistant to isoniazid in vitro and does not have catalase activity 
(data not shown). We observed that this strain has reduced ability to survive in human 
macrophages. However, katG deletion mutants can cause disease in humans. One 
possible explanation is that the bacteria can acquire compensatory mutations to resist 
the oxidative burst in vivo (51). We also observed a reduction of the fitness of the strain 
with the mutation S315T on katG. Strain 269/03 retains catalase activity and 




isoniazid resistance-conferring mutation found in clinical settings. Although, it is 
assumed that strains with katG315 can maintain katG activity and virulence in mice 
without significant loss of fitness (44); others show that M. tuberculosis strains with 
katG315 mutation are less fit on murine macrophages (47). It has been shown that the 
genetic background of a strain influences the fitness of drug-resistant M. tuberculosis 
(18). Altogether, it seems that intracellular fitness of the M. tuberculosis strains varies 
according to their resistance pattern and the mutations associated. The multidrug 
resistant strains studied showed an increased replication rate inside macrophages 
indicating a higher fitness for strains with this genotype, clusters Lisboa3 and Q1. 
Furthermore, overexpression of efflux pumps was more evident on multidrug resistant 
strains than in isoniazid monoresistant strains and the compounds were shown to be 
more effective on the multidrug resistant strains. From these results we can establish 
association between drug resistance, the genetic background and overexpression of 
efflux pumps.  
 
5. Discussion 
The global emergence of multi- and extensively drug resistant tuberculosis has 
hampered the perspectives of tuberculosis control and elimination. Multidrug resistant 
tuberculosis requires a prolonged treatment with second-line drugs that are less effective 
and more toxic. In addition, for extensively drug resistant tuberculosis the chances to 
achieve a successful treatment are further reduced. The therapeutic options for these 
patients can be limited to second-line oral bacteriostatic agents and to drugs with 
questionable reliability and reproducibility known as WHO Group V (65). Therefore, 
there is an urgent need for the identification of compounds with different mechanisms 
of action that can be used in combination with the existing antituberculosis drugs in 
order to shorten the treatment. Some new drugs have been developed in the latest years 
which have demonstrated potential to achieve this objective (48). However, they are still 
limited in number which emphasizes the need for new approaches.  
 In this study, we provide evidence that verapamil, flupenthixol, thioridazine, 
chlorpromazine, and haloperidol act synergistically with the main first line antibiotics to 
restrict M. tuberculosis growth in either drug susceptible or resistant strains. However, 




assist in the reduction of the resistance level to the antibiotics and, by this manner, 
potentiate their activity. This evidence was confirmed by time-kill studies through 
which we were able to demonstrate that these compounds are capable to prevent the 
emergence of resistance and preserve the activity of the co-administered antibiotics. 
Besides, the low mutation frequencies determined for each ion channel blocker tested 
(10-10-10-11) indicate that they are less subject to acquire spontaneous mutations for 
resistance. Assuming that the M. tuberculosis burden in the lungs is around 108-109 and 
the mutations rates for isoniazid and rifampicin are approximately 10-8 and 10-10 (12), 
respectively, the ion channel blockers when combined with antituberculosis drugs 
currently in use, will reduce the probability of development of spontaneous mutations 
during tuberculosis drug therapy.  
 At this moment we do not know the exact mechanism or the assembly of 
mechanisms by which these inhibitors act as antimicrobial agents against M. 
tuberculosis. We observed that all compounds lead to a significant decrease in the 
intracellular mycobacterial load as result of phagosome acidification inducement and 
enhanced expression of lysosomal hydrolases. Our previous research has leaded us to 
propose that the enhancement of the killing activity of macrophages by these type of 
compounds was dependent upon the availability of potassium and calcium ions inside 
the cells. (6; 35; 61). In support of these, Gupta et al. (22) elegantly demonstrate that the 
inhibition of L-type channels results in significant increase of calcium from intracellular 
stores within macrophages leading to a reduction in bacterial burden. This rise of 
protons was assumed to be responsible for the phagosome acidification and activation 
of lysosomal hydrolases that reduce the bacterial load (6; 35; 61). Consequently, it is 
expected that the use of inhibitors of potassium and calcium transport, such as 
verapamil, haloperidol and the phenothiazines, will enhance the killing of internalized 
M. tuberculosis, as we have observed in this study. Additionally, in support of this it 
was recently proposed that phagosomal acidification is controlled by the Abelson (Abl) 
tyrosine kinase by increasing the transcription and expression of V-ATPases and that 
the inhibition of tyrosine kinase triggers the phagosome acidification (9). The authors 
also show that imatinib, an inhibitor of the tyrosine kinase used for the treatment of 
cancer and pulmonary arterial hypertension, induce phagosomal acidification and 




kinase expression is dependent on calcium influx, partially through L-type channels 
(46), the impact of calcium on tyrosine inhibition can be associated with a decrease in 
the intracellular ATP availability. The increase of the expression of V-ATPase activity 
can induce phagosome acidification and consequently, increase the concentration of 
calcium on the cytosol resulting in enhanced bacterial killing. Both models act 
synergistically and strongly suggest the involvement of calcium and potassium ions on 
the mechanism of action of these inhibitors. 
Our in vitro results show that the ion channel blockers are good antimycobacterial 
agents, especially when used in combination with antituberculosis drugs, indicating that 
they interfere directly with the bacteria. In eukaryotic cells it is known that these drugs 
act by blocking receptors for neurotransmitters such as dopamine and their neuroleptic 
activity is attributed to their role on the mitochondrial electron transport chain; 
haloperidol and chlorpromazine inhibit the mitochondrial NADH: ubiquinone 
oxidoreductase (complex I) (7). In M. tuberculosis it is believed that phenotiazines also 
inhibit one of the key enzymes of the mycobacterial respiratory chain, the type II 
NADH: menaquinone oxidoreductase (NDH-2) (62; 63). M. tuberculosis possesses two 
NADH dehydrogenases: the NDH-1, encoded by the nuo operon, which is non-essential 
in M. tuberculosis (45) and, the non-proton-translocating NDH-2, encoded by the ndh 
gene, which is essential for M. tuberculosis survival (36). NDH-1 is an equivalent of 
mitochondrial complex I, while NDH-2 is a single subunit enzyme with NADH/quinol 
oxidoreductase activity (68). In M. tuberculosis, energy generation is mainly performed 
by NDH-2 (45) whereas NDH-1 is mostly implicated on anti-apoptotic activity of host 
cells and, not on its original function of generation of energy (59). Rao et al. (45) 
established a link between NDH-2 and the proton motive force (PMF) through the 
demonstration that the inhibition of NDH-2 by thioridazine dissipates the membrane 
potential. Since thioridazine and chlorpromazine act as partial uncouplers of oxidative 
phosphorylation in mitochondria (38) and besides their inhibitory effect on NDH-2 they 
also act as uncoplers of oxidative phosphorylation in Staphylococcus aureus (50), it is 
expected that they indirectly promote the collapse of PMF. Uncouplers of oxidative 
phosphorylation are able to transport protons across biological membranes (17). By 
transporting protons down the electrochemical potential gradient, these agents collapse 




increased production of reactive oxygen species (ROS), inhibition of ATP synthesis 
(without affecting the respiratory chain and ATP synthase), and disruption of calcium 
homeostasis.  
 All the compounds tested were able to promote intracellular accumulation of 
ethidium bromide, a broad substrate for PMF dependent efflux pumps, in both drug 
susceptible and resistant strains. Hence, we can conclude that ethidium bromide 
accumulation promoted by the ion channel blockers is a result of efflux pump inhibition 
caused by dissipation of PMF. This was previously shown in our studies with 
susceptible and antibiotic-adapted M. tuberculosis strains (32). In this study it is now 
demonstrated, for the first time, on M. tuberculosis multidrug resistant clinical strains. 
Moreover, we showed that several efflux pumps are induced upon exposure to isoniazid 
and rifampicin in these multi- and extensively drug resistant clinical strains. We have 
detected a general and marked expression of almost all efflux genes tested, which is 
consistent with a stress response to a hostile environment. Afterwards, we sought to see 
if some of these pumps are also expressed within the macrophage. We found that some 
of the efflux genes were expressed inside macrophage upon drug exposure mimicking 
the inducible adaptative response seen in vitro. Using the zebrafish larval model, Adams 
et al. (2) demonstrated that drug-tolerant bacteria originate in macrophages dependent 
on the inducible overexpression and activity of bacterial efflux pumps. In their model, a 
bacterial subpopulation tolerant to drugs arise after few days post-infection, in response 
to host defenses, by the inducement of bacterial efflux pumps, that rendered the bacteria 
tolerant to several antituberculosis drugs (2; 3). This result further strengthens the 
importance of the design of rational strategies to prevent the emergence of drug 
resistance in M. tuberculosis. Furthermore, during infection, pathogens like M. 
tuberculosis have developed strategies to neutralize NADPH oxidase function and to 
inhibit phagosomal generation of ROS. Velmurugan et al. (59) identified nuoG gene of 
M. tuberculosis, which encodes a subunit of the NADH dehydrogenase type I, as an 
anti-apoptotic gene in M. tuberculosis. Therefore, a complete functional NDH-1 
complex mediates the anti-apoptotic properties of the bacteria (59). We hypothesize that 
the disruption of the membrane potential triggered by the compounds, will lead to the 
impairment of the respiratory chain, promoting apoptosis during infection. It is not clear 




specific targets or is just a consequence of the dissipation of the membrane potential. 
We have tried to obtain mutants for these compounds in an attempt to identify their 
target. So far, we were unable to isolate such mutants. The reason for this can be related 
with the reduced mutation rates for these compounds and also with the essentiality of 
their putative targets as is the case of ndh and the phenothiazines. Further analyses are 
under way to explore this subject.  
 These compounds have been used for years as antipsychotics and 
antihypertensives, are affordable and, can be taken as oral formulation. Several other 
drugs whose mechanism of action is known to affect the mycobacterial metabolic 
energy and respiration are now in the pipeline. These include bedaquiline, an ATP 
synthase inhibitor (14; 26), and PA-824 and demalanid, which target the cytochrome 
oxidase (34). Although haloperidol, thioridazine and chlorpromazine are widely used 
for the treatment of psychosis, these compounds have significant toxic effects on 
mitochondrial bioenergetics function, which may result in serious tardive dyskinesia 
and Parkinson-like disease (7; 38) and cardiotoxicity (20). As such, caution should be 
taken when designing new compounds that target the respiratory chain, since that due to 
the impairment of the oxidative phosphorylation, mitochondria became unable to meet 
the energetic needs of cell. On the other hand, verapamil is shown to be extremely well 
tolerated with few side-effects documented (52). The significant differences observed in 
the effective concentrations of the ion channel blockers required to inhibit M. 
tuberculosis in vitro versus that needed to produce similar effects on macrophages 
(Table IV.S2), indicates an interaction that involves (i) the biochemical mechanism 
underlying the inhibitory effect of the drugs within the bacteria, (ii) the ability of the 
macrophages to concentrate the compounds (41) so they can reach therapeutic 
concentrations, and (iii) the consequences of the stimulation of macrophage bactericidal 
mechanisms. Altogether they result in the elimination of the bacteria. The activity of 
verapamil, thioridazine, chlorpromazine, flupenthixol, and haloperidol against drug 
resistant M. tuberculosis at concentrations usually reached in the human serum when 
they are employed clinically was demonstrated. The results presented in this study 
enable us to propose the following mechanism of action for these compounds: a) in the 
bacteria: after entering the cell the compounds will generate a cascade of events that 




direct target, we cannot say at the present moment. The inhibition of the respiratory 
chain will lead to: i) dissipation of membrane potential; ii) reduction of ATP levels; iii) 
ROS generation; iv) increase in intracellular calcium levels; and v) cell death; b) on the 
host cell, the treatment with the inhibitors will lead to an increased transcription of the 
V-ATPases which results in the phagosome acidification. The phagosomal acidification 
will synergize with several components of the host immune response, such as lysosomal 
hydrolases and reactive oxygen and nitrogen species, and lead to bacterial growth 
restriction.  
 Ongoing work aims to test these hypotheses and determine the exact mechanism 
by which these compounds can eliminate M. tuberculosis. Furthermore, it will be 
interesting to evaluate the impact of the genotype of the strains studied on their capacity 
to trigger the mechanisms described above. M. tuberculosis strains of the Latino-
American-Mediterranean (LAM) genotype, specifically the Lisboa3 and Q1 clusters, is 
the main genotype circulating in Lisbon (42). Our study provides evidence that strains 
from both clusters interact differently with the host, when compared with the other 
strains. Strains from Lisboa3 and Q1 clusters demonstrated enhanced fitness inside the 
macrophages. In conclusion, our study should provide valuable information for the 
improvement of known drugs and for the design and development of new ones. Such 
increased knowledge will allow for better epidemiological predictions and assist in the 
development of new therapeutic strategies to fight drug resistant tuberculosis.  
 
6. Materials and Methods 
Mycobacterial strains and growth conditions. A panel of nine M. tuberculosis strains 
were selected for this study: M. tuberculosis H37Rv ATCC27294T, M. tuberculosis 
H37RvΔkatG (32) and seven drug-resistant clinical strains obtained from the culture 
collection of the Mycobacteriology laboratory of the Instituto de Higiene e Medicina 
Tropical, Universidade Nova de Lisboa (Table IV.1). M. bovis BCG Pasteur 
ATCC35734 expressing green fluorescent protein (BCG-GFP) was kindly provided by 
Prof. M. Niederweis (University of Alabama). Cultures of M. tuberculosis were 
routinely grown in MGIT media (Becton Dickinson, Diagnostic Systems, Sparks, MD, 
USA) supplemented with 10% OADC (oleic acid/albumin/dextrose/catalase) (Becton-




susceptibility testing and minimum inhibitory concentration determinations (MIC) were 
conducted using the BACTECTM MGITTM 960 system (MGIT960). 
 
Antibiotics and chemicals. Isoniazid, rifampicin, ofloxacin, amikacin, capreomycin, 
verapamil, flupenthixol, thioridazine, chlorpromazine, haloperidol, and the efflux 
substrate ethidium bromide (EtBr), were purchased from Sigma-Aldrich (St. Louis, 
MO, USA). All drugs were prepared in sterile deionized water except rifampicin and 
haloperidol which were prepared in dimethyl sulfoxide (DMSO). The lyophilized drugs 
(BACTECTM MGITTM 960 SIRE and PZA kits; SIRE: streptomycin, isoniazid, 
rifampicin and ethambutol; PZA: pyrazinamide) used in standard susceptibility testing 
were purchased from Becton Dickinson and the stock solutions prepared as per 
manufacturer’s instructions.  
 
Susceptibility testing. (i) First and second line drug susceptibility testing. The 
MGIT960 was used for first and second line drug susceptibility testing according to the 
manufacturer’s instructions. MGIT tubes were inoculated with 0.8 ml SIRE supplement 
(Becton Dickinson), 0.1 ml of antibiotic at the critical concentrations (0.1 µg/ml for 
isoniazid, 1 µg/ml for rifampicin, 1 µg/ml for streptomycin, 5 µg/ml for ethambutol, 
100 µg/ml for pyrazinamide, 1 µg/ml for amikacin, 2.5 µg/ml for capreomycin, and 1 
µg/ml for ofloxacin) and 0.5 ml of the suspension of the strain. For preparation of the 
drug-free proportional control strain suspension was diluted 1:100 (1:10 for PZA) and 
0.5 ml inoculated in the tube. The results were interpreted as follows: at the time of 
positivity of the proportional control (Growth units [GU] =400), the comparison 
between this tube and the tubes containing the drugs(s) was performed. If the GU of the 
tubes containing the drug were >100, they were considered to be resistant to that 
concentration. If the GU of the tube containing the drug was <100 they were considered 
susceptible (53). Growth of the cultures was monitored with the Epicenter V5.80A 
software equipped with the TB eXIST module. 
(ii) MIC determination of antibiotics and inhibitors. MIC determination was done 
within MGIT960 and the growth monitored with the Epicenter V5.80A software. 
Verapamil and haloperidol were tested at concentrations ranging from 16 to 512 μg/ml; 
thioridazine, chlorpromazine and flupenthixol were tested at concentrations from 3.75 to 




rifampicin and amikacin were tested from 1 to 640 μg/ml and ofloxacin was tested from 
1 to 10 μg/ml. At the time of testing, two-fold serial dilutions were prepared to achieve 
the desired concentrations. The MIC was considered as the lowest concentration with 
GU <100 when the drug-free control tube reached a GU value of 400.  
(iii) Quantitative drug susceptibility testing of antibiotics in presence and absence 
of inhibitors.  
Quantitative drug susceptibility testing of rifampicin, isoniazid, ofloxacin and amikacin 
was conducted using the MGIT960 and the Epicenter V5.80A/TB eXIST. Isoniazid was 
tested at 0.1, 0.4, 1, 3 and 10 µg/ml, rifampicin and amikacin at 1, 4 and 20 µg/ml, and 
ofloxacin at 1, 2 and 10 µg/ml. The interpretation of the results was performed as per 
Springer et al. (53). For the quantification of the resistance levels of each strain, the 
following criteria was used: isoniazid low-level resistance when resistant (R) at 0.1 and 
susceptible (S) at 1 µg/ml; isoniazid high-level resistance when R ≥ 1; rifampicin and 
amikacin low-level resistance when R at 4 and S at 20 µg/ml; rifampicin and amikacin 
high-level resistance when R ≥ 20 µg/ml; ofloxacin low-level resistance when R at 1 
and S at 2 µg/ml; ofloxacin high-level resistance when R ≥ 2 µg/ml. The inhibitors were 
used at ½ of the respective MIC. 
(iv) Determination of the synergistic effect of the inhibitors. The analysis of the 
effect of drug combination was achieved by calculating the fractional inhibitory 
concentration (FIC) index as follows: FIC= MICATB in combination/MICATB alone. The FIC 
was interpreted as: FIC≤0.5, synergism; >0.5-1, indifference; and >1, antagonism (29).  
 
Time-kill kinetics. To assess the bactericidal activity of the inhibitors, time-kill studies 
were performed with two strains: the reference strain H37Rv (drug-susceptible) and one 
clinical strain, 149/09 (drug-resistant with XDR pattern – see Table IV.1). Mid-log 
phase cultures were diluted to 1×105 CFU/ml and challenged with the compounds alone 
or in combination with antibiotics. Strains were inoculated in 100 ml of MB7H9 
(DIFCO, Madrid, Spain) containing 10% OADC enrichment, 0.05% Tween 80 and the 
compounds at five times the MIC. A drug-free control was included in the assay to 
monitor the normal growth of the strains. Cultures were sampled for CFU determination 
after 1, 2, 3 and 7 days of incubation at 37ºC. For CFU determination, the samples were 
pelleted once by centrifugation at 16060 x g for 10 minutes to reduce drug carry-over 




MGIT960 and the Epicenter software. Briefly, to generate calibration curves, the 
number of viable cells was first determined by standard plate counting method. Cell 
suspensions were grown to an optical density at 600 nm (OD600) of 0.8 and 1 ml was 
added to 9 ml of MB7H9. Tenfold serial dilutions (100 to 10-7) were made in MB7H9 
and 100 µl from each dilution plated onto MB7H11 plates (DIFCO) supplemented with 
10% OADC. Plates were sealed and the CFU´s determined after incubation at 37ºC 
during 21 days. Simultaneously, MGIT tubes supplemented with 10% OADC were 
inoculated in triplicate with 100 µl of the same serial dilutions, incubated in the 
MGIT960 system and the time to detection (TTD, the time to reach the threshold of 75 
GU) recorded. Calibration growth curves for each dilution were generated with the 
Epicenter software and the TTD for each dilution plotted against log10 CFU. To obtain 
the cell concentration for each drug exposed culture, CFU´s were predicted by the 
theoretical log10 CFU based TTD multiplied by the corresponding dilution factor. The 
killing effect of the compounds on in vitro M. tuberculosis growth was defined as the 
lack of growth in MGIT tubes after 100 days of incubation (16).  
 
Quantification of intracellular ATP  
Intracellular ATP was quantified by using the ATP Determination Kit (Invitrogen, Life 
Technologies, Paisley, UK) according to the manufacturer’s instructions. Briefly, strains 
were exposed to the compounds and at various time points, aliquots of 1 ml of bacteria 
were collected, heat inactivated and immediately deep frozen. Cell lysates were 
transferred into white flat bottom 96-well plates and the ATP content measured using a 
Tecan’s Infinite® M200 plate reader (Tecan Trading AG, Switzerland) and expressed as 
relative luminescence units. ATP standards were used in all experiments as internal 
controls. Sample ATP levels were calculated from the calibration curve, with correction 
for background luminescence. Isoniazid and rifampicin were used as controls. Cultures 
were sampled for CFU determination as described above.  
 
Growth rate measurements  
Cell suspensions were adjusted to 150 GU with sterile saline solution and 0.5 ml 
transferred into a MGIT tube containing 10% OADC. Growth rates were measured at 
37°C with the MGIT960 and the Epicenter software. First, we determined the TTD as a 




rates were determined according to Gullberg et al. (21) with modifications. The 
calculations were based on TTD values between 75 and 400 GU which corresponds to 
OD600 values between ≈0.02 and 0.1 (data not shown). The relative growth rates were 
determined as the ratio between the growth rate of each strain and the growth rate of the 
control strain. Data was normalized against the control strain M. tuberculosis H37Rv. 
 
Mutation frequency determinations 
M. tuberculosis H37Rv was grown in 200 ml Erlenmeyer flasks supplemented with 
10% OADC and 0.05% Tween 80 and incubated at 37ºC until they reach an OD600 of 
0.8-0.9. Cultures were diluted to 1×104 CFU/ml in MB7H9. Spontaneous mutants 
resistant to the inhibitors were detected by plating 0.1 ml of this dilution onto MB7H11 
agar plates containing the compounds at concentrations five times the MIC. Plates were 
sealed in plastic bags and the colonies counted after three weeks of incubation at 37ºC. 
The mutation frequency corresponds to the ratio of the average number of mutants per 
milliliter to the total number of cells per milliliter (12). 
 
Detection of catalase activity 
Catalase activity was assessed according to the protocol described by David (13), at 
room temperature. The M. tuberculosis H37Rv strain served as a positive control. 
 
Acid resistance evaluation 
M. tuberculosis H37Rv was grown in 25 ml of MB7H9 containing 10% OADC and 
0.05% Tween 80 until they reach an OD600 of 0.8. Cells were washed by centrifugation 
at 2940 x g during 3 minutes, to remove Tween 80. Washed cells were diluted to 1×105 
CFU/ml in 100 ml of MB7H9 at different pH’s ranging from 6.8 to 3.5 plus 10% 
OADC without Tween 80 (58). Cultures were sampled for CFU determination after 1, 
2, 3 and 7 days of incubation at 37ºC. For CFU determination, samples were washed 
once by centrifugation at 16060 x g for 10 minutes and resuspended in MB7H9. Colony 
forming units were determined with the MGIT960 and the Epicenter software as 








Antimycobacterial activity on infected macrophages 
i) Mycobacterial cultures. M. tuberculosis strains and M. bovis BCG-GFP were 
cultured in MB7H9 broth supplemented with 10% OADC and 0.05% tyloxapol (Sigma-
Aldrich) at 37ºC, with occasional shaking. For BCG-GFP, 50 µg/ml hygromycin 
(Sigma-Aldrich) were added to the media. Prior to any experiment, bacteria were 
prepared in order to achieve a single cell suspension. Bacterial cultures on exponential 
growth phase were centrifuged at 3000 x g for 10 minutes, washed in phosphate 
buffered saline (PBS) solution and resuspended in cell culture medium without 
antibiotics. In order to disrupt bacterial clumps, the cell suspension was passed through 
a 21G needle. Residual clumps were removed by 1 minute centrifugation at 500 x g.  
ii) Isolation and culture of human monocyte-derived macrophages. Human 
monocyte-derived macrophages were obtained from buffy coat preparations kindly 
donated by Instituto Português do Sangue. The buffy coat was diluted (1:1) in PBS 
containing 0.5% bovine serum albumin (BSA) and 2 mM EDTA and then gently 
overlaid on Ficoll-Paque Plus (GE Healthcare, Freiburg, Germany) at a ratio of 2:1 
followed by 800 x g centrifugation for 20 minutes at room temperature. The interface 
was then recovered and washed two times. Selection of CD14 monocytes was 
performed using MACS LS cell separation system (MiltenyiBiotec, Cologne, Germany) 
according to the manufacturer instructions. Briefly, cells were incubated during 30 
minutes at 4ºC with anti-CD14 MicroBeads (MiltenyiBiotec) and then passed through a 
magnetic separator. CD14 monocytes were recovered and differentiated into 
macrophages during 7 days in macrophage medium containing RPMI-1640 medium 
with 10% fetal calf serum (FCS), 1% GlutaMAX™, 1 mM sodium pyruvate, 10 mM 
HEPES at pH 7.4, 100 IU/ml penicillin and 100 µg/ml streptomycin (Gibco, Life 
Technologies), and 20 ng/ml M-CSF (Immunotools, Friesoythe, Germany) and 
incubated at 37ºC in 5% CO2 atmosphere. Fresh medium was added at day 4 post 
isolation. 
iii) Determination of macrophage viability after treatment with compounds. 
Human monocyte-derived macrophages were seeded 3x105 cells per well in 24-well 
plates and treated with the compounds. After 3 days of treatment, cell viability was 
determined using AlamarBlue (Molecular Probes, Life Technologies) following the 




and incubated for 4 hours at 37ºC and 5% CO2. Then, fluorescence was measured at an 
excitation of 570 nm and emission of 595 nm in a Tecan’s Infinite M200 plate 
spectrophotometer. For the subsequent intracellular assays, the compounds were used at 
concentrations that were shown to be non-toxic to the macrophages. Isoniazid was used 
at critical concentration of 0.1 µg/ml. 
iv) Quantification of intracellular bacterial survival. Human monocyte-derived 
macrophages were infected with M. tuberculosis strains at a multiplicity of infection 
(MOI) 1:1 and were allowed to uptake the bacteria for 3 hours. Next, they were washed 
three times with PBS and maintained in macrophage medium without antibiotics. At 3 
hours, and 1, 3, 5 and 7 days post-infection, cells were lysed with 0.05% Igepal (Sigma-
Aldrich) solution in water. Serial dilutions of the lysate were plated on MB7H11 
medium supplemented with 10% OADC. Colony forming units were counted upon 3 
weeks of incubation at 37ºC. The capacity of intracellular growth of each strain was 
calculated as the ratio between the CFU during the 5 day protocol and the CFU on day 0 
(47). 
v) Quantification of compound-induced macrophage acidification. Human 
monocyte-derived macrophages were infected with BCG-GFP at MOI 1:10 as described 
above. At 24 hours post-infection, cells to be analysed by fluorescence microscopy were 
incubated with LysoSensor™ Yellow/Blue DND-160 (Molecular Probes) at 1 µM for 
10 minutes and then washed and observed under a fluorescence microscope 
(Axioskop®, ZEISS, Germany). Quantification of acidified cells by flow cytometry was 
performed by detaching the cells with 0.05% Trypsin-EDTA (Sigma-Aldrich). After 
cells were washed with PBS and further incubated with 100 nM LysoTracker Red 
DND-99 (Molecular Probes) for 2 hours at 37ºC and 5% CO2. Cells were washed and 
analyzed on an easyCyte™ 5HT flow cytometer (Millipore Corporation, Billerica, MA, 
USA). 
vi) Measurement of cathepsin B activity. Human monocyte-derived macrophages 
were infected with M. tuberculosis H37Rv at MOI 1:1 as described above. After 24 
hours post-infection cells were washed with PBS and transferred into black flat bottom 
96-well plates. The cells were incubated with the compounds during 24 hours at 37ºC 
with 5% CO2. Cathepsin B activity was measured using a fluorometric cathepsin B 




instructions. Briefly, cells were lysed in chilled cathepsin B cell lysis buffer and 
incubated on ice for 10 minutes. Cell lysates were recovered and cathepsin B substrate 
(Ac-RR-AFC) added to a final concentration of 200 µM. Cells were further incubated 
during 2 hours at 37°C. Cathepsin B activity was measured at 400 nm excitation and 
505 nm emission using a Tecan’s Infinite® M200 plate reader and expressed as relative 
fluorescence units (RFU).  
 
Assessment of efflux activity.The detection of ethidium bromide efflux was performed 
by a semi-automated fluorometric method using a Rotor-Gene 3000TM thermocycler 
(Corbett Research, Sidney, Australia) (60) with a modified protocol for M. tuberculosis 
(32). The semi-automated fluorometric method was applied to all strains. Briefly, the 
strains were grown in 10 ml of MB7H9 medium containing 10% OADC enrichment 
(Becton Dickinson) and 0.05% Tween 80. Cultures were incubated at 37ºC, without 
stirring, until they reached an OD600 of 0.8. After the cultures reached the desired OD600, 
cultures were centrifuged at 2940 x g, during 3 minutes at 25ºC. After this, the 
supernatant were discarded, the pellet washed, resuspended in PBS and centrifuged as 
before.  
(i) Accumulation of ethidium bromide. For the ethidium bromide accumulation 
assays, the washed cells were resuspended in PBS and the OD600 adjusted to 0.8. In 
order to determine the lowest concentration of ethidium bromide that causes 
accumulation, 50 µl of the bacterial suspension was added to 0.2 ml PCR tubes 
containing different concentrations of ethidium bromide that ranged from 0.125 to 5 
µg/ml and glucose at a final concentration of 0.4%. The final OD600 of the bacterial 
suspension in the assay was 0.4. The assays were conducted at 37ºC in a Rotor-Gene 
3000TM, and the fluorescence of ethidium bromide was measured (530/585 nm) at the 
end of each cycle of 60 seconds, for 60 minutes. After determining the higher 
concentration of ethidium bromide that do not causes accumulation, the effect of the 
inhibitors on the accumulation of ethidium bromide was evaluated. These assays were 
performed as described above with each efflux inhibitor at ½ of the MIC (a 
subinhibitory concentration that do not affect bacterial viability but inhibits efflux), 
ethidium bromide at the higher concentration that do not cause accumulation 
(determined for each strain), 37ºC and with and without glucose. To better evaluate the 




determined the relative final fluorescence (RFF) at the last time point (minute 60) of the 
assay in comparison with the control condition using the formula RFF = (RFtreated- 
RFnon-treated)/(RFnon-treated) (33). Here, RFtreated corresponds to the relative fluorescence for 
each strain treated with the compound at the last time point of the accumulation assay 
and the RFnon-treated corresponds to the relative fluorescence of the cells only in the 
presence of ethidium bromide at the same time point. High RFF values indicated that 
cells accumulate more ethidium bromide under the condition used than those of the 
control (non-treated cells). Negative RFF values indicated that treated cells accumulated 
less ethidium bromide than those of the control condition. Each assay was performed in 
triplicate and the results presented correspond to the average ±SD of three independent 
assays.  
ii) Efflux of ethidium bromide. For the efflux assays, the washed cells were 
resuspended in PBS and the OD600 adjusted to 0.4. The ethidium bromide loaded cells 
were prepared by incubating the bacterial suspension, in glass test tubes, with the higher 
concentration of ethidium bromide that do not cause accumulation (determined above), 
under conditions that promote accumulation: the most effective efflux inhibitor at ½ of 
the MIC, absence of glucose at 25ºC during 60 minutes. For all strains tested in this 
work, the most effective inhibitor was verapamil. After ethidium bromide accumulation, 
the cells were collected by centrifugation at 4860 x g during 5 minutes at 25ºC and 
resuspended in PBS to an OD600 of 0.8. After adjusting de OD600, 50 µl of the bacterial 
suspension was added to 0.2 ml PCR tubes containing (1) PBS only; (2) PBS plus 
glucose, to a final concentration of 0.4%; (3) verapamil at ½ of MIC only; and (4) 
glucose to a final concentration of 0.4% plus verapamil at ½ of MIC. The final OD600 of 
the bacterial suspension in the assay was 0.4. The fluorescence of ethidium bromide was 
measured, as described above. The fluorescence was acquired first, at the end of 15 
seconds and at the end of every 30 seconds during the following 30 minutes. The efflux 
activity was quantified by comparing the fluorescence data obtained for the cells under 
conditions that allow maximum efflux (incubation at 37ºC in the presence of glucose 
and absence of a compound) against the data from the control tube that contains the 
ethidium bromide-load cells under conditions that inhibit the efflux (with a compound 





Efflux pump gene expression. (i) RNA extraction. Total RNA was isolated from the 
cells using a GTC/Trizol based method. Briefly, cultures were centrifuged at 2940 x g 
during 16 minutes. Then, supernatant was removed leaving about 500 µl above the 
pellet. Five volumes of a 5M GTC solution were added to each culture and incubated 5 
minutes at room temperature. The mixture was then centrifuged at 2940 x g for 30 
minutes and the supernatant was discarded. The pellet was resuspended in 1 ml of TRI 
reagent (Sigma). The suspension was transferred to lysis tubes containing glass beads 
(QIAGEN, GmbH, Hilden, Germany) and sonicated at 35 kHz (Gen-Probe, California, 
USA) during 3 x 5 minutes with 1 minute of cooling on ice between intervals. The 
disrupted cells were incubated at room temperature during 10 minutes and centrifuged 
at 16060 x g for 45 seconds. Supernatant above the beads and cellular debris were 
transferred to a tube containing 300 μl of chloroform: isoamyl alcohol (24:1). 
Afterwards, the mixture was incubated during 5 minutes at room temperature followed 
by centrifugation at 16060 x g for 10 minutes. The top aqueous layer was then 
transferred to a clean tube containing an equal volume of isopropanol and the mixture 
incubated overnight at -20°C. Precipitated nucleic acids were recovered by 
centrifugation at 18000 x g for 30 minutes at 4oC and RNA pellet washed twice with 1 
ml ice cold 70% ethanol. RNA was dissolved in RNase-free water and contaminating 
chromosomal DNA was digested with RNase-free DNase I (QIAGEN) at room 
temperature during 30 minutes. RNA was purified with phenol: chloroform (4:1) during 
10 minutes of incubation on ice and the mixture centrifuged at 18000 x g for 10 minutes 
at room temperature. The top aqueous layer was transferred to a new tube, to which 0.1 
volumes of RNase-free sodium acetate pH 5.2 and 2.5 volumes of 100% RNase-free 
ethanol were added. Samples were incubated overnight at -20°C. After this incubation, 
RNA was collected by centrifugation at 18000 x g for 30 minutes at 4ºC, and washed 
twice with 1 ml ice cold 70% ethanol. The purified RNA was air-dried and then 
dissolved in 70 µl RNase-free water. Quantity and quality of the purified RNA was 
measured using a NanoDrop 1000 spectrophotometer (Thermo Scientific, Waltham, 
USA). 
(ii) RT-qPCR analysis. The relative expression level of 10 efflux genes that code for 
membrane efflux transporters in M. tuberculosis and the transcriptional regulator whiB7 




inhibitory concentrations of isoniazid or rifampicin. The primers employed are available 
upon request. The RT-qPCR procedure was performed in a Rotor-GeneTM 3000 
thermocycler and followed the protocol recommended for use with the QuantiTect 
SYBR Green RT-PCR Kit (QIAGEN). The following amplification program was used: 
reverse transcription for 30 minutes at 50ºC; initial activation step for 15 minutes at 
95ºC; 35 cycles of denaturation at 94ºC for 30 seconds, annealing at 52ºC for 30 
seconds and extension at 72ºC for 30 seconds; a final extension step at 72ºC for 5 
minutes; and an additional step at 50ºC for 15 seconds followed by melt analysis (50-
99ºC). The determination of the relative mRNA expression level was performed using 
the comparative quantification cycle (Cq) method (28). The relative expression of the 
11 genes was determined by comparison of the relative quantity of the respective 
mRNA in the presence of the antibiotic to the non-exposed condition. Each strain was 
assayed in triplicate using total RNA obtained from three independent cultures. Data 
was normalized to the M. tuberculosis 16S rDNA reference gene and presented as the 
mean fold change (±SD) compared with the control.  
iii) RNA extraction and RT-qPCR from infected macrophages. Total RNA was 
isolated from control and isoniazid-treated M. tuberculosis-infected macrophages at day 
1, 3, 5 and day 7 post-infection as described above. The RT-qPCR procedure was 
performed in a Rotor-GeneTM 3000 thermocycler and followed the protocol 
recommended for use with the QuantiTect SYBR Green RT-PCR Kit. The amplification 
program was as follows: reverse transcription for 30 minutes at 50ºC; initial activation 
step for 15 minutes at 95ºC; 45 cycles of denaturation at 94ºC for 1 minute, annealing at 
52ºC for 1 minute and extension at 72ºC for 1 minute; a final extension step at 72ºC for 
5 minutes; and an additional step at 50ºC for 15 seconds followed by melt analysis. Data 
was normalized to the M. tuberculosis 16S rDNA reference gene and presented as the 
mean fold change (±SD) compared with the control.  
 
Genetic characterization. (i) Detection of mutations associated with resistance. 
Genomic DNA was extracted using the QIAamp DNA mini kit (QIAGEN) according to 
the manufacturer’s instructions. The most common mutations in katG gene and inhA 
regulatory region were investigated using Genotype MTBDRplus (HainLifescience 
GmbH, Nehren, Germany). For the detection of the most frequent mutations in gyrA 




manufacturer’s instructions. Genomic analysis of the complete inhA gene and eis 
promoter region was performed by PCR amplification and DNA sequencing using the 
primers described previously (27; 39; 43). The reaction mixtures were prepared for a 
total reaction volume of 50 µl consisting of 1x Taq buffer (Fermentas, Ontario, 
Canada), 1.5 mM MgCl2, 200 mM of each dNTP, 20 pmol of each primer (10 pmol for 
eis), 1.5U Taq DNA Polymerase (Fermentas), and 5 µl of chromosomal DNA. The PCR 
reactions were performed with the following amplification profile: initial denaturation at 
94ºC for 5 minutes, followed by denaturation at 94ºC for 1 minute, annealing at 60ºC 
(56 ºC for eis) for 1 minute and extension at 72ºC for 1 minute during 40 cycles. The 
final extension occurred at 72ºC for 10 minutes.  
(ii) Detection of mutations in drug transporters. The genes were analysed by PCR 
amplification and DNA sequencing to search for mutations. The primer sequences are 
available upon request from the authors. The reaction mixtures were prepared for a total 
reaction volume of 50 µl consisting of 1x Taq buffer (Fermentas), 1.5 mM MgCl2, 200 
mM of each dNTP, 20 pmol of each primer, 1.5U Taq DNA Polymerase (Fermentas), 
and 5 µl of chromosomal DNA. The PCR reactions were performed with the following 
amplification profile: initial denaturation at 94ºC for 5 minutes, followed by 
denaturation at 94ºC for 1 minute, primer dependent annealing temperature for 1 minute 
and extension at 72ºC for 1 minute during 40 cycles. The final extension occurred at 
72ºC for 10 minutes. 
(iii) Strain typing. Mycobacterial interspersed repetitive unit-variable number of 
tandem repeats (MIRU-VNTR) genotyping was performed for each strain by multiplex 
PCR amplification 24 MIRU-VNTR loci, as described by Supply et al. (5). The 
genotype of these strains was analysed using the MIRU-VNTRplus web application (4) 









Figure IV.1. Quantitative drug susceptibility testing of isoniazid for the M. tuberculosis 
29/12 strain, in the presence or absence of verapamil. Quantitative drug susceptibility testing 
of isoniazid was conducted using the BACTEC 960 system and the Epicenter V5.80A software 
equipped with the TB eXIST module. Full and dotted dark-blue line indicates the drug-free 
proportional and absolute growth control, respectively. Coloured full lines correspond to the 
growth curves of the strain in the presence of isoniazid; the dotted lines correspond to the 
growth curves with isoniazid in combination with verapamil. At the time of growth of the 
proportional growth control (GU=400), the comparison between this tube and the tubes 
containing the drugs(s) was performed. If the GU of the tubes containing the drug were >100, 
they were considered to be resistant to that concentration. If the GU of the tube containing the 
drug was <100 they were considered susceptible. Isoniazid was tested at 0.1, 0.4, 1, 3 and 10 





































Absolute growth control (undiluted) Proportional growth control (1:100) Growth control threshold (GU=400)
Drug interpretation help (GU=100) Isoniazid 0.1 µg/ml Isoniazid 0.4 µg/ml
Isoniazid 1 µg/ml Isoniazid 3 µg/ml Isoniazid 0.1 µg/ml + verapamil












Figure IV.2. Time-kill curves for flupenthixol, chlorpromazine, thioridazine, haloperidol, 
verapamil and the antituberculosis drugs isoniazid, rifampicin, amikacin and ofloxacin. 
Compounds were used at 5X MIC and CFU/ml was determined at days 1, 2, 3 and 7. A) Killing 
activity of the ion channel blockers; B) Killing activity of the antibiotics in the presence or 
absence of verapamil. In the Figure, is represented the assay for the H37Rv strain. Data 
corresponds to the average of two experiments.  VP, verapamil; TZ, thioridazine; CPZ, 
chlorpromazine; HAL, haloperidol; FPX, flupenthixol; INH, isoniazid; RIF, rifampicin; AMK, 
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Figure IV.3. Mycobacterial intracellular ATP levels and viability. Cultures of M. 
tuberculosis H37Rv were exposed to the inhibitors during 7 days. ATP was determined by using 
a luciferin-luciferase bioluminescence detection system at day 1, 2, 3 and 7. Cell viability was 
measured in parallel with MGIT960 system as described in Material and Methods. Isoniazid 
(INH) and rifampicin (RIF) were used as controls. VP, verapamil; TZ, thioridazine; CPZ, 









































Figure IV.4. Effect of the inhibitors on the accumulation and efflux of ethidium bromide 
by the M. tuberculosis strains. In the Figure is presented an assay for the strain 29/12 as an 
example. A) Accumulation and B) efflux of ethidium bromide. Ethidium bromide was tested at 
0.25 µg/ml. Efflux inhibitors were tested at ½ the MIC. EtBr, ethidium bromide; VP, verapamil; 




Figure IV.5. Relative expression of genes coding for efflux pumps in M. tuberculosis 82/09 
strain during intracellular growth when exposed to isoniazid. M. tuberculosis infected 
macrophages were exposed to 0.1 µg/ml isoniazid during 3 days. Relative expression of 



















































0.25 µg/ml EtBr 0.25 µg/ml EtBr + 128 µg/ml  VP
0.25 µg/ml EtBr + 15 µg/ml CPZ 0.25 µg/ml EtBr + 7.5 µg/ml TZ
































Figure IV.6. Antimycobacterial activity of the ion channel blockers on M. tuberculosis 
infected macrophages. Effect of the inhibitors on the intracellular survival of M. tuberculosis 
within human monocyte-derived macrophages, 3 days post infection. INH was tested at 0.1 
µg/ml, VP, 10 µg/ml; TZ, 2.5 µg/ml; CPZ, 1.25 µg/ml; HAL, 1.25 µg/ml; FPX, 1.25 µg/ml. 
INH: isoniazid; VP: verapamil; TZ: thioridazine; CPZ: chlorpromazine; HAL: haloperidol; 



























































































A) H37Rv B) 82/09






Figure IV.7.  Fluorescence microscopy images of M. bovis BCG-GFP-infected human 
monocyte-derived macrophages stained with LysoSensor. A) Non-treated cells, B) cells 
treated with 2.5 µg/ml thioridazine; C) bright-field for non-treated cells, and D) bright-field for 




Figure IV.8. Quantification of phagolysosome acidification. Human monocyte-derived 
macrophages were infected with M. bovis BCG-GFP and treated with verapamil, thioridazine, 
chlorpromazine, flupenthixol, and haloperidol, stained with Lysotracker Red, and analyzed by 
flow cytometry. VP was tested at 10 µg/ml; TZ at 2.5 µg/ml; CPZ at 1.25 µg/ml; HAL at 1.25 
µg/ml; FPX at 1.25 µg/ml. VP, verapamil; TZ, thioridazine; CPZ, chlorpromazine; HAL, 













































Figure IV.9. Determination of cathepsin B activity. Human monocyte-derived macrophages 
were treated with verapamil, thioridazine, chlorpromazine, flupenthixol, and haloperidol. 
Cathepsin activity was evaluated also with cultures infected with M. tuberculosis H37Rv and 
treated with the compounds. VP was tested at 10 µg/ml; TZ at 2.5 µg/ml; CPZ at 1.25 µg/ml; 
HAL at 1.25 µg/ml; FPX at 1.25 µg/ml. INH: isoniazid; VP: verapamil; TZ: thioridazine; CPZ: 




Figure IV.10. Growth rate of M. tuberculosis strains in human monocyte-derived 




















































H37Rv 82/09 - LAM Lisboa 3 149/09 - LAM Q1




8. Tables  
 








 Gene mutations  
Antibiotics (µg/ml)  Inhibitors (µg/ml) 
INH RIF AMK OFX  VP TZ CPZ FPX HAL 
H37Rv  H37Rv Susceptible  none  0.1 1 1 1  256 15 30 30 64 
H37RvΔkatG  H37Rv INH   katG deletion  128 1 1 1  128 15 30 30 32 
82/09  LAM –Lisboa3 INH; RIF - MDR  inhA C-15T/S94A; rpoB S531L  3 320 1 1  256 15 30 30 64 
149/09  LAM – Q1 




inhA C-15T/I194T; rpoB 531L; gyrA D94A; 
 rrs A1401G  
 
 
3 320 640 10  256 15 30 30 64 
286/09  LAM –Lisboa3 




inhA C-15T/S94A; rpoB S531L; gyrA S91P; 
 eis G-10A 
 
 
20 80 4 10  128 15 30 30 32 
69/11  Beijing 
INH; RIF; AMK; CAP; OFX 
- XDR 
 katG S315T; rpoB S531L; rrs A1401G/wt*  20 320 40 1  256 15 30 30 32 
29/12  LAM – Q1 








3 320 640 10  256 15 30 30 64 




INH   inhA C-15T  0.4 1 1 1  256 15 30 30 64 
Δ, deletion; MDR, multidrug resistant; XDR, extensively drug resistant; INH, isoniazid; RIF, rifampicin; AMK, amikacin; CAP, capreomycin; OFX, ofloxacin; VP, verapamil; TZ, 
thioridazine; CPZ, chlorpromazine; FPX, flupenthixol; HAL, haloperidol. *mixed pattern: simultaneous presence of drug susceptible and drug resistant genotype. *VNTR international 





Table IV.2. Fractional inhibitory concentration (FIC) values of the inhibitors when 
combined with isoniazid, rifampicin, amikacin or ofloxacin, against the nine M. 
tuberculosis strains.  
Drug 
combinations 





82/09 149/09 286/09 69/11 29/12 269/03 294/09 
INH  0.1 128 3 3 20 20 3 10 0.4 
INH + VP  0.1/1 128/1 1/0.33 1/0.33 1/0.05 10/0.50 1/0.33 10/1 0.4/1 
INH + TZ  0.1/1 128/1 1/0.33 1/0.33 20/1 3/0.15 3/1 3/0.30 0.4/1 
INH + CPZ  0.1/1 128/1 1/0.33 1/0.33 1/0.05 3/0.15 1/0.33 3/0.30 0.4/1 
INH + FPX  0.1/1 128/1 1/0.33 1/0.33 1/0.05 3/0.15 1/0.33 3/0.30 0.4/1 
INH + HAL  0.1/1 128/1 1/0.33 1/0.33 1/0.05 10/0.50 1/0.33 10/1 0.4/1 
RIF  1 - 320 320 80 320 320 - - 
RIF + VP  1/1 - 20/0.06 20/0.06 20/0.25 20/0.06 20/0.06 - - 
RIF + TZ  1/1 - 320/1 320/1 20/0.25 320/1 320/1 - - 
RIF + CPZ  1/1 - 320/1 20/0.06 4/0.05 20/0.06 20/0.06 - - 
RIF + FPX  1/1 - 320/1 320/1 4/0.05 320/1 320/1 - - 
RIF + HAL  1/1 - 320/1 320/1 20/0.25 320/1 320/1 - - 
AMK  1 - - 640 4 40 640 - - 
AMK + VP  1/1 - - 640/1 4/1 1/0.03 640/1 - - 
AMK+ TZ  1/1 - - 640/1 4/1 1/0.03 640/1 - - 
AMK + CPZ  1/1 - - 40/0.13 4/1 1/0.03 40/0.13 - - 
AMK + FPX  1/1 - - 640/1 4/1 1/0.03 640/1 - - 
AMK + HAL  1/1 - - 640/1 4/1 1/0.03 640/1 - - 
OFX  1 - - 10 10 - 10 - - 
OFX + VP  1/1 - - 10/1 10/1 - 10/1 - - 
OFX+ TZ  1/1 - - 10/1 10/1 - 10/1 - - 
OFX + CPZ  1/1 - - 10/1 10/1 - 10/1 - - 
OFX + FPX  1/1 - - 10/1 10/1 - 10/1 - - 
OFX + HAL  1/1 - - 10/1 10/1 - 10/1 - - 
Δ, deletion; INH, isoniazid; RIF, rifampicin; AMK, amikacin, OFX, ofloxacin; VP, verapamil; TZ, thioridazine; 
CPZ, chlorpromazine; FPX, flupenthixol; HAL, haloperidol. FIC, fractional inhibitory concentration; MIC, minimum 
inhibitory concentration; The lowest concentration tested corresponds to the critical concentration for each antibiotic 
(See Material and Methods section for details). The FIC was interpreted as: FIC≤0.5, synergism; >0.5-1, indifference; 








Table IV.3. Quantitative drug susceptibility testing for isoniazid, rifampicin, amikacin and ofloxacin in the presence of inhibitors for the M. tuberculosis 
strains. 
 
Δ, deletion; INH, isoniazid; RIF, rifampicin; AMK, amikacin, OFX, ofloxacin; VP, verapamil; TZ, thioridazine; CPZ, chlorpromazine; FPX, flupenthixol; HAL, haloperidol. R, resistant; 
S, susceptible; ICB, ion channel blocker; ND, not determined.  
 
Strain 




















+VP +TZ +CPZ +FPX +HAL 
H37Rv 
 
0.1 S S S S S S 1 S S S S S S 1 S S S S S S 1 S S S S S S 
0.4 S S S S S S 4 S S S S S S 4 S S S S S S 2 S S S S S S 
1 S S S S S S 20 S S S S S S 20 S S S S S S 10 S S S S S S 
3 S S S S S S                      
10 S S S S S S                      
H37Rv 
ΔkatG 
0.1 R R R R R R 
ND 
      
ND 
      
ND 
      
0.4 R R R R R R                   
1 R R R R R R                   
3 R R R R R R                   
10 R R R R R R                    
82/09 
0.1 R R R R R R 1 R R R R R R 
ND 
      
ND 
      
0.4 R R R R R R 4 R R R R R R             
1 R S S S S S 20 R S R R R R             
3 S S S S S S                    
10 S S S S S S                    
149/09 
0.1 R R R R R R 1 R R R R R R 1 R R R R R R 1 R R R R R R 
0.4 R R R R R R 4 R R R R R R 4 R R R R R R 2 R R R R R R 
1 R S S S S S 20 R S R S R R 20 R R R R R R 10 S S S S S S 
3 S S S S S S                      
10 S S S S S S                      
286/09 
0.1 R R R R R R 1 R R R R R R 1 R R R R R R 1 R R R R R R 
0.4 R R R R R R 4 R R R S S R 4 S S S S S S 2 R R R R R R 
1 R S R S S S 20 R S S S S S 20 S S S S S S 10 S S S S S S 
3 R S R S S S                      
10 R S R S S S                      
69/11 
0.1 R R R R R R 1 R R R R R R 1 R S S S S S 
ND 
      
0.4 R R R R R R 4 R R R R R R 4 R S S S S S       
1 R R R R R R 20 R S R S R R 20 R S S S S S       
3 R R S S S R                     
10 R S S S S S                     
29/12 
0.1 R R R R R R 1 R R R R R R 1 R R R R R R 1 R R R R R R 
0.4 R R R R R R 4 R R R R R R 4 R R R R R R 2 R R R R R R 
1 R S R S S S 20 R S R S R R 20 R R R R R R 10 S S S S S S 
3 S S S S S S                      
10 S S S S S S                      
294/09 
0.1 R R R R R R 
ND 
      
ND 
      
ND 
      
0.4 S S S S S S                   
1 S S S S S S                   
3 S S S S S S                   
10 S S S S S S                   
269/03 
0.1 R R R R R R 
ND 
      
ND 
      
ND 
      
0.4 R R R R R R                   
1 R R R R R R                   
3 R R S S S R                   




Table IV.4. Relative final fluorescence (RFF) based on the accumulation of ethidium 
bromide for the M. tuberculosis strains in the presence of the inhibitors.  
Strain  
RFF of the inhibitors 
VP TZ CPZ FPX HAL 
H37Rv 1.58 0.97 0.84 0.90 0.32 
H37RvΔkatG 0.37 0.09 0.03 0.15 -0.06 
82/09 2.17 0.96 0.63 1.24 0.44 
149/09 2.31 1.13 1.16 1.45 0.58 
69/11 1.19 0.23 0.47 0.95 0.21 
29/12 2.00 1.14 1.04 1.03 0.24 
294/09 1.21 0.52 0.44 0.98 -0.18 
269/03 0.73 0.17 0.07 0.35 -0.02 
VP, verapamil; TZ, thioridazine; CPZ, chlorpromazine; FPX, flupenthixol; HAL, haloperidol.  
Strain 286/09 was not evaluated due to poor growth under the conditions required for the accumulation assays.  




Table IV.5. Average quantification of the relative expression level, by RT-qPCR, of the 
genes that code for efflux pumps in the M. tuberculosis exposed to isoniazid. 
Gene 
Relative expression level ± SD 
82/09 149/09 286/09 29/12 69/11 294/09 269/03 
mmr 6.29 ± 3.23 2.22 ±0.11 0.78 ± 0.22 1.63 ± 0.16 0.76 ± 0.07 0.64 ± 0.03 0.74 ± 0.04 
mmpl7 0.49 ± 0.38 2.49 ± 0.49 2.23 ± 0.33 4.03 ± 2.87 0.76 ± 0.00 0.83 ± 0.24 0.72 ± 0.21 
Rv1258c 0.79 ± 0.40 1.34 ± 0.26 0.48 ± 0.40 2.22 ± 0.11 0.79 ± 0.30 0.85 ± 0.12 0.64 ± 0.03 
p55 26.06 ± 2.55 1.65 ± 0.92 0.67 ± 0.13 4.04 ± 0.78 0.86 ± 0.41 1.38 ± 0.20 0.69 ± 0.17 
whiB7 3.38 ± 1.29 0.19 ± 0.01 0.71 ± 0.07 0.87 ± 0.00 0.61 ± 0.15 0.67 ± 0.13 2.55 ± 1.32 
1217c 5.94 ± 1.44 0.08 ± 0.01 0.60 ± 0.30 5.12 ± 1.96 0.69 ± 0.17 1.33 ± 0.26 0.62 ± 0.06 
1218c 1.36 ± 0.91 0.04 ± 0.00 0.50 ± 0.00 2.17 ± 0.42 0.44 ± 0.08 1.28 ± 0.06 0.72 ± 0.13 
efpA 10.11 ± 3.82 1.38 ± 0.21 0.80 ± 0.18 1.76 ± 0.34 1.39 ± 0.33 0.81 ± 0.00 1.52 ± 0.15 
Rv2459 0.44 ± 0.15 1.62 ± 0.00 0.44 ± 0.26 1.86 ± 0.63 0.68 ± 0.19 0.73 ± 0.04 0.94 ± 0.09 
pstB 1.54 ±0.66 1.12 ± 0.16  0.49 ± 0.24 1.94 ± 0.28 0.74 ± 0.11 1.08 ± 0.21  0.55 ± 0.11  
iniA 0.26 ± 0.05 0.05 ± 0.00 1.41 ± 0.23 1.53 ± 0.30 0.46 ± 0.02 1.00 ± 0.00 0.38 ± 0.18 
The relative expression of the 11 genes was determined by comparison of the relative quantity of the respective 
mRNA in the presence of isoniazid to the non-exposed condition. Each strain was assayed in triplicate using total 
RNA obtained from three independent cultures. Data was normalized to the M. tuberculosis 16S rDNA reference 
gene and presented as the mean fold change (±SD) compared with the control. Results in bold type were considered 











Table IV.6. Average quantification of the relative expression level, by RT-qPCR, of the 
genes that code for efflux pumps in the M. tuberculosis exposed to rifampicin. 
Gene 
Relative expression level ± SD 
82/09 149/09 286/09 69/11 29/12 
mmr 1.31 ± 0.62 0.73 ±0.49 2.49 ± 0.49 1.00 ± 0.33 0.71 ± 0.00 
mmpl7 1.85 ± 0.87 0.46 ±0.23 3.23 ± 1.09 0.39 ± 0.08 1.02 ± 0.30 
Rv1258c 1.40 ± 0.66 1.31 ± 0.44 0.94 ± 0.18 0.20 ± 0.03 0.93 ± 0.31 
p55 4.27 ± 1.44 2.30 ± 0.23 9.88 ± 0.97 1.54 ± 0.66 2.59 ± 0.63 
whiB7 0.87 ± 0.29 1.61 ± 0.76 1.04 ± 0.16 2.47 ± 0.24 1.83 ± 0.44 
1217c 0.71 ± 0.07 0.52 ± 0.07 0.98 ± 0.76 0.14 ± 0.08 1.12 ± 0.57 
1218c 0.72 ± 0.40 0.36 ± 0.12 0.69 ± 0.10 0.51 ± 0.05 1.44 ± 0.62 
efpA 1.94 ± 0.09 1.83 ± 0.44 1.41 ± 0.47 1.81 ± 0.27 3.47 ± 1.17 
Rv2459 0.69 ± 0.35 0.41 ± 0.04 0.74 ± 0.04 0.28 ± 0.08 1.08 ± 0.21 
pstB 0.41 ± 0.30 0.46 ± 0.11 0.47 ± 0.04 0.22 ± 0.01 1.41 ± 0.47 
iniA 1.94 ± 0.28 0.89 ± 0.25 54.50 ± 21.35 1.47 ± 0.21 3.11 ± 1.20 
The relative expression of the 11 genes was determined by comparison of the relative quantity of the respective 
mRNA in the presence of rifampicin to the non-exposed condition. Each strain was assayed in triplicate using total 
RNA obtained from three independent cultures. Data was normalized to the M. tuberculosis 16S rDNA reference 
gene and presented as the mean fold change (±SD) compared with the control. Results in bold type were considered 
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10. Supplementary Figures 
 
 
Figure IV.S1. Quantification of acidification in treated human macrophages by flow cytometry. Human monocyte-derived macrophages were 
infected M. bovis BCG-GFP, and treated with verapamil, thioridazine, chlorpromazine, flupenthixol, haloperidol, stained with Lysotracker Red, and 
analyzed by flow cytometry. VP was tested at 10 µg/ml; TZ at 2.5 µg/ml; CPZ at 1.25 µg/ml; HAL at 1.25 µg/ml; FPX at 1.25 µg/ml. INH: isoniazid; 



























Figure IV.S2. Effect of pH on survival of M. tuberculosis H37Rv. Cells, at a concentration of 
105, were incubated in MB7H9, without Tween 80, at pHs from 6.8 to 3.5 during 7 days. CFU 




Figure IV.S3. In vitro determination of the fitness of the M. tuberculosis strains. A) 
Comparison between the capacities of the strains to adapt to a new environment measured as the 
time to reach the positivity threshold of 75 GU; B) Relative growth rates determined as the ratio 
between the growth rate of each strain and the growth rate of the control strain. The growth rates 



































































11. Supplementary Tables 
 
Table IV.S1. Genetic characterization of the efflux transporters studied. 
Wt, wild type; ∆, deletion 
 
 
Table VI.S2. Concentrations required to inhibit M. tuberculosis in vitro versus that needed 
to produce similar effects on macrophages. 
Compound 
Concentration (µM) 
in vitro ex vivo 
Verapamil 260 20.4 
Thioridazine 18.4 6.1 
Chlorpromazine 42.2 3.5 
Flupenthixol 29.6 2.5 










 82/09 149/09 286/09 69/11 29/12 269/03 294/09 
iniA 
 ∆GCG after nt 
285 
wt 
∆GCG after nt 
285 
wt wt wt wt 
Rv1258c  wt wt wt C194del wt wt wt 
p55  wt Q506 Q506 Q506 Q506 wt Q506 
Rv1217c  wt A531 A531 A173T/S204/A531 A531 wt wt 
Rv1218c  wt wt wt Q243R wt wt wt 






































































Chapter V. General discussion and future perspectives 
 
“Every wild strain of tubercle bacilli contains some mutants resistant to antibacterial 
drugs. The difference between a resistant strain and a susceptible strain is that the 
proportion of resistant bacteria among the total number of bacteria making up the 
strain is much higher in a resistant strain than in a susceptible one.” 
Canetti et al.  (7)  
 
 Despite several efforts to control the disease, tuberculosis remains the world’s 
leading cause of death due to a single bacterial infectious agent. The emergence of 
multi- and extensively drug-resistant tuberculosis suggests that M. tuberculosis has been 
adapting and evolved towards drug resistance. Drug resistance in M. tuberculosis is 
essentially a manmade phenomenon and occurs when resistant mutants that are 
naturally present in the mycobacterial population are selected as a consequence of 
irregular drug supply, inadequate drug prescription, and/or non-adherence to the 
treatment. At the site of the infection, M. tuberculosis bacterial burden can be up to 108-
109 cells and the mutations rates for isoniazid and rifampicin are approximately 10-8 and 
10-10, respectively (8). Since the chromosomal loci responsible for the resistance to the 
various antibiotics are not linked, the probability of the development of double 
mutations is extremely reduced. Over the last two decades, numerous studies have 
shown that M. tuberculosis drug resistance emerges through the sequential acquisition 
of chromosomal mutations in the genes that encode for the drug targets (11; 20; 29). In 
this work (Chapter II) we have identified a panel of drug resistance markers among the 
multidrug resistant M. tuberculosis strains circulating in Lisbon. The results show that 
there is a strong correlation between the development of gene mutations in the drug 
targets and the resistance phenotype of a strain, and that the chromosomal alterations 
associated with resistance are highly conserved (Chapter IIA). Moreover, the 
application of quantitative drug susceptibility testing (6; 24) allowed us to determine the 
levels of resistance for each strain and its correlation with the mutations associated with 
drug resistance. It was known that, in M. tuberculosis clinical strains, different levels of 
phenotypic drug resistance can be found, from low, intermediate to high-level drug 
resistance (11). We know now that these different levels of resistance are associated 




in rpoB (rifampicin and rifabutin), inhA (isoniazid and ethionamide), ethA 
(ethionamide), rpsL (streptomycin), and rrs (amikacin) were associated with high-level 
resistance, and mutations in embB (ethambutol), gidB (streptomycin), tlyA and rrs 
(capreomycin), eis (amikacin), and gyrA (quinolones) confer only low-level resistance. 
The standard drug susceptibility testing fails to detect the clinically relevant levels of 
drug resistance. From the clinical point of view, the report of resistance to a given 
antibiotic will have the same consequence whether it is low- or high-level resistance- 
the antibiotic is excluded from the therapeutic regimen. However, low-level drug 
resistance does not always correspond to clinical resistance, whereas for a high-level 
resistance strain, the antibiotic will be useless. Therefore, in the presence of a low-level 
resistant strain it might be possible to attain a good clinical outcome if a high dose of 
the antibiotic is implemented. Susceptibility testing based on the critical concentration 
of a drug is unquestionably appropriate for screening of drug resistance, however, when 
in the presence of a drug resistant strain this information should be complemented by 
quantitative drug susceptibility testing (3). In support of this rational we demonstrated 
that the use of high dose isoniazid for the therapy of multidrug drug resistant strains 
circulating in Lisbon will not improve the clinical outcome of the patient due to the 
presence of double mutations in inhA that confer high-level resistance (Chapter IIB). 
The prompt identification of patients infected with a drug resistant M. tuberculosis 
strain is thus of major importance in order to prevent the transmission of drug resistant 
tuberculosis. We applied two molecular methods for the detection of mutations 
associated with resistance to first- and second-line antituberculosis drugs. These assays 
proved to be reliable methods for predicting multidrug resistance and high-level 
resistance. Nevertheless, the results showed that low-level resistance will remain 
undetected by these methods. Therefore, these findings indicate that molecular methods 
for the diagnosis of drug resistance cannot replace the phenotypic drug susceptibility 
testing. Finally, by MIRU-VNTR typing we detected two related genetic clusters in 
circulation, Lisboa3 and Q1, as previously demonstrated by Perdigão and colleagues 
(15; 16; 17; 18). The analysis of the distribution of the mutational pattern by genetic 
cluster showed that cluster Lisboa3 can be characterized by five gene mutations, inhA 
S94A, rpsL K43R, tlyA GT 755/766, eis G-10A, and gyrA S91P; and cluster Q1 by six 




gyrA D94A. GidB A80P was previously described as a surrogate marker for Q1 isolates 
with strong association with multi- and extensively drug resistance (19). The 
identification of the mutational pattern of the M. tuberculosis strains circulating in 
Lisbon will permit the application of more suitable methods for the detection and 
quantification of drug resistance, clinical management and therapeutic selection of these 
patients. From the above described laboratory and basic scientific findings it’s easy to 
perceive how difficult is, for the clinicians, to manage these patients, not only in 
Portugal and in Europe but worldwide (12; 14).  
In order to prevent the emergence of drug resistance it is necessary to understand the 
chain of events that explains how M. tuberculosis develops drug resistance. In Chapter 
III, we focused our attention on the understanding of the chain of events leading to the 
development of resistance in M. tuberculosis, with particular emphasis on the 
differential activity of genes that code for the main M. tuberculosis efflux pumps prior 
to, during and, after the establishment of the resistance phenotype and their interaction 
with the genetically based resistance. From the results obtained in this study we propose 
the following hypothesis for the emergence of drug resistance in a susceptible strain: the 
addition of isoniazid at therapeutic effective concentrations will activate KatG leading 
to the ineffectiveness of InhA with consequent inhibition of biosynthesis of mycolic 
acids and cell death (25) (Figure V.1.I). However, the addition of isoniazid at 
subtherapeutic concentrations will select the drug resistant subpopulation, the so-called 
persisters (28). After the exposure to the antibiotic, the activity of efflux pumps will 
increase in response to antibiotic stress as previously demonstrated by our group (26). 
This increased activity results in the reduction of intracellular levels of the antibiotic, 
which may enable the survival of the bacterial subpopulation under constant stress 
promoted by a sub-lethal level of the antibiotic. During this period, mutants with 
alterations in the genes that favour resistance can be selected, therefore insuring the 
establishment of an antibiotic resistant population presenting high-level resistance that 
is clinically significant (Figure V.1.II). This induced resistance against the antibiotic can 
be reduced by the use of efflux inhibitors (Figure V.1.III). In this chapter, we further 
described a panel of five genes that encode for efflux pumps associated with isoniazid 
resistance in M. tuberculosis: mmr, p55, mmpL7, Rv1258c, Rv2459 and efpA. These 




isoniazid resistance. Although we detected a general and marked increase of efflux 
pumps genes, we also noted the absence of a clearly defined pattern of specific gene 
expression in response to isoniazid exposure. Altogether these results indicated that 
efflux pumps are promiscuous in their activity as we cannot associate extrusion of 
isoniazid to a specific gene as reported by others (13). 
 
 






The major conclusions of Chapter III are that the increased activity of efflux pumps, as 
a result of the exposure to subinhibitory concentrations of isoniazid, allows a 
sustainable resistant population to be maintained in the patient under therapy, from 
which genetically resistant mutants will emerge with increased frequency and the 
addition of an efflux inhibitor is able to reduce this level of resistance. 
From the work developed in Chapter III several questions arised such as: what is the 
role played by the efflux systems in M. tuberculosis strains that carry mutations in the 
drug target genes? Do they respond in the same way to the same antituberculosis 
antibiotic pressure? What is the mechanism by which the efflux inhibitors can reduce 
the level of resistance that leads to cell death? To address these questions a panel of 
drug resistant M. tuberculosis strains were selected to investigate the in vitro activity of 
the putative efflux inhibitors, verapamil, thioridazine, chlorpromazine, haloperidol and 
flupenthixol, on the resistance levels of isoniazid, rifampicin, amikacin and ofloxacin. 
From here we also wanted to evaluate changes in the expression of efflux pump genes 
upon exposure to isoniazid and rifampicin and evaluate the antimycobacterial properties 
of these inhibitors, both in vitro and in the macrophage model, against these strains 
(Chapter IV).  
Concerning the first question: what is the role played by the efflux systems in M. 
tuberculosis strains that carry mutations in the drug target genes? The results obtained 
in Chapter IV revealed that the addition of inhibitors enhances the clinical effect of the 
main antituberculosis drugs, isoniazid and rifampicin, against multidrug resistant 
strains, despite the presence of a mutation conferring resistance. In the presence of a 
isoniazid and rifampicin high-level resistance strain, these drugs are obviously predicted 
to be useless. However, we have demonstrated the effectiveness of a synergistic 
combination of drugs with conventional therapy that showed to be beneficial since it 
reduced the resistance level of the strain and these results strongly support the relevance 
of these inhibitors as adjuvants in tuberculosis chemotherapy. Importantly, we found 
that the activity of these compounds is limited to strains with inhA mutations which 
points to a genotype-specificity of these compounds. However, how drug resistant M. 
tuberculosis strains responds to the antibiotic pressure imposed by the antibiotics? At 




following chain of events (Figure V.2.I): with the addition of isoniazid to an isoniazid 
resistant strain, the presence of a mutation in the target of isoniazid- inhA - will reduce 
the affinity of the katG-activated isoniazid for NAD (21; 22). The inhibition of the INH-
NAD adduct will lead to isoniazid resistance. The presence of a mutation in inhA will 
prevent the binding of isoniazid to its target resulting in the accumulation of isoniazid 
inside the cells. The creation of such toxic effect will make the cell respond by changing 
the expression of several genes, such as stress genes, which includes the genes that code 
for efflux pumps in order, to reduce the intracellular concentration of the drug. The 
addition of an efflux inhibitor will reduce the efflux activity leading to an increase in 






Figure V.2. The effect of isoniazid exposure on a drug resistant M. tuberculosis strain. 
 
We also demonstrated that the compounds were able to promote intracellular 
accumulation of ethidium bromide, a broad range substrate for efflux pumps, on M. 
tuberculosis multidrug resistant strains, clearly putting in evidence that active efflux is 
inhibited by these compounds. We increased the panel of efflux pumps related factors to 
be studied and included the regulator whib7 that was recently described to be involved 
in the regulation of intrinsic antibiotic resistance in M. tuberculosis (4). Similar to the 
results obtained in Chapter III, we have noticed a general inducible overexpression of 
almost all efflux genes studied upon exposure to isoniazid and rifampicin in multi- and 
extensively drug resistant strains. These results allow us to conclude that the level of 




in drug target genes and a general stress response to the presence of noxious compounds 
that regulates the intracellular level of a drug whose primary line of defensive response 
involves the overexpression of efflux pumps. Therefore, the results obtained in Chapter 
IV, combined with the all sum of results from Chapter II and III, demonstrated that the 
main mechanisms associated with drug resistance in M. tuberculosis correlates 
mutations in target genes with increased efflux and compounds that inhibit efflux can 
significantly reduce the phenotypic level of such resistance. 
Next we focused on the understanding of the mechanism of action of these compounds 
both on bacterial and host cell. Specifically we were interested to unravel the chain of 
events occurring between the addition of an inhibitor and the death of the bacilli (Figure 
V.2). For that purpose, we evaluated the antimycobacterial activity of these compounds 
against a panel of drug resistant M. tuberculosis strains, in vitro, and assessed their 
effect on the enhancement of the killing activity of human monocyte-derived 
macrophages. The results obtained showed that verapamil, thioridazine, 
chlorpromazine, flupenthixol and haloperidol are efflux inhibitors with 
antimycobacterial activity towards M. tuberculosis in vitro and ex vivo. Their 
bactericidal activity was investigated through time-kill studies and the results 
demonstrated that these compounds display rapid and high killing activity. This 
increased bactericidal activity is correlated with intracellular ATP depletion. For ex vivo 
studies we evaluated the activity of the compounds against intracellular M. tuberculosis, 
their potential to induce phagosome acidification, the expression of lysosomal 
hydrolases and the efflux pump gene expression of internalized M. tuberculosis. Gene 
expression analysis showed that, mimicking what was seen previously in vitro, efflux 
genes were also overexpressed in response to isoniazid ex vivo, demonstrating that M. 
tuberculosis drug resistance inside macrophages is also mediated by expression of 
efflux pumps that can be inhibited by such efflux inhibitors. All compounds lead to a 
significant decrease in the intracellular mycobacterial load through a dual effect: 
enhanced synergistic killing activity with antibiotics plus the acidification of 
phagosomes and expression of lysosomal hydrolases.  
Coming to the completion of this thesis we can affirm that the studies developed and the 
results obtained herein provided a preliminary, yet detailed, description of the molecular 




allow us to rename these compounds from efflux inhibitors to ion channel blockers, as a 
more appropriate designation for their plethora of direct and indirect inhibitory effects, 
and to propose the following model for their mechanism of action: a) on the host cell, 
their inclusion on the antituberculosis treatment will lead to an increased transcription 
of the V-ATPases which results in the phagosome acidification. The phagosomal acid 
will synergize with several components of the host immune response, such as lysosomal 
hydrolases, promoting the bacterial growth restriction, therefore being strong cell-
immune boosters, the most important component of the host defenses against 
tuberculosis (Figure V.3); in the bacteria: and after entering the cell, the compounds will 
generate a cascade of events that starts with the inhibition of the respiratory chain 
complexes due to the collapse of PMF by transporting protons down the 
electrochemical potential gradient. The collapse of PMF has detrimental effects on the 
bacterial cell such as increased production of reactive oxygen species (ROS), inhibition 
of ATP synthesis, and disruption of calcium homeostasis. We hypothesize that the 
disruption of PMF results in the inhibition of M. tuberculosis efflux systems that 
depends on PMF. As such, the inhibition of the respiratory chain will lead to i) 
dissipation of membrane potential; ii) reduction of ATP levels; iii) ROS generation; iv) 
increase in intracellular calcium levels; v) intracellular retention of any efflux substrate 
(e.g. ethidium bromide or antituberculosis drugs); and ultimately vi) cell death (Figure 
V.4). As a corollary of the above detailed demonstration of this hypothesis one can 
easily correlate these effects with the increased retention of the antituberculosis drugs, 
such as isoniazid and rifampicin (whose in vitro synergistic activity was demonstrated), 
if these ion channel blockers are to be included in the multidrug long-term 
antituberculosis therapy and the anticipated benefits that they will bring to the treatment 
outcome and shortening of the therapeutic regimen. 
  In conclusion, due to their dual role as antimicrobial agents and enhancers of 
macrophage killing activity, this work highlights the value of these compounds as 
adjuvants of tuberculosis therapeutics, with particular relevance for the treatment of the 
multidrug resistant forms. The objectives of this thesis were fully achieved and the 
several experimental procedures applied during this work revealed to be appropriate for 
the intended objectives and can be used to characterize and evaluate the bactericidal 




potential to be used as antituberculosis agents. The study was divided into three main 
chapters each focusing on the major aspects of M. tuberculosis drug resistance, namely: 
(i) the description of the molecular genetic basis of drug resistance in M. tuberculosis 
clinical strains (Chapter II); (ii) the study on the contribution of efflux to the 
emergence of drug resistance in M. tuberculosis (Chapter III), and (iii) the description 
of the mechanism of action of putative efflux inhibitors that can be used as adjuvants on 










Figure V.3. Hypothetical model for the mechanism of action of the ion channel blockers on human macrophages. The treatment with the 
inhibitors will lead to an increased transcription of the V-ATPases which results in the phagosome acidification. The phagosomal acid will synergize 










Figure V.4. Proposed mechanism of action of the ion channel blockers in M. tuberculosis. I) Ion channel blockers cross the membrane and inhibit 
calcium and potassium channels. The loss of these ions resulted in immediate dissipation of the membrane potential (∆ψ) and II) hydrolysis of internal 
ATP, leading to an eventual collapse of the pH gradient at the membrane, ROS generation; increase in intracellular calcium levels; and cell death. The 
disruption of PMF results in the inhibition of M. tuberculosis efflux systems that depends on PMF. ICB, ion channel blockers; ROS, reactive oxygen 
species; PMF, proton motive force; SMR, small multidrug resistance; RND, resistance-nodulation division; MFS, major facilitator superfamily ; ABC, 




The above enumerated conclusions of this work provides insights to the biological 
foundations of the mechanisms of acquired resistance in tuberculosis that will certainly 
contribute to design new therapeutic agents and strategies to circumvent its 
development, but it’s necessary go further and deeper with the characterization of these 
mechanisms and compounds. Important issues remain to be elucidated and they open a 
new range of future research perspectives. The following aspects can be listed and 
should be the focus of our efforts and attention in the near future – It’s important to: 
 Determine the membrane potential, ROS production, and the effect of ROS 
scavengers when exposed to the compounds. This will allow the precise 
determination of the relation between the mechanism of action of the 
compounds and the integrity of the mycobacterial membrane; 
 Study the interplay between calcium, ROS and NO. Calcium and ROS are 
known to be involved in the response to various cell stresses and NO production 
has been shown to be calcium dependent; 
 Quantify the intracellular concentration of calcium upon exposure to the 
compounds and its correlation with the reduction of ATP levels. The increase on 
intracellular calcium levels is one of the major consequences of the inhibition of 
the respiratory chain. The study of the involvement of calcium homeostasis in 
M. tuberculosis will definitely help to elucidate the mechanism of action of the 
ion channel blockers studied in this thesis;  
 Identify the precise molecular target of these compounds. The biological targets 
of the compounds are a matter of debate (23; 27). It is important to know if the 
inhibition promoted by the compounds is due to their interaction with specific 
target or is just a consequence of the dissipation of membrane potential;  
 Identify the genes required for M. tuberculosis survival in an intracellular acidic 
pH environment. The identification of pathways utilized by M. tuberculosis to 
cope within an acidic environment can and should be looked as potential targets 
for tuberculosis chemotherapy;    
 Determine the intracellular concentration of calcium inside macrophages and its 





 Investigate the effect of the compounds on the activity of the Abelson (Abl) 
tyrosine kinase. Abl tyrosine kinase is described to control phagosome 
acidification (5). Given the effect of these compounds on phagosome 
acidification is likely that they could also have an effect on Abl tyrosine kinase;  
 Evaluate the expression of cathepsin D and V-ATPases. Phagosomal 
acidification is established by the V-ATPases and the accumulation of V-
ATPases is associated with an enhancement of the expression of the aspartic 
protease cathepsin D. It will be interesting to determine the expression of 
cathepsin D and V-ATPases and understand if the compounds-mediated 
acidification could be inhibited by a V-ATPase inhibitor and, if this inhibition 
can lead to enhanced mycobacterial replication inside the macrophages;  
 Evaluate the mitochondrial membrane potential and intracellular calcium 
concentrations of M. tuberculosis infected macrophages. We postulate that the 
ion channel blockers have an effect on the bacterial membrane potential but do 
not affect macrophage membrane potential. It is of major importance to 
investigate their effect on the host cell since increased intracellular calcium 
concentrations is required for the manteinance of mitocodrial functions and 
drugs that increase calcium concentration and protect mitocondrial integrity can 
be suitable tools to boost microbiocidal mechanisms of the macrophage against 
M. tuberculosis as is expected from the preliminary evidences on the effect of 
these compounds on the phagosomal V-ATPases and the mechanism of 
acidification;  
 Characterize the patterns of cytokine production from drug-treated human 
macrophages and its correlation with the genetic background of the strains. In 
Chapter III we have noticed that the in vitro effect of the ion channel blockers is 
dependent on the genetic background of the strains. It would be of interest to 
determine whether these strains demonstrate a strain-specific pattern of cytokine 
production that may explain the success of these strains, principally of Lisboa 
Family, in the infection, disease and drug resistance development among the 
patients of the Lisbon metropolitan area;         
 Explore the role of NDH-1 during macrophage infection upon exposure to the 




properties of the bacteria. We hypothesize that the disruption the membrane 
potential triggered by the tested compounds, will lead to the impairment of the 
respiratory chain and initiate apoptosis.  
 
 
The complete characterization of the in vitro and ex vivo antimycobacterial activity of 
these compounds, initiated with this thesis, will serve as the basis for the future 
characterization of their mechanism of action in vivo using, e.g. a zebrafish larval 
model, as previously described (1). Other groups have already started to demonstrate 
that the foundations of our initial hypothesis is true – the acceleration of tuberculosis 
treatment by adjunctive therapy with an efflux inhibitor (1; 2; 10).  
 
The understanding of the mechanism of action of these compounds will definitely 
contribute for the design of new ones and can provide the basis for the development of 
new therapeutic strategies to fight drug resistant tuberculosis. In Europe and in Portugal 
these new therapeutic strategies will be of utmost importance since the management of 
multidrug and extensively drug resistant tuberculosis patients is a challenge for the 
clinicians whose support and therapeutic weapons to fight the disease is scarce due to 
the evident failures of the World Health Organization standardized second and third line 
therapeutic regimens and the reduced drugs available with known efficacy against drug 
resistant tuberculosis (12; 14). Furthermore, these new therapeutic strategies will be of 
tremendous assistance for the management of the national tuberculosis programs in 
order to cut and stop the chain of events that promotes acquired resistance during 
treatment and the transmission of drug resistant strains (10).  
 
It’s our wish and belief that, with a concerted action between biological, medical and 
public health sciences, the problems posed by drug resistant tuberculosis will be 
severely restrained in the near future by the development of new combined therapeutic 
strategies and new mycobacteria laboratory diagnostic procedures to assist the clinicians 
and the health system in its treatment and control – we hope to have modestly 
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